The Role of Surface Tension of Upper Airway Lining Liquid and Breathing Route in Sleep Disordered Breathing by Chien, Jimmy Kin Yuen
 
 
 i 
 
 
 
The Role of Surface Tension of Upper Airway 
Lining Liquid and Breathing Route in 
Sleep Disordered Breathing 
 
Jimmy Chien 
 
 
A thesis submitted to Sydney Medical School at the University of Sydney in 
fulfilment of the requirements for the degree of  
Doctor of Philosophy 
 
 
 
 
Ludwig Engel Centre for Respiratory Research                          The University of Sydney 
 
December 2015 
 
 
 
 ii 
 
Preface 
 
The work described in this thesis was carried out in the Ludwig Engel Centre 
for Respiratory Research, Westmead Millennium Institute, The University of 
Sydney at Westmead Hospital under the supervision of Professor John 
Wheatley and Associate Professor Terence Amis. The submission of this 
thesis fulfils the requirements for the Degree of Doctor of Philosophy. 
 
I am entirely responsible for the work presented in this thesis, although it 
would not have been possible without the assistance of many people. Most 
of the work in this thesis has been previously presented at the annual 
scientific meetings of The Australasian Sleep Association and the American 
Thoracic Society. 
   
  
 
 
 
 
 
 
 
 
 
 
 
 iii 
Dedication 
 
 
 
 
 
 
 
This work is dedicated to my wife, Jennifer, and my children, Lucinda and 
Xavier 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
Acknowledgements 
 
Completing a PhD is never done without the help and encouragement of 
others. I have been fortunate to be surrounded by friends and colleagues 
who have helped and encouraged me along the way.  I am grateful for the 
opportunities given to me to present my data at multiple local and overseas 
conferences on behalf of the Ludwig Engel Centre for Respiratory Research 
and the University of Sydney.  
 
I would like to firstly thank Professor John Wheatley. Without his guidance, 
mentorship, and support, this work would not have been possible. Despite 
the multiple roles he has to play, and the immense workload he maintains, he 
has always made time to review my work, give insightful feedback, and offer 
ongoing  encouragement. I will always remain grateful for all the support he 
has given me during the course of my PhD. 
 
Associate Professor Amis taught me how to think as a scientist and not a 
clinician. I thank him for all the guidance he has provided me, and the 
numerous hours he has devoted to helping me analyse the data for the 
studies in this thesis. He has taught me the value in scientific rigour, and that 
there are a multitude of ways to look at and analyse data. I will always 
remain thankful for the support and teaching he has provided me over the 
past 8 years. 
 
 
 
 v 
 I would like to thank my colleagues many of whom were essential in the 
completion of this work. I extend my heartfelt thanks to Manisha Verma for all 
the work she has done to help me with surface tension measurements. She 
is a constant source of good cheer and I thank her for her friendship and 
support. I would like to Sharon Lee for her help and friendship. My thanks go 
to her for all the support and advice she has given me over the years. I would 
also like to acknowledge my PhD colleagues including Jodie Narayan and 
Jason Amatoury for their friendship, camaraderie, and help. I would like to 
especially thank Dr Jin Gun Cho for his great friendship and the great 
experiences we’ve had in our very similar PhD journeys. He has also 
contributed his time as a gracious research subject for me, which is more 
than I have reciprocated in return. I would like to extend my thanks to Hugh 
House and Melanie Madronio for their friendship, support, and technical 
expertise. These colleagues have all enriched my experience immensely. 
 
I have spent many nights in the Sleep Laboratory at Westmead Hospital, and 
they are fortunate to have a number of experienced and dedicated scientists 
and technicians. I would like to thank Louise Tyler for all her hard work with 
the sleep studies and Naomi Newton for her help with subject setup and 
sample collection. They always provided great company during nights in the 
sleep laboratory. I would also like to extend my thanks to Stephen Lambert 
for his support, friendship, and the bike rides around Parramatta Park which 
were always a welcome break. 
 
 
 
 
 vi 
 
 
Associate Professor Peter Middleton has been a friend and colleague 
since the beginning of my PhD, and I thank him for all the advice, support 
and encouragement he has given me.  I would also like to thank Associate 
Professor Kristina Kairaitis for her encouragement, friendship, the many 
coffees, the insightful physiology discussions, and for her shoulder the few 
times I have fallen asleep at international conferences. I have valued the 
friendship and support of Dr Peter Wu, and I would like to extend my 
heartfelt thanks to him for always being present to provide help and  
advice.  
 
Without inspiration from the late Dr Tracey Robinson, I may not have 
undertaken a PhD at all, and I thank her for her enthusiasm, sage advice, 
and her friendship. I will sorely miss her probing questions, her sharp 
intellect, and her company on the weekend bike rides, which were 
essential in maintaining a positive outlook. 
 
I would like to acknowledge the scholarships and financial support 
provided to me to undertake this research, and to travel locally and 
internationally to present my data. I have been thankful in receiving a 
University of Sydney Postgraduate Award, and a ResMed Research Entry 
Scholarship from the Royal Australasian College of Physicians. I would 
like to thank the Australasian Sleep Association, the Westmead Charitable 
Trust Research Program, and the American Thoracic Society for awarding 
 
 
 vii 
me the Travel Grants which have enabled me to present my data at local  
and overseas meetings. I am grateful for the financial support given me 
(courtesy of the Leece family) through a Westmead Medical Research 
Foundation Stipend Enhancement Grant. 
 
Finally, I would like to thank my wife, Jennifer, and my children Lucinda 
and Xavier. Without their love and support this work would not have been 
possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
Abstract 
 
This thesis examines the relationship between surface tension in the 
upper airway liquid, breathing route, and sleep disordered breathing. 
Although anatomical factors play the predominant role in sleep disordered 
breathing, surface tension forces may influence upper airway patency.  
 
The range of surface tension values for upper airway liquid was examined 
by collection of upper airway liquid samples and salivary samples across 
the day for healthy subjects. This demonstrated that surface tension 
values for upper airway liquid were relatively stable across the day for 
healthy subjects, but depending on the time of day, surface tension of 
saliva may not accurately reflect the surface tension of upper airway liquid, 
although values for both were similar. 
 
Following on from the study examining the range of surface tension values 
for healthy subjects, evening  samples of upper airway liquid and saliva 
were collected, and surface tension values examined in subjects with 
obstructive sleep apnoea. The results demonstrated a wide range of 
values in these subjects, in addition to a positive association between 
older subjects with severe OSA and increased surface tension in upper 
airway liquid. 
 
 
 
 ix 
The relationship between uncontrolled route of breathing and surface 
tension was examined in subjects with severe obstructive sleep apnoea. 
Nasal route of breathing occurred in all subjects, and was the predominant 
breathing route, while oronasal breathing route was observed in most 
subjects. There was no association found between breathing route and the 
surface tension of upper airway liquid in this study, however, breathing 
route was not enforced. 
 
Enforced oral breathing route in healthy subjects was shown to induce 
sleep disordered breathing. Two separate sleep study nights were 
undertaken, one with enforced nasal breathing route and one with 
enforced oral breathing route. Enforced oral breathing route not only 
induced sleep disordered breathing, but also increased the surface tension 
of upper airway liquid. 
 
To determine whether the enforced oral breathing route induced sleep 
disordered breathing via surface tension mediated mechanisms, these 
healthy subjects were given exogenous surfactant with enforced oral route 
of breathing during sleep. Lowering the surface tension of upper airways 
lining liquid reduced, but did not eliminate oral breathing induced sleep 
disordered breathing. Therefore oral breathing induced sleep disordered 
breathing in healthy subjects appears to be partially mediated by 
increases in surface tension of upper airway liquid. 
 
 
 
 x 
Finally, exogenous surfactant and normal saline were administered to 
subjects with mild to moderate obstructive sleep apnoea on separate 
nights, following an initial diagnostic sleep study confirming the presence 
of mild to moderate obstructive sleep apnoea.  Although a reduction in 
upper airway surface tension was seen on the exogenous surfactant night, 
there was no associated reduction in the severity of obstructive sleep 
apnoea. Individual subjects demonstrated a substantial variability in the 
severity of obstructive sleep apnoea between the initial diagnostic sleep 
study, the normal saline night and the exogenous surfactant night. This 
study concluded that although exogenous surfactant resulted in a 
decrease in surface tension of upper airway liquid, the variable response 
in sleep apnoea severity suggests that a suitable patient phenotype may 
need to be defined for exogenous surfactant therapy. 
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 1 
 
Chapter 1:  General Introduction 
 
  
 Sleep disordered breathing encompasses a wide spectrum of sleep 
related breathing abnormalities, and includes snoring and obstructive sleep 
apnoea (OSA). The basis of sleep related breathing abnormalities are due to  
a number of pathophysiological factors. The recurrent narrowing, airflow 
limitation, and closure of the upper airway during sleep may be due to a 
number of factors. These include structural defects and anatomical narrowing 
due to bony structures , changes in soft tissue mass compromising or 
collapsing the upper airway, inadequate neuromuscular responses from 
upper airway dilating muscles, abnormal arousal responses (or threshold to 
wake up) due to upper airway narrowing, abnormalities in the sensitivity of 
the ventilatory control system leading to ventilatory instability, and more 
recently, surface tension of the liquid on mucosal surfaces of the upper 
airway has been recognised as a factor influencing upper airway patency. 
 
 Previous work done in our laboratory by Kirkness et al, has examined 
the role of surface tension of liquid lining the upper airway in obstructive 
sleep apnoea (Kirkness et al., 2003c). A new method of measuring surface 
tension was devised call the “Pull Off Force” Technique and this involved 
measuring the force required to separate two silica discs bridged by a 
microliter volume of the  liquid being examined. The force required to result in 
disc separation was taken as the surface tension of the liquid measured 
 
 
 2 
(Kirkness et al., 2005a). Previous studies have examined the influence of 
exogenous surfactant agents on the patency of the upper airway in humans 
(Van der Touw et al., 1997, Morrell et al., 2002), and the series of 
experiments undertaken by Kirkness et al extensively described the 
measurement of surface tension forces, and the effect of instilled exogenous 
surfactant on lowering surface tension, and the influence of this lowered 
surface tension on upper airway patency (Kirkness et al., 2003a, Kirkness et 
al., 2003b, Kirkness et al., 2005b).  
 
 An animal model using anaesthetized rabbits demonstrated that 
surfactant administered into the upper airway  lowered the surface tension of 
the upper airway liquid (STUAL) and this correlated strongly with decreases 
in upper airway opening  and closing pressures (Kirkness et al., 2003a). 
 
 A similar study was performed in anaesthetised human subjects and 
this study similarly demonstrated that a decrease in STUAL using instilled 
exogenous surfactant resulted in decreases in upper airway resistance, 
opening pressures and closing pressures. The authors concluded that 
lowering the STUAL with exogenous surfactant into the upper airway 
increases the upper airway patency and augments reopening of a collapsed 
airway (Kirkness et al., 2003b). 
 
 Finally, Kirkness and his co-workers  instilled exogenous surfactant 
into the upper airway of subjects with OSA. This demonstrated that instilled 
exogenous surfactant lowered the STUAL and reduced the severity of OSA, 
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leading the authors to conclude that manipulation of surface tension may be 
a potential therapeutic intervention for sleep disordered breathing (Kirkness 
et al., 2005b). 
 
 Further studies carried out in our laboratory have demonstrated oral 
route of breathing increases STUAL in awake subjects, with significant 
increases in STUAL seen following 2 hours of enforced oral route of 
breathing (Verma et al., 2006). Furthermore, oral route of breathing is 
observed to occur during sleep (Madronio et al., 2004). Hence, changes in 
route of breathing during sleep may provide a mechanism where alterations 
in STUAL with breathing route may potentially influence the severity of sleep 
disordered breathing. 
 
 This thesis will explore the role of STUAL and breathing route in sleep 
disordered breathing.  Chapters 2 - 3 represents a literature review on the 
anatomical and pathophysiological causes of upper airways collapse in sleep 
disordered breathing, in addition to the role of surface tension forces and the 
measurement of STUAL. Chapter 4 will review the literature regarding 
Obstructive Sleep Apnoea, the characteristics, epidemiology, burden of 
disease, and current therapeutic options. Previous literature examining the 
role of surface tension forces in obstructive sleep apnoea will also be 
reviewed here.  
 
The experimental chapters 5 and 6 will describe  the STUAL in healthy 
subjects and subjects with OSA. Chapters 7 to 9 will investigate the role of 
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enforced and non-enforced breathing route, with and without exogenous 
surfactant,  on the severity of sleep disordered breathing. Chapter 10 is a 
clinical trial investigating the effect of exogenous surfactant on sleep 
disordered breathing in patients with mild to moderate obstructive sleep 
apnoea. 
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Chapter 2:  Upper Airway Anatomy 
 
  
 The upper airway includes the anatomical structures from the nares 
and oral cavity, and caudally to the point where the airway divides into the 
laryngeal and oesophageal structures. The nose is comprised of the external 
nasal structures and the nasal cavity. 
 
 Externally, the nares are supported by cartilage, fibrous connective 
tissue, and the levator labii superioris alaeque nasi provide muscular 
dilatation. The cavity of the nose is separated by a nasal septum. On each 
side there is a roof, floor, medial and lateral wall. The medial wall is formed 
by the nasal septum. On each side there is an inferior, middle and superior 
turbinate that increases surface area to facilitate humidification and warming 
of inspired air. Posterior to this, the divided nasal cavities on each side meet 
to form the airway lumen of the nasopharynx. The Eustachian tubes originate 
from the nasopharynx and the origin is located in the lateral nasopharyngeal 
walls. 
 
 The velopharynx is the portion of upper airway bounded by the soft 
palate anteriorly, and the lateral and posterior pharyngeal walls. This joins 
with the oral cavity at the oropharynx. The mouth and lips form the opening 
to the oral cavity. Superiorly, the hard palate forms the roof, and the bony 
hard palate extends posteriorly until it forms the muscular soft palate, ending 
in a small, posterior, central conical projection of tissue called the uvula. 
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 The tongue forms the floor of the oral cavity. The posterior boundary 
of the oral cavity is formed by the palatoglossal arch, which joins the lateral 
walls of the soft palate to the tongue laterally, and distal to this is the 
oropharynx. Here, the oropharynx divides into two regions, the velopharynx 
or retropalatal oropharynx, which extends from the hard palate to the caudal 
margin of the soft palate, and the retroglossal oropharynx. The hypo -
pharynx extends from the tip of the epiglottis to the inferior border of the 
cricoid cartilage (Figure 2.1). 
 
 The pharyngeal muscles that are important in maintaining patency can 
divided into anatomical/ functional groups and include the extrinsic muscles 
of the tongue, the muscles controlling palate shape and function, the muscles 
influencing hyoid bone position, and the pharyngeal constrictor muscles. 
 
 The muscles of the tongue include the Genioglossus which protrudes 
and depresses the tongue, the Styloglossus, which raises and retracts the 
tongue, while the Hyoglossus depresses and retracts the tongue. Activation 
of the Genioglossus widens the oropharynx in the anterior-posterior 
dimension and has a major role in opening the pharyngeal airway.  
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Figure 2.1   Mid sagittal view of the anatomy and musculature of the upper airway 
This demonstrates the 4 subdivisions of the upper airway which include the nasopharynx, 
the retropalatal oropharynx or velopharynx, the retroglossal oropharynx, and the 
hypopharynx. Adapted from Kryger, Roth and Dement 2005. 
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 Muscles responsible for palatal shape and position include the Tensor 
Palatini, which tenses the soft palate, Palatoglossus, which elevates and 
pulls the palate onto the posterior tongue, the Palatopharyngeus which  lifts 
the pharyngeal wall and moves the soft palate anteriorly, and the Musculus 
Uvulae, which raises the uvula.  
 
  The hyoid bone position is influenced by insertion and contraction of 
multiple muscles including the Geniohyoid, Mylohyoid, Thyrohyoid, 
Sternohyoid, Stylohyoid, and Omohyoid muscles. These work to elevate, 
depress, or to stabilise the Hyoid bone. The pharyngeal constrictor muscles 
consist of the Superior, Middle, and Inferior Constrictor muscles which have 
origins in the skull, mandible, hyoid, and larynx. They insert into various 
structures in the anterior pharynx including the tongue, and at high lung 
volumes can act as constrictors while at lower lung volumes dilate to 
maintain airway patency. 
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Chapter 3:  Upper Airway Physiology and 
Airway Closure 
 
 
3.1  Functions of the Upper Airway 
 
 In humans, the pharynx serves as a conduit for airflow from the nose 
and mouth to the larynx. It also serves other functions including secretory, 
phonation, and swallowing. Its patency during wakefulness is due to 
continual neuromuscular control by the higher nervous system which 
supervises the action of the pharyngeal muscles and ensures a patent 
pharynx. During sleep, this pharyngeal control is altered and may 
compromise airway patency. When the neurological changes in sleep occur 
in the presence of anatomical abnormalities, severe narrowing or closure 
may occur, leading to sleep hypopnoea or apnoea. The pharynx consists of 
four anatomical subsegments, the nasopharynx, velopharynx, oropharynx, 
and hypopharynx. 
  
 During inspiration, pharyngeal structures are pulled inward by sub 
atmospheric luminal pressure. The pharyngeal structures return to resting 
position during expiration. The pharyngeal muscles receive phasic activation 
during inspiration which promotes patency of the pharyngeal lumen. The 
most important dilator muscles in the upper airway promoting airways 
patency include the genioglossus, levator palatini, and hyoid muscles. The 
tensor palatini enhances the patency of the most rostral part of the airway, 
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while activation of the genioglossus muscle increases the stiffness of the mid 
portions of the pharynx, with the hyoid muscles maintain patency of the 
caudal portion of the pharynx, and also pulls the epiglottis anteriorly/ 
ventrally. 
 
 In the upper airway, the anatomical and neurological interactions that 
allow  it to change shape and calibre to enable functions such as swallowing 
and phonation, also makes it vulnerable to collapse, due to alterations in the 
anatomical structures that make up non-rigid and collapsible portions , and 
changes in neurological input particularly during the sleep state. 
 
 
3.2  Anatomical Box Model of the Upper Airway 
 
 The propensity for the upper airway to collapse may be determined by 
several interacting anatomical factors. The size of the upper airway 
boundary, or “bony enclosure”, the amount of soft tissue within this 
enclosure, and the intraluminal pressure within the airway surrounded by soft 
tissue, may interact to determine airway collapsibility (Watanabe et al., 
2002). An alteration in any of these factors i.e. a small bony enclosure, an 
increase in extraluminal soft tissue, and a reduction in intraluminal pressure 
may lead to increased collapsibility of the upper airway (Figure 3.1). 
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Figure 3.1   Mechanical model of the pharyngeal airway 
The size of the pharyngeal lumen (circle labelled “Airway”) can be viewed as being 
dependent on the size of the bony enclosure (box with solid line) and the amount of soft 
tissue within it (shaded grid within the box). Adapted from Watanabe et al. 2003.   
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 Upper airway collapse in OSA has been associated with anatomical 
factors such as tonsillar enlargement, retrognathia, and facial bone 
abnormalities/ craniofacial structure (Miyazaki et al., 1989). These factors 
lead to a smaller luminal area in the upper airway which predisposes upper 
airway collapse. 
 
 Similarly, head position and mandible position may influence the 
collapsibility of the upper airway by potentially altering the “bony enclosure” 
size. Neck flexion and bite opening decreases the size and increased 
collapsibility of the velopharynx and oropharynx while neck extension 
increases the oropharyngeal airway size (Isono et al., 2004). 
 
 Obesity leads to increased fat deposition in the tongue, 
parapharyngeal fat pads, lateral pharyngeal walls and soft palate. This again, 
leads to a smaller pharyngeal luminal area, with greater predisposition to 
collapse (Welch et al., 2002). However, weight loss can reverse these 
anatomical changes and improve OSA severity (Sampol et al., 1998). 
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3.3  Balance of Forces Concept 
 
 This concept proposes that the size of the pharyngeal lumen is 
dependent on a balance between the outward forces produced by 
contracting muscles, and the inward collapsing forces from extraluminal 
tissue pressure, and subatmospheric intraluminal pressures during 
inspiration (Remmers, 1978).  
 
Intraluminal Pressure 
 The collapsing force of negative pressure generated by the diaphragm 
would be transmitted to the upper airway, causing a narrowing  of the airway, 
the degree of which would be dependent on the compliance of the airway 
wall as well as the opposing dilating forces from pharyngeal muscles.  
 
 However, this mechanism does not explain the pathogenesis of 
airways obstruction in the presence of positive intraluminal pressures. 
Schneider et al showed that dynamic changes in respiratory phase and 
airflow  could modulate upper airway collapsibility (Schneider et al., 2002). 
 
Extraluminal Tissue Pressure 
 The pharynx can be viewed as a collapsible tube. Extraluminal tissue 
pressure (ETP) exerts a collapsing force upon the pharyngeal airway that is 
dependent upon the amount of soft tissue within an “anatomical box” bound 
by the mandible and spinal column (Isono et al, Watanabe et al). Moreover, 
upper airway collapsibility can vary with mandibular size and position, and 
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the opening and closing pressures in the upper airway may be manipulated 
by change in mandibular position (Kairaitis et al., 2007).  
 
        Extraluminal tissue pressure alters the transmural pressure and hence 
can influence the degree of airway collapse. The transmural pressure is the 
difference between the intraluminal airway pressure and the extraluminal 
tissue pressure. The transmural pressure determines the degree of airways 
collapse. A positive transmural pressure maintains upper airway patency, 
while a negative transmural pressure ( e.g. by applying subatmospheric  
intraluminal pressure) promotes airways collapse(Schwartz et al., 2006). In 
OSA patients, the airway can occlude at above atmospheric pressures, 
suggesting a higher extraluminal tissue pressure in OSA patients contributing 
to airways collapse (Smith et al, 1988).  
 
         Reduction in ETP by mandibular advancement in a rabbit model results 
in a reduction in extraluminal tissue pressures,  while mouth opening, which 
can reduces the size of the bony enclosure and causes compression of 
extraluminal tissues by the mandible, is associated with an increase in upper 
airway collapsibility. Mandibular advancement results in the opposite, with a 
decrease in lateral peripharyngeal tissue pressure, and an improvement in 
airway patency (Kairaitis et al., 2006). 
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3.4  The Starling Resistor model of the Upper Airway 
 
 The pharyngeal airway can be described as a Starling resistor 
because the pressure flow dynamics are the same as in other collapsible 
biological conduits (Pride et al., 1967). The term is used to describe a highly 
collapsible tube having infinite compliance, changing from completely open to 
completely closed with little change in intraluminal pressure near that at 
which complete collapse occurs. The luminal pressure at which the airway 
shifts from fully open to fully closed is determined by the extramural pressure 
and is known as the critical pressure (Pcrit). Pcrit can be extrapolated by 
varying upstream pressure (for example by CPAP) under conditions of 
inspiratory flow limitation, and by monitoring pressure associated with zero 
flow. The model describes the conditions where changes in the pressure flow 
profile can lead to upper airway occlusion (Figure 3.2). 
 
3.5  Lung Volume 
 
 Lung volume may interact with the upper airway to influence patency 
and collapsibility. Changes in lung volume can influence upper airway 
patency. Caudal traction exerts longitudinal tension on all components of the 
pharyngeal wall to reduce the propensity for upper airway collapse (Kairaitis 
et al., 2007, Schwartz et al., 2006). Decreased lung volumes may lead rostral 
movement of the diaphragm and thorax, and a loss of caudal traction hence 
increasing upper airway collapsibility (Figure 3.3).  
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Figure 3.2   Starling Resistor Model of the Upper Airway 
In this model, the airway can be represented as a rigid tube with a collapsible segment. 
Pressures in the fixed, rigid upstream and downstream segments are represented by Pus 
and Pds respectively. The collapsible segment is subject to the surrounding pressure, and 
the pressure required to collapse it is represented by Pcrit. Normal breathing occurs when 
Pus > Pds > Pcrit. When Pcrit is greater than the downstream pressure, collapse occurs in 
the upper airway, but airflow still occurs. However, when the Pcrit exceeds both the 
upstream and downstream pressures, complete occlusion of the airway occurs, with no 
airflow. Adapted from Kirkness et al. 2006 
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Figure 3.3  Tracheal traction and airway patency 
Effects of caudal and radial traction on mucosal tension and extraluminal tissue pressure.  
Caudal traction can “stiffen” the airway wall via increased mucosal tension whilst radial 
traction leads to decompression of surrounding soft tissues. Adapted from Schwartz et al. 
2006. 
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3.6  Neuromuscular and Neuroventilatory Factors 
 
 The upper airway’s patency is strongly influenced by the dilating 
function of the pharyngeal musculature. A reduction in pharyngeal muscle 
activity  during sleep induces pharyngeal narrowing and is a significant 
mechanism in the pathogenesis of OSA. The largest pharyngeal dilator 
muscle in humans is the genioglossus. In most animals, tracheal obstruction/ 
occlusion or subatmospheric pressures causes a neurologically mediated 
activation of  the pharyngeal muscles. In addition, neuromuscular reflexes 
are present in upper airway cause pharyngeal muscle dilation with inspiration 
and prevent upper airway closure.  
 
 Subjects with Obstructive Sleep Apnoea have increased EMG and 
genioglossus activity in wakefulness (Mezzanotte et al., 1992), but a blunting 
of this activity and reflexes during sleep may predispose to pharyngeal 
airway collapse (Wheatley et al., 1993). Weiner et al demonstrated that 
upper airway reflexes also occurred in the presence of chemical stimuli in the 
upper airways. Increased activity was observed in the phrenic, hypoglossal, 
and pharyngeal nerves of dogs when hypoxia or hypercapnia was induced in 
anaesthetised, paralysed dogs, in addition to the increased activity seen with 
inspiration (Weiner et al., 1982).  
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 Recently, single motor unit recording techniques have been used to 
determine the activity of individual motor units in the genioglossus muscle, 
and its role in OSA (Bailey et al., 2007). A better understanding may 
potentially lead to therapies targeting neuromuscular activity, thereby 
reducing the severity of OSA in some patients. However, due to the 
multifactorial influences on upper airway patency, modifying upper airways 
neuromuscular output alone may not lead to an improvement for all OSA 
patients. Interestingly, Puhan et al demonstrated that upper airway muscle 
training with 4 months of didgeridoo playing reduced the severity of sleep 
disordered breathing in OSA patients (Puhan et al., 2006), suggesting a 
training effect in strengthening or improving upper airway muscle tone may 
decrease the propensity for the upper airway to collapse during sleep.  
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3.7  Route of Breathing 
 
 Nasal, oral, and oronasal breathing may occur overnight during sleep. 
Oronasal breathing in sleep may be increased in older individuals (Madronio 
et al., 2004). Oral route of breathing leads to increased upper airways 
resistance and increases the severity of sleep disordered breathing 
(Fitzpatrick et al., 2003). The mechanism may be due to changes in upper 
airways geometry with the open jaw position, and possibly related changes in 
length/ tension relationships of upper airway muscles with an open jaw 
position. However, even though there is a relationship between the  increase 
in tendency to sleep apnoea and nasal obstruction, this may not necessarily 
be due to mouth breathing, but may be due to a component of continued 
nasal breathing through a higher resistance nasal airway.  
 
 Chronic nasal obstruction may play a role in upper airway collapse in 
OSA by reducing intra luminal pressure, thereby predisposing to upper 
airway vibration (snoring) and partial collapse, resembling a Starling resistor 
with flow limitation.  In patients enrolled in the Wisconsin sleep cohort study, 
nocturnal nasal congestion frequency was associated with increased snoring 
frequency (Young et al., 2001). There is some evidence that improving nasal 
breathing during sleep by medical intervention, for example with nasal 
steroids for rhinitis, and surgical therapy for correction of turbinate 
hypertrophy, septal deviation, and nasal polyposis , may reduced nasal 
resistance and reduce the severity of sleep disordered breathing (Kohler et 
al., 2007). 
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 In patients with allergic rhinitis, treating severe nasal obstruction 
results  in reduced nasal resistance, reduced oral breathing during sleep, and 
a reduction in the severity of obstructive sleep apnoea (McLean et al., 2005). 
 
 The effect of bite opening and mandibular position has also been 
studied and may contribute to upper airway collapse. Isono et al 2004 
described the influence of head posture and jaw position on upper airway 
collapsibility (Isono et al., 2004), while time spent with an open mouth during 
sleep was greater in patients with OSA than in normal subjects (Miyamoto et 
al., 1999). Mouth opening changes mandibular position, which may cause i) 
posterior displacement of the tongue at the velopharynx, increasing the 
amount of soft tissue enclosed by the maxilla and ii) reduce the size of the 
“bony box” due to posterior displacement of the mandible. 
 
 An increased propensity to upper airway collapse may also occur in 
oral breathing due to changes in surface tension with route of breathing. 
Enforced oral route of breathing in awake subjects during daytime 
demonstrated an increase in surface tension after 2 hours of enforced oral 
breathing from 64.4 ± 2.7 mN/m to 77.4 ± 1.1 mN/m (Verma et al., 2006). 
The authors concluded that an enforced oral breathing route may impede the 
maintenance of a low surface tension in the upper airway lining liquid. The 
implication of this is oral breathing and the associated increase in surface 
tension may increase the severity of sleep disordered breathing. 
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3.8  The Upper Airway Mucosal Surface 
 
 Surface tension is defined as the force exerted across the surface of a 
liquid at a liquid - gas interface. This is caused by the attraction of molecules 
of the liquid. Liquid molecules are pulled equally by other liquid molecules. At 
the surface of the liquid (at the liquid-gas interface), the surface liquid 
molecules are pulled inwards towards the centre of the liquid. This inward 
pull acts to decrease the surface area, and hence the surface of the liquid 
acts as a tensed elastic membrane. (An example is a drop of water, where a 
smallest possible surface area causes it to assume a characteristic spherical 
shape). The interface between a liquid and a solid wall is also subject to 
surface tension forces, an example being the meniscus (contact angle) seen 
at the glass/ water interface. 
 
 Pulmonary Surfactant is a naturally occurring surface active 
phospholipid which exerts surface active forces in the alveoli, lower airways 
and upper airways. 
Pulmonary surfactant contains 90% lipids and approximately 10% protein, of 
which half has surfactant properties with the rest being contaminant from 
lung tissue or plasma (Halliday, 2005). 
 
 The main surfactant phospholipid in the respiratory system is 
dipalmitoylphosphatidylcholine, secreted from phospholipid lamellar bodies in 
type II alveolar cells. Similar cells producing surfactant have also been found 
in upper airways (Bradford, 2005), suggesting a possible physiological role in 
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the upper airway. The hydrophilic head group remains on the liquid side of 
the interface while the hydrophobic tails extend into the gas. In the alveolus, 
surfactant serves to reduce surface tension forces that would otherwise 
collapse alveoli, thereby maintaining alveolar size and improving lung 
compliance (West).  
 
 Surfactants (surface acting agents) lower the surface tension at the 
liquid-gas interface. These agents are described as being amphipathic, with 
both a polar and non polar portion (or a hydrophilic and hydrophobic portion). 
 
 Four surfactant proteins have been identified: SP-A, SP-B, SP-C, and 
SP-D. SP-B and SP-C have surface tension lowering effects with SP-B 
having secondary effects on surfactant protein synthesis. SP-C is important 
in facilitating film formation, promoting film stability and respreading during 
compression and expansion that occurs with respiration. SP-A and SP-D 
both have immunological roles in host defence against micro-organism 
invasion (Halliday, 2005, Griese, 1999).  
 
 The study of pulmonary surfactant arose from research into neonatal 
respiratory distress syndrome, previously known as hyaline membrane 
disease. Prior to surfactant replacement therapy, premature infants who died 
from this condition were found to have collapsed alveoli, with respiratory 
surfaces having increased adhesiveness. There was no effective treatment 
until exogenous surfactant was instilled into neonatal airways (Fujiwara and 
Adams, 1980). 
 
 
 24 
 
 The role of exogenous surfactant in the treatment of neonatal 
respiratory distress syndrome by stabilising alveolar surface tension, and 
preventing alveolar collapse is now well established (Raghavendran et al., 
2011).  
 
 It is also becoming clear that surface effects in the upper airway play a 
role in airways collapse. In the upper airways, surface tension is a force that 
contributes to airways closure by modulating the opening and closing 
pressures. The increased “stickiness” of the mucosal surface needs to be 
overcome in a collapsed airway to facilitate airway re-opening and is the 
reason opening pressures are greater than closing pressures. 
 
 Surfactant lamellar bodies similar to those found in type II 
pneumocytes, are also present in sinus mucosa (Bradford, 2005) indicating a 
source of surfactant production in the upper airways mucosa.  
 
 Human saliva has surface active properties and exhibits a lower 
surface tension than water, the primary component of saliva. Human saliva 
has a mean surface tension of approximately 53.1 to 57 mN/m (Braddock et 
al., 1970) with values from more recent data demonstrating a surface tension 
of 59 mN/m (Kirkness et al., 2005b), with the surfactant effect due to surface 
active phospholipids present in saliva, while water exhibits a surface tension 
of 71 mN/m.  
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 Previous investigators (Reed et al., 1985, Wilson et al., 1980) reported 
collapsed airways in post-mortem studies in infant cadavers, as well as in 
living infants, showing that airways re-opening required a greater pressure 
than that for airways collapse. 
 
 A link between surface tension of upper airways and airways 
obstruction was first described in a study investigating the effects of upper 
airway lubrication and surface active agents on the opening of the obstructed 
airway in dogs (Widdicombe and Davies, 1988). 
 
 Surface active agents (surfactant) instilled into the upper airways 
lower the opening pressures in the upper airway (Kirkness et al., 2003b, 
Kirkness et al., 2003a, Morrell et al., 2002). It has therefore been proposed 
that intraluminal surface tension and adhesive forces play a role in upper 
airways patency, and that modulating the surface tension in the upper airway 
may change patency, and opening and closing pressures (Van der Touw et 
al., 1997). 
 
 The usual range for surface tension in normal subjects ranges from 52 
to 59 mN/m with nasal breathing. This increases to 64 to 77mN/m with 
enforced oral breathing  suggesting that oral breathing may lead to loss/ 
evaporation of the lower surface tension liquid layer in the upper airway 
(Kirkness et al., 2005b). Subsequent studies in OSA patients have shown 
that the reference range for STUAL is similar in OSA patients, ranging from 
50 to 72 mN/m in both saliva and UAL. The STUAL and ST saliva also 
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correlate well suggesting the fluid lining the upper airway is very similar to 
swallowed saliva. Possible explanations accounting for small differences may 
be postnasal drip/ nasal sinus secretions and possibly even refluxed 
surfactant containing fluid from the lower respiratory tract. 
 
 In a series of studies, Kirkness firstly developed a new method of 
measuring surface tension in microliter volumes of fluid collected from the 
upper airway using the “Pull-off force” technique (Kirkness et al., 2005a). The 
apparatus consists of two , cylindrically polished silica discs, with the top disc 
mounted on a stable platform, with the lower disc mounted on a double 
cantilever spring (Figures 3.4 and 3.5).  
 
 The surface tension of microliter volumes of liquid could be measured 
by this method. Microliter volumes (approximately 0.2 microliters) of the liquid 
sample were placed on the lower silica disc, which was then raised up until 
the two silica discs met with the liquid bridging the two silica discs. The lower 
silica disc was mounted to the double cantilever spring, which was lowered 
via the micrometer screw gauge driven by the DC motor. The force required 
to separate the two silica discs bridged by the liquid was measured and the 
surface tension calculated from this.  
 
 In a rabbit model, Kirkness et al demonstrated that upper airway 
opening and closing pressures were affected by changes in surface tension. 
When saline was applied to the upper airway, the increased surface tension 
resulted in an increase in both opening and closing pressures, while reducing 
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the surface tension by applying exogenous surfactant reduced both the 
opening and closing pressures. The surface tension of liquid lining the upper 
airway, is hence a factor which may modulate upper airway collapsibility and 
re-opening, particularly airway walls that are in close apposition (Kirkness et 
al., 2003a). 
 
 Exogenous surfactant was studied by Kirkness et al in an 
anaesthetised human model (Kirkness et al., 2003b). This demonstrated a 
reduction in STUAL when exogenous surfactant was instilled into the upper 
airway, with the reduction in surface tension from approximately 62mN/m to 
50mN/m. The reduction in STUAL also correlated with reductions in upper 
airway resistance and opening pressures (Figure 3.6). 
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Figure 3.4   “Pull-off” force apparatus 
(Refer to schematic in Figure 3.5). 
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Figure 3.5  Schematic diagram of the “pull-off” force apparatus 
“Pull off force” technique device used for measuring Surface Tension in micro litre volumes. 
The fluid sample is placed between 2 silica discs as a fluid “bridge”. The DC motor is 
connected to a micrometer and translating stage which moves the double cantilever spring 
downwards. The force required to separate the discs was taken to be the surface tension of 
the liquid. 
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Figure 3.6  STUAL, upper airway re-opening pressure, and upper airways resistance 
Effect of changing STUAL on upper airway reopening pressure and upper airways 
resistance. A decrease in STUAL resulted in a reduction in both re-opening pressure and 
upper airways resistance. Adapted from Kirkness et al 2003. 
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 The surface tension in upper airway lining liquid may also be 
manipulated with exogenous surfactant to decrease the severity of sleep 
disordered breathing in patients with obstructive sleep apnoea. 
 
 The values for surface tension of upper airway lining liquid (STUAL) 
were compared between a small cohort of healthy subjects, and subjects 
with obstructive sleep apnoea, and a small increase in surface tension was 
found in the OSA group when compared with the healthy subject group. The 
occurrence of nasal breathing during sleep was associated with a fall in 
STUAL in both groups (Kirkness et al., 2005b)  
 
 Surface tension forces play an important part in modulating upper 
airway patency. In an anaesthetised rabbit model, decreasing the surface 
tension by instillation of exogenous surfactant closed and re-opened the 
upper airway at lower intraluminal pharyngeal pressures (Lam et al., 2008, 
Kirkness et al., 2003a). Similarly, in anaesthetised human subjects, there is a 
relationship between the surface tension in the upper airway and its passive 
mechanical properties (Kirkness et al., 2003b). Lowering the surface tension 
in the upper airway lining liquid reduced re-opening pressures, and upper 
airway resistance. In a single blind crossover placebo- controlled study, 
Morrell et all demonstrated that exogenous surfactant instilled into the upper 
airway reduced the upper airway resistance and respiratory disturbance 
index in sleeping human subjects (Morrell et al., 2002). 
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Chapter 4:  Obstructive Sleep Apnoea 
 
 
4.1  Definition 
 
 In early research into upper airway collapse , episodic apnoeas were 
detected by oronasal thermistors and chest and abdominal strain gauges/ 
bands. This, in combination with EEG monitoring, allowed sleep related 
obstructive events to be identified (Guilleminault et al , Ann Rev Med 1976). 
Respiratory events and apnoeas at ≥ 5 events per hour of sleep were 
described as abnormal, with obstructive apnoeas defined by cessation of 
airflow on nasal pressure transducer or thermistor of > 10s. The scoring of 
sleep stages, EEG arousals, and respiratory events were the culmination of 
early consensus guidelines used for sleep staging (Rechtschaffen and Kales 
1968), and the American Academy of Sleep Medicine consensus reports 
which have evolved into the current American Academy of Sleep Medicine 
criteria for scoring (Berry et al., 2012). 
 
 An apnoea is defined as a ≥ 90% reduction in airflow for ≥ 10 seconds. 
It is classified as obstructive if respiratory effort is present and central if no 
respiratory effort is present. Hypopnoeas are defined by a ≥  30% reduction 
in airflow for ≥ 10 seconds associated  with a  ≥ 4% oxygen desaturation. 
The alternative hypopnoea definition requires a ≥ 50% reduction in airflow for 
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≥ 10 seconds associated with a ≥ 3% oxygen desaturation or electro-
encephalogram (EEG) arousal. Increased respiratory effort and arousals 
related to these may contribute to sleep fragmentation and are currently 
scored as Respiratory Effort Related Arousals or RERAs. (Berry et al., 2012). 
 
 Hypopnoeas have also previously been described according to the 
“Chicago Criteria” based on a 1999 consensus report published by the 
American Academy of Sleep Medicine (AASM, 1999) . These guidelines 
defined standardized scoring criteria for 2 types of hypopnoeas. The first 
were events with a 50% decrease in airflow (using a valid measure of 
airflow), without oxygen desaturation or arousal, and the second type of 
hypopnoea was a lesser subjective airflow reduction with a ≥ 3% oxygen 
desaturation or an arousal.  
 
 An Apnoea-Hypopnoea Index (AHI) is calculated as the total number 
of apnoeas and hypopnoeas divided by the Total Sleep Time (TST). The  
Respiratory Disturbance Index (RDI) is calculated as the total number of 
apnoeas, hypopnoeas, and RERAs divided by the TST. The AHI and RDI 
can be used to describe the frequency of respiratory events that can 
influence sleep fragmentation, and are currently used as markers for severity 
of sleep disordered breathing. 
 
 The Obstructive Sleep Apnoea Syndrome (OSAS) is defined as the 
presence of at least 5 obstructive respiratory events per hour of sleep in 
conjunction with excessive daytime sleepiness. Other frequently described 
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symptoms include snoring, gasping/ choking during sleep, unrefreshing 
sleep, sleep fragmentation, sleep maintenance insomnia, nocturia, morning 
headaches, decreased concentration, impaired short term memory, 
decreased libido, and irritability.  
 
 
4.2  Epidemiology 
 
 A number of studies with large samples representative of the 
population provide more recent estimates for OSA in various countries 
including Australia. The prevalence of the condition with accompanying 
daytime sleepiness has been estimated at 3-7% for adult men, and 2-5% for 
women (Punjabi et al., 2008). There are differences in disease prevalence 
depending on obesity, race, gender, and age. Data from the Wisconsin 
Cohort Study looked at age and gender specific prevalence and showed a 
prevalence of having sleep disordered breathing with an AHI > 5 events per 
hour of sleep was 9% for women and 24% for men. The prevalence of OSA 
with AHI greater than 15 was 4% for women and 9% for men.  
 
 More recent data from the Swiss population, with PSG data from 2121 
subjects demonstrated that the prevalence of moderate to severe OSA was 
23.4% in women and 49.7% in men, with an AHI >20.6 events per hour of 
sleep associated independently with the presence of hypertension, diabetes, 
metabolic syndrome and depression (Heinzer et al., 2015).  
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 The high prevalence of OSA in this population may be due increased 
sensitivity of current recording techniques and scoring criteria. The authors 
from this study suggested that the true prevalence in other Western 
Countries could be higher, since BMI is lower in Switzerland  than in other 
Western Countries  such as the USA. 
 
 There is an increase in the prevalence of OSA with ageing. In a 
random population of people aged > 65 years, 24% had an apnoea index > 5 
events per hour of sleep, with 62% having an RDI ≥ 10 events per hour of 
sleep (Ancoli-Israel et al., 1991) . 
 
 There is a strong predilection for a higher prevalence of OSA in males. 
This has been shown in numerous large cohort studies where men are more 
predisposed to OSA (Redline et al., 1994). The reasons of why this is so are 
not completely clear, and factors may include truncal and neck fat/ body fat 
distribution pattern in men, hormonal factors, and possibly differences in 
reporting patterns for symptomatic snoring and witnessed apnoeas. This is 
supported by evidence of increased prevalence of sleep disordered breathing 
in postmenopausal women (Bixler et al., 2001). 
 
 Prevalence may also differ depending on ethnicity and may be 
accounted for by differences in craniofacial anatomy. For example there is a 
higher prevalence among South East Asian and African populations that may 
be explained on the basis of differences in body fat distribution, habits, and 
craniofacial shape (Ralls and Grigg-Damberger, 2012). 
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4.3  Pathophysiologic Consequences and Burden of Disease 
 
 The consequence of OSA on mortality and morbidity have been 
investigated by observational cohort studies and population based studies. 
Increased mortality from cardiovascular complications was seen in the Sleep 
Heart Health Study (Shahar et al., 2001) while increased cardiovascular and 
cerebrovascular mortality was seen in untreated severe OSA patients (Marin 
et al., 2005). This study also demonstrated that CPAP therapy reduced 
mortality in severe OSA.  The postulated mechanisms whereby OSA leads to 
an increase in cardiovascular risk may be vascular/ endothelial dysfunction, 
systemic inflammation and metabolic dysregulation. Tissue vibration from 
snoring may lead to endothelial dysfunction inducing vascular disease (Cho 
et al., 2011, Lee et al., 2008). Oxidative stress during sleep apnoea may 
induce a cascade of inflammatory pathways which may have an effect on the 
progression of vascular disease. There is increased insulin resistance, and 
diabetes mellitus amongst OSA patients and treatment with CPAP therapy 
may mitigate glucose intolerance, possibly by ameliorating sleep deprivation 
and sympathetic activation (Spiegel et al., 1999). 
 
 The associated cardiovascular diseases include hypertension, cardiac 
failure and cardiac arrhythmias. The causal relationship between OSA and 
hypertension was demonstrated by the Wisconsin Sleep Cohort Study 
(Shahar et al., 2001). Furthermore, increasing severity of OSA increases the 
risk for developing hypertension. Randomised studies have shown that 
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treating obstructive sleep apnoea in mild hypertension may have a small yet 
significant effect in decreasing blood pressure (Becker et al., 1987). 
 
 There is an association between OSA and cardiac failure, firstly with 
an increased prevalence of OSA in heart failure patients, and secondly that 
there may potentially be increased nocturnal upper airway oedema in 
patients with cardiac failure, predisposing them to OSA. The Sleep Heart 
Health study demonstrated that the presence of OSA conferred an increased 
relative risk of developing cardiac failure. Fluid overload, such as that seen 
with cardiac failure and redistribution of body fluid may also predispose to 
sleep apnoea. In patients with drug resistant hypertension, it has been found 
that a rostral shift of fluid overnight is associated with a greater severity of 
OSA (Friedman et al., 2010) (Friedman et al., 2010). 
 
 Upper airways collapse that predisposes to snoring may lead to 
vibration induced damage that, in turn, may increase the risk of 
cerebrovascular disease. Heavy snoring may increase the risk of carotid 
atherosclerosis, independent of other risk factors including the degree of 
overnight hypoxia and severity of sleep disordered breathing. The prevalence 
of atherosclerosis was greater for severe snoring (64%) as compared to 
moderate (32%) or mild snoring (20%), with the severity of snoring 
determined by the proportion of the night spent with snoring (Lee et al., 
2008). The relationship between OSA and stroke risk has also been 
demonstrated in the Sleep Heart Health Study (Redline et al., 2010). 
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 Two recent meta-analyses have been published which describe firstly 
the risks of all-cause mortality, and secondly the effect of CPAP on 
cardiovascular events and mortality in OSA. Patients with OSA exhibit an 
increased risk in all-cause mortality, with those having severe OSA 
demonstrating a significantly increased mortality (Pan et al., 2016). CPAP 
therapy had no significant effect on mortality, stroke, and cardiovascular 
events compared with control groups, however, CPAP therapy was 
associated with a non-significant trend to lower mortality rate, reduced rate of 
stroke (Guo et al., 2016). 
 
 The increased risk of motor vehicle accidents has been associated 
with OSA, with the relationship clearly identified through many studies. A 
meta-analysis of studies looking at the relationship between OSAS and 
collisions found an overall estimated risk  (odds ratio) of 2.5 (Sassani et al., 
2004). Besides the increased motor vehicle accident risk, OSA is associated 
with increased accidents in the household and in the workplace (Hortsmann 
et al., 2000). Sleep related breathing disorders are also associated with 
depression, with an increase in the severity of OSA from mild to moderate 
being associated with a 1.8 fold increased adjusted odds for development of 
depression Peppard et al., 2006). 
 
 
 
 
 
 
 39 
4.4  Current Therapeutic Options 
 
 The current treatment modalities for OSA include weight loss, 
treatment or avoidance of factors that can precipitate sleep apnoea, devices 
such as CPAP or mandibular advancement devices, and surgery. The choice 
of treatment is predominantly determined by the severity of obstructive sleep 
apnoea. 
 
Conservative measures for the management of OSA include weight loss, 
positional therapy, avoidance of alcohol and sedatives, in addition to smoking 
cessation.  
 
 Measures such as avoidance of alcohol and sedating agents, may 
reduce the severity of OSA. Weight loss may improve indices of OSA, but 
response to dieting and lifestyle modification has a delayed effect. The 
reduction in weight, especially central adiposity, may reduce the adipose 
tissue around the upper airway, improve lung volumes, and ameliorate the 
blunting of neuromuscular response found in obesity, to reduce the severity 
of sleep disordered breathing (Schwartz et al., 2008). 
 
 Oral devices may be preferable in some patients with mild to moderate 
OSA and work by preventing or ameliorating  retroglossal collapse. A 
mandibular  advancement splint may be effective as an alternative to 
treatment for snoring, and mild to moderate obstructive sleep apnoea. Oral 
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appliances can improve subjective sleepiness and reduce the severity of 
OSA, but may be less effective than CPAP therapy (Lim et al., 2006). 
 
 CPAP therapy was first described as an effective means of preventing 
upper airways collapse in 1981 (Sullivan et al., 1981). CPAP works as a 
“pneumatic splint” for the upper airway, with intramural pressure exceeding 
the surrounding tissue pressure to maintain airway patency. CPAP therapy 
may alleviate the symptoms of OSA and improve symptoms of excessive 
daytime somnolence, and nocturnal snoring. The patients who are most 
symptomatic are more likely to have better long term compliance to treatment 
with CPAP therapy (Kohler et al., 2010). CPAP therapy has also benefits in 
being a cost effective management in reducing cardiovascular and 
cerebrovascular risk (Marin et al., 2005). 
 
 Surgery remains an option for patients with snoring and sleep apnoea, 
but the  magnitude of improvement in sleep disordered breathing is usually 
small. The options for surgical treatment includes uvulopalatopharyngoplasty, 
tongue reduction surgery, maxillary and mandibular advancement. An 
aggressive, radical surgical approach achieves a “cure” (AHI < 5 events per 
hour) rate of 43%, and remains an option for selected patients (Holty and 
Guilleminault, 2010). Tracheostomy completely bypasses the site of 
obstruction in the upper airway, but such an invasive approach may not 
appeal with less invasive options available. 
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 Hypoglossal nerve stimulation has emerged as an experimental 
surgical therapy but the clinical application of this procedure has not yet 
clearly been defined (Schwartz et al., 1993, Schwartz et al., 2001, Eastwood 
et al., 2011). 
 
 
4.5  Summary of Studies Investigating Surface Tension and 
       Upper Airway Collapse 
 
 Currently, exogenous surfactants are not utilised as mainstream 
therapy for obstructive sleep apnoea. Some over the counter sprays are 
available, and may reduce the surface tension in upper airway lining liquid, 
but their efficacy in the treatment of snoring and obstructive sleep apnoea 
has not been shown in any randomised controlled trials.  
 
 Earlier studies have shown that exogenous surfactant may reduce 
upper airway collapsibility and maintain upper airway patency in awake 
human subjects. A study which investigated the effect of instillation of 
surfactant vs saline into the upper airway of 5 subjects observed a decrease 
in opening pressures after exogenous surfactant (5ml Exosurf neonatal, 
Burroughs Wellcome Australia). Supraglottic airway measurements were 
taken by measuring the anteroposterior intraluminal diameter on X-ray 
fluoroscopy. Saline instillation did not produce any consistent reduction in 
closing pressure, while surfactant instillation resulted in a consistent 
reduction in closing pressure. Similarly, although there was no consistent 
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increase in the upper airway opening pressure with saline, there was a 
reduction in opening pressure with surfactant. In addition, it was observed 
that positive pressure was required to reopen a closed upper airway in the 
control or saline instillation patients, while no positive pressure was required 
to re-open a collapsed upper airway after surfactant instillation (Van der 
Touw et al., 1997). 
 
 The role of a soft tissue lubricant in sleep apnoea was previously 
investigated using phosphocholinamin (Sonarite; Guardian chemicals, New 
York, NY) in 10 subjects with previous polysomnography demonstrating mild 
to moderate OSA. The surface tension of this soft tissue lubricant was 
25.4mN/m at 37 degrees centigrade. 0.4 ml was introduced nasally by 
pipette at lights out, and also at 3.5 hours while placebo was administered on 
the other (control) night. There was a significant reduction in the AHI on the 
soft tissue lubricant night compared to the placebo night with all 10 subjects 
demonstrating a lower AHI. The AHI decreased from a mean AHI of 24 
events per hour of sleep on the placebo night to 14 events per hour of sleep 
on the lubricant night. This effect was seen in both supine (AHI reduction 
from 33 to 20 events/hour) and lateral sleep (AHI reduction from 18 to 11 
events/hour). There was a difference in effect of soft tissue lubricant between 
REM and NREM sleep however, with soft tissue lubricant resulting in a 
significant reduction of AHI in NREM sleep (25 to 14 events/hour),  while 
there was no reduction with soft tissue lubricant in REM sleep (Jokic et al., 
1998). 
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 Exogenous surfactant may decrease critical closing pressures by 3cm 
H2O post instillation (Kirkness et al., 2003c), and has been shown to reduce 
the frequency of hypopnoeas, although there is no significant reduction in 
frequency of apnoeas. Similar decreases in critical pressures have previously 
been demonstrated with postural change, with lateral sleep reducing opening 
pressures compared to supine sleep opening pressures (Neill et al., 1997). 
 
 The most recent series of studies investigating the role of surface 
tension in upper airway collapse, and obstructive sleep apnoea, are the 
studies performed by Kirkness and his co-workers. This series of studies 
have demonstrated that a higher surface tension in upper airways lining 
liquid promotes upper airway collapsibility, that lowering surface tension 
reduces the propensity to airway closure, and reduces opening pressures in 
a collapsed airway. In studies performed on anaesthetised rabbits, and 
subsequently on anaesthetised humans, lowering surface tension in the 
upper airway with exogenous surfactant administration, led to decreased 
critical opening pressures, reduced upstream resistance, promoting upper 
airway patency (Kirkness et al., 2003a, Kirkness et al., 2003b). In patients 
with obstructive sleep apnoea, instillation of exogenous surfactant reduced 
STUAL from 60.9 ± 3.1 mN/m to 45.2 ± 2.5mN/m, whilst reducing the Pcrit 
from 1.19 ± 1.14 cm H2O to -0.56 ± 1.15 cm H2O. There was a reduction in 
the RDI which correlated to the reduction in surface tension, with the main 
reduction in respiratory events due to a reduction in obstructive hypopnoeas 
(Kirkness et al., 2005b). There was a wide variation seen in the STUAL of 
these subjects, and proposed mechanisms included changes in salivary flow 
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across the night, changes in route of breathing, and pharyngeal mucosal 
properties. 
 
 The relationship between STUAL and route of breathing was 
investigated in awake subjects. Verma et al examined relationships between 
breathing route, oral mucosal wetness, and STUAL. The subjects were 
randomised to oral only or nasal only route of breathing for a period of 
120minutes, with sampling for measurement of upper airway mucosal 
“wetness” and STUAL taken at the beginning, and at 15 minute intervals. 
With enforced oral breathing route, there was a significant reduction in 
mucosal “wetness” , and concurrently a significant increase in STUAL over 
120 minutes by approximately 14 mN/m. Enforced nasal route of breathing, 
however, resulted in no significant change in mucosal wetness, and a 
decrease in STUAL of approximately 10 mN/m (Verma et al., 2006). This 
relationship between STUAL and route of breathing may potentially be 
important in determining upper airway patency, with increased oral route of 
breathing and increased surface tension promoting upper airway collapse.  
 
 The role of increased surface tension in upper airway collapse has 
also been investigated in patients with primary Sjogren’s  Syndrome. Patients 
with this condition suffer from symptomatic xerostomia, potentially leading to 
increased surface tension. These patients also demonstrate increased levels 
of sleepiness and fatigue, and despite their increased STUAL  compared to 
normal control subjects, they do not appear to have any significant difference 
in upper airway collapsibility index (Hilditch et al., 2008). The same research 
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team subsequently reported an increased prevalence of OSA amongst 
Sjogren’s syndrome patients, with primary Sjogren’s syndrome patients 
having twice the frequency of obstructive apnoeas and hypopnoeas 
compared with control subjects (Usmani et al., 2012).  
 
 In summary, OSA is characterized by repeated episodes of partial or 
complete upper airways collapse. Anatomical factors and muscle activation 
play major roles, but other factors such as surface tension may also play a 
significant role in upper airway collapsibility. There is evidence that surface 
tension forces play a role in upper airway collapsibility with changes in 
surface tension affecting upper airway collapsibility. Lowering the surface 
tension in upper airway liquid reduces closing and re-opening pressures in 
the upper airway, and instillation of exogenous surfactant is a method in 
which the surface tension forces of the airway may be manipulated. Other 
factors which include route of breathing, may also have a role in modifying 
the  surface tension  in upper airway liquid via local effects such as 
evaporation. 
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Chapter 5:  Surface Tension of Upper 
Airway Liquid in Healthy Subjects 
 
5.1  Introduction 
 
 Surface tension arises from cohesive forces between liquid molecules 
at a liquid-gas interface. Surface tension forces are present in the collapsible 
upper airways, and the STUAL influences upper airway opening and closing 
pressures. In previous work performed in our laboratory, the STUAL in 
healthy subjects and in OSA patients was studied. OSA patients were found 
to have a higher STUAL than healthy subjects (Mean [95% confidence 
interval] 59.9 mN/m [53.8, 58.8] vs 56.3 mN/m [57.7, 62.1] ) (Kirkness et al., 
2005b). No overnight difference in STUAL was found when evening and 
morning samples were compared in either group, although a reduction in 
STUAL was observed in those subjects with > 50% of total sleep epochs with 
nasal breathing.  This study observed a range of surface tension in both 
saliva and UAL in a small group of healthy subjects and OSA patients. 
However, it is not known if STUAL varies during the course of a 24 hour 
period, or if it follows any biological (i.e. circadian or diurnal) rhythm. The 
hypothesis raised was that saliva production would vary over a 24 hour cycle 
and follow a circadian rhythm, thereby potentially influencing measured 
STUAL values across the day. 
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5.2  Aims 
 
 The aim of the first part of this project is to establish, in healthy 
subjects, the range of baseline values for ST of Saliva and STUAL. The 
second aim is to determine the variability of STUAL and ST Saliva over a 24 
hour period. 
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5.3  Methods 
  
5.3.1  Subjects 
 
 Healthy subjects were recruited from amongst staff members from 
Westmead Hospital and from the Ludwig Engel Centre for Respiratory 
Research. Subjects were screened by the MAP Sleep Symptom Frequency 
Questionnaire (Maislin et al., 1995) to exclude sleep disordered breathing, 
with all subjects scoring a MAP  index < 0.6. Subjects were  excluded if they  
had a history of allergic rhinitis or snoring. No inhaled or oral medications 
were taken by any of the subjects for 12 hours prior to the study. 
 
 16 healthy volunteers were recruited for this study (10 female, 6 male; 
mean age ± SD: 33 ± 10.4 years, range 20 - 54 years; BMI 24.8 ± 3.2kg/ m2 , 
range 21.0 - 31.8kg/m2).  
 
 Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service Ethics 
Committee. 
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5.3.2  Measurements 
 
Surface Tension 
 Surface Tension of Upper Airway Lining Liquid was measured by the 
“Pull Off Force Technique” as discussed in more detail previously in chapter 
3 (figure 3.5) . Microliter volumes of upper airway lining liquid are placed 
between two silica discs, and the surface tension measured as the force 
required to separate the discs. 
 
Upper Airway Lining Liquid and Saliva Sampling 
 Upper airway lining liquid and saliva were sampled from the posterior 
oropharyngeal wall and sublingually respectively, with approximately 0.2 μL 
sampled from each site. Samples were aspirated into polyethylene tubing 
(Tyco Electronics; external diameter 0.8mm; internal diameter 0.5mm), using 
a 23g needle (BD Precision Glide 0.6mm x 32mm) attached to a 3ml syringe 
(Terumo Medical Corporation 3cc / ml). Surface tension of UAL or saliva was 
measured by the “Pull Off Force Technique”. 
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5.3.3  Protocol 
 
 All subjects abstained from any food or drink for 30 minutes prior to 
the study. Nasal only route of breathing was enforced (mouth taped) for 15 
minutes prior to sampling of UAL and saliva. Sample collection was 
performed with the subject in the upright seated position, with salivary or 
posterior pharyngeal wall samples collected as described above. 
 
 UAL samples were obtained at 3 hourly intervals from 0900 hrs to 
1800 hrs, with sampling the following morning at 0900 hrs.  
 
 Salivary samples were obtained at 3 hourly intervals from 0900 hrs to 
2100 hrs with sampling the following morning at 0600 and 0900 hrs.  The 
0600 hrs salivary collection was performed by the subject either at, or as 
close to 0600 hrs as possible.  
 
 All subjects remained nil by mouth for 30 minutes with 15 minutes of 
enforced nasal breathing before each sampling. Subjects were, however, 
permitted to eat and drink outside of these periods.  Route of breathing was 
not enforced outside of sampling periods. 
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5.3.4  Data Analysis 
 
 Data were expressed as mean ± SEM and compared using repeated 
measures ANOVA. Single comparisons were made using paired t-test. 
Variance was expressed as coefficient of variation (CV). Relationships 
between STUAL, ST Saliva, and time of day were statistically modelled using 
linear mixed effects modelling. Correlations were examined using linear 
regression. P < 0.05 was considered significant.  
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5.4  Results 
 
 The overall range of surface tension values obtained for both STUAL 
and ST Saliva for all subjects across all time periods is demonstrated in 
Figure 5.1. The surface tension for saliva and UAL ranges from 56 mN/m to 
71.4 mN/m. 
 
 The ST of saliva was positively correlated with the STUAL across all 
time periods (Figure 5.2). Additionally, there were no significant differences 
between STUAL and ST of Saliva when data were compared across all 
common time points. However, there was a large variability in differences 
between ST of saliva and STUAL of up to approximately 9mN/m within the 
same time point (Figure 5.3). 
 
 The values of STUAL across all time periods demonstrated a mean of 
63.7 mN/m, with a range from 56.5 mN/m to 70.4 mN/m. The mean values at 
sequential time points were: 0900 Hrs = 63.8 ± 0.9 mN/m, 1200 Hrs = 62.9 ± 
0.9 mN/m, 1500 Hrs = 63.6 ± 0.9 mN/m, 1800 Hrs = 64.5 ± 0.8 mN/m, 0900 
Hrs (following morning) = 63.7 ± 0.9 mN/m (Figure 5.4). 
 
 Across all time periods, the mean intra-subject coefficient of variation 
was 3.3% with a range of 1.4% to 7.6%. The mean inter-subject coefficient of 
variation was 5.5% with a range of 5.1 to 5.8% .  
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 For ST of Saliva, the values across all time periods demonstrated a 
mean of 63.9 mN/m, with a range from 56.0 to 71.4 mN/m. Mean values at 
sequential time points  were: 0900 Hrs = 62.7 ± 1.0 mN/m, 1200 Hrs = 63.5 ± 
0.9 mN/m, 1500 Hrs = 63.7 ± 0.7 mN/m, 1800 Hrs = 65.1 ± 0.9 mN/m, 2100 
Hrs = 64.3 ± 0.9 mN/m, 0600 Hrs = 64.4 ± 1.0 mN/m, 0900 Hrs (following 
morning) = 63.6 ± 1.1 mN/m. (Figure 5.5). 
 
 Across all time periods, the mean intra-subject coefficient of variation 
was 3.4% with a range of 1.8% to 5.5%. The mean inter-subject coefficient of 
variation was 5.9% with a range of 4.6% to 5.8%  
 
 The variation in STUAL and ST Saliva was also analysed using a 
Mixed Effects Model to look for any significant trend during the sampling 
period undertaken. The STUAL appeared unaffected by the time of day, 
while ST Saliva varied with time of day, with ST values reaching a peak in 
the evening at the 1800 Hrs sampling time (Figure 5.6). 
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Figure 5.1   Range of Surface Tension values for Saliva and UAL 
Frequency histogram with the count of ST values in 1 mN/m bins for the full range of both 
STUAL and ST Saliva values for all subjects and all collection times. UAL = Upper Airway 
Liquid. 
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Figure 5.2   STUAL vs ST of Saliva 
STUAL correlated well with ST Saliva across all time periods. Line = regression line. ST = 
Surface Tension; UAL = Upper Airway Liquid; STUAL = Surface Tension Upper Airway 
Liquid. 
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Figure 5.3   Bland-Altman graph of STUAL and ST Saliva 
Bland-Altman graph of Average ST of UAL and ST of Saliva vs the difference between ST of 
Saliva and ST of UAL. No overall difference between STUAL and ST Saliva at all common 
time points. There was some variability seen in differences between ST of Saliva and ST of 
UAL (up to ~ 9mN/m) but generally less than 5 mN/m. Blue lines = 95% Confidence Interval 
limits. Dashed green line = mean difference. Thin black line = zero difference. ST= surface 
tension; UAL = Upper Airway Liquid 
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Figure 5.4  Group mean (± SEM) values for STUAL at sequential time points 
There was little change in ST of UAL values across the time points sampled. The mean 
values at sequential time points were: 0900 Hrs = 63.8 ± 0.9 mN/m, 1200 Hrs = 62.9 ± 0.9 
mN/m, 1500 Hrs = 63.6 ± 0.9 mN/m, 1800 Hrs = 64.5 ± 0.8 mN/m, 0900 Hrs (following 
morning) = 63.7 ± 0.9 mN/m. The horizontal bars represent 95% Confidence Interval limits. 
ST = Surface Tension; UAL = Upper Airway Liquid. 
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Figure 5.5  Group mean (± SEM) values for ST of Saliva at sequential time points 
Mean values at sequential time points were: 0900 Hrs = 62.7 ± 1.0 mN/m, 1200 Hrs = 63.5 ± 
0.9 mN/m, 1500 Hrs = 63.7 ± 0.7 mN/m, 1800 Hrs = 65.1 ± 0.9 mN/m, 2100 Hrs = 64.3 ± 0.9 
mN/m, 0600 Hrs = 64.4 ± 1.0 mN/m, 0900 Hrs (following morning) = 63.6 ± 1.1 mN/m. The 
horizontal bars represent 95% Confidence Interval limits. ST = Surface Tension. 
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Figure 5.6  Mixed Effects Models for STUAL and ST of Saliva 
Mixed Effects Models for ST of Saliva (red line = quadratic) and STUAL (blue line = linear) 
versus time. ST of UAL did not vary with time. ST of Saliva varied with time of day according 
to the relationship: ST of Saliva = 64.9 + 0.04 (time) - 0.01 (time)2  (p<0.05).  
Zero time = 2100 hours 
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5.5  Discussion 
 
 This study demonstrated a range of normal surface tensions for UAL 
and saliva in healthy subjects, and established a range of surface tension 
values over a 24 hour period for saliva and UAL in these subjects. Whilst 
there was a trend towards higher ST Saliva in the evening, the STUAL did 
not change across the day and evening when route of breathing is controlled. 
 
5.5.1  Critique of Methods 
 
 The ST Saliva and UAL were measured using the previously 
described “Pull Off Force technique”. Compared to the values obtained by 
Kirkness et al, the mean values for ST of both UAL and Saliva appeared 
higher. The mean ST of UAL in anaesthetized human subjects is 62 mN/m 
(Kirkness et al., 2003b), whilst the mean ST of UAL in this study was 63.7 
mN/m. In the Kirkness et al study looking at ST values and OSA, both normal 
subjects and OSA patients were studied with sampling performed at 10pm in 
the evening and between 5.30-6.00 am the following morning (Kirkness et 
al., 2005b). Overnight, there were no meals between evening and morning 
sampling, and since the subjects were asleep for the most part there was no 
vocalization or conversation as would be expected from normal activities of 
subjects in the daytime. In the present study, sampling times were different, 
with five sampling times for UAL and seven sampling times for Saliva. During 
the day, in between sampling times, the subjects were permitted to talk, eat, 
or drink with the exception of 30 minutes before sampling time. Variable oral 
route of breathing, in addition to food and drink intake across the day in-
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between sampling times, may potentially effect the surface tension of both 
UAL and Saliva and account for the apparent differences in ST values in this 
study compared with previous studies.  
 
 Despite multiple samplings of UAL and Saliva, there was a prolonged 
period overnight where sampling was not performed. There was a sampling 
for ST Saliva, but not STUAL at 6.00 am in the morning (the ST Saliva 
sample was self-collected by the subject at 6.00 am). Route of breathing was 
not controlled during this period of time, and oral route of breathing may 
potentially have evaporative effects leading to changes in surface tension 
overnight which we have not measured. 
 
 Otherwise, the methodology used in the sampling and processing of 
UAL and Saliva sample for the purpose of measuring ST was identical to that 
used previously in our laboratory. 
 
 
5.5.2  ST Saliva and STUAL 
 
 The ST of Saliva tended to be slightly higher in the evening. Linear 
effects model of the data for ST of Saliva demonstrated a quadratic 
relationship with time, with increased values in the evening, and with 
maximal recorded values at approximately 2100 hours. The postulated 
mechanisms for this may include uncontrolled route of breathing during the 
day between sampling times, in addition to oral intake of food and liquids 
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potentially affecting subsequent measured surface tension of sampled fluids. 
In this study, the subjects were kept nil by mouth for 30 minutes prior to 
sampling, however, it remains unclear regarding the magnitude and duration 
of effect of food or drink on surface tension. Factors such as eating or 
drinking food or liquid with higher surface tensions, talking (with increased 
associated oral breathing route), and possibly changes salivary production 
with diurnal rhythm may potentially  lead to the gradual increase in surface 
tension of saliva seen by the evening.  
 
 There is a diurnal rhythm in salivary production, with decreased levels 
of saliva seen overnight. Unstimulated whole saliva does demonstrate a 
significant circadian effect, particularly with flow, rate, as well as sodium and 
chloride content (Dawes, 1975), and this may have an influence on the 
surface tension of saliva, potentially contributing to a circadian pattern of 
surface tension values over a 24 hour period. 
 
 Saline has a relatively high surface tension in comparison to water 
(approximately 82 mN/m vs 70 mN/m). Most western diets have a significant 
salt content, with a typical daily intake of approximately 10 g/day (Brown et 
al., 2009). This may potentially account for some of the increase in ST Saliva 
seen across the day as meals are consumed. Since the salivary sample was 
taken sublingually, to some degree it may reflect the surface tension of fluids 
/ salt content of ingested food and liquids across the day. 
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 Interestingly, STUAL did not demonstrate any significant change over 
the course of the day. The reasons and potential for increased oro-nasal 
route of breathing during working hours are identical to those which may be 
responsible for the increase in ST of saliva, however, whilst ST saliva 
changes with time of day, STUAL remains stable. The sampling of STUAL is 
from the posterior pharyngeal wall rather than sublingually for ST Saliva, and 
may be less affected by ingested food or drink. While the ST of sublingual 
samples may be affected by the surface tension of ingested food/ liquids, the 
posterior pharyngeal samples represent fluid that may be a composite of 
sublingual, submandibular, and parotid glands, in addition to surfactant 
containing mucus and liquid from the nasopharyngeal mucosa. Hence, 
although the STUAL and ST Saliva were positively correlated, there are 
possible reasons why the surface tension values may differ related to both 
the origin of the fluid and to different environmental exposures during the 
course of the day. 
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5.6  Conclusion: 
 
 In conclusion, for healthy subjects, ST of Saliva tends to be slightly 
higher in the evening than the morning. The reasons for this may relate to the 
influence of route of breathing and oral intake of food and drink on the 
surface tension of saliva in the sublingual sampling site, and/or to the origin 
of the actual fluid.  
 
 The STUAL appears to be relatively stable across the day.  This 
implies that the origin of the fluid may differ or that the environmental 
influences in the posterior pharynx are different to those in the mouth.  
 
 In this study, we have been able to establish a range of surface 
tension values over a 24 hour period for healthy subjects. Although there is 
considerable variability in individual measures of STUAL, the values remain 
relatively constant over a 24 hour period. Overall, ST of Saliva and STUAL 
values are very similar, with their means being 63.7 and 63.9 mN/m 
respectively. However, dependent upon the time of day, the ST of saliva may 
not accurately reflect the ST of UAL. Therefore, studies investigating the 
surface tension properties of the upper airway should continue to take 
samples from the posterior pharyngeal airway and not use saliva as a 
substitute. 
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Chapter 6:  Surface Tension of Upper 
Airway Liquid in Obstructive Sleep Apnoea 
Subjects 
 
6.1  Introduction 
 
 In the previous chapter, a range of surface tension values for both 
saliva and UAL was demonstrated for healthy subjects with no history of 
OSA. A range of surface tension values for UAL has been previously 
published by Kirkness et al who examined the surface tension of UAL in both 
healthy subjects and patients with OSA before and after sleep (Kirkness et 
al., 2005b).  The results were described for 11 healthy adult subjects (5 men, 
6 women), and 15 patients with OSA (14 men, 1 woman). The mean STUAL 
for the OSA group in this study was 59.9 mN/m, compared with 56.3 mN/m in 
the healthy subject group (pooled AM and PM samples). These values are 
lower compared with the healthy subjects studied in the previous chapter, but 
fall within the broad range of surface tension values described.   
 
 For other patient groups, the surface tension for human saliva has 
previously been described in cystic fibrosis patients and in the dental 
literature (Braddock et al., 1970), and more recently in patients with Primary 
Sjogren’s Syndrome (Hilditch et al., 2008). In contrast, the surface tension of 
UAL has only been described in a limited number of OSA subjects. 
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Previous measurements of STUAL in OSA subjects have demonstrated an 
increase in ST when compared with healthy subjects, of approximately 3.5 
mN/m (Kirkness et al., 2005b).  The authors suggested this result should be 
interpreted with caution in light of the small difference and the small sample 
size.  
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6.2  Aims 
 
 The aim of the work in this chapter is to determine the range of 
surface tension values in a larger cohort of subjects diagnosed with 
untreated OSA. The secondary aim is to examine the OSA patient cohort for 
any factors associated with the STUAL including, but not limited to, age and 
the severity of sleep disordered breathing. 
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6.3  Methods 
 
6.3.1  Subjects 
 
 Study subjects were recruited from the Westmead Hospital Sleep 
Laboratory between June 2008 and June 2011. Subjects were recruited from 
patients referred to the Sleep Laboratory for investigation of possible sleep 
disordered breathing. Subjects who were current smokers, aged less than 18 
years or older than 80 years were excluded from the study. None of the 
subjects had prior sleep studies nor did they have any history of prior CPAP 
use. Of the 95 subjects recruited, 22 were females and 73 were males. Age 
ranged from 23 years to 82 years with a mean ± SD of 52 ± 13.8 years. BMI 
ranged from 21.5 kg/m2 to 65.6 kg/m2 with a mean of 31.7 ± 7.3 kg/m2 . 
 
 Subjects were also excluded if they were current smokers, had a 
current upper respiratory tract infection, any inflammatory condition or 
medical illness affecting the mouth or upper aerodigestive tract mucosa, 
previous head and neck irradiation, and any history of airways disease 
requiring inhaled anticholinergic or inhaled steroid medication. Inhaled 
anticholinergic agents such as tiotropium or ipratropium and inhaled steroids 
were identified as medications which could potentially affect salivary or upper 
airways secretion production, which may, in turn affect ST values. 
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 Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service Ethics 
Committee. 
 
 
6.3.2  Measurements 
 
Surface Tension 
 Surface Tension of Upper Airway Lining Liquid (STUAL) was 
measured by the “Pull Off Force Technique”. This technique is the same as 
that used in the measurement of ST in previous chapter and is described in 
further detail previously in chapter 3 (Figure 3.5). Following sampling of UAL 
and Saliva from the subject, microliter volumes of upper airway lining liquid 
are placed between two silica discs, and the force required to separate the 
discs with the microliter volume of liquid bridging both disc surfaces, is taken 
to be the surface tension. 
 
Upper Airway Lining Liquid and Saliva 
 Upper airway lining liquid was sampled from the posterior oropharynx 
and saliva sampled sublingually. Samples were aspirated into polyethylene 
tubing (Tyco Electronics; external diameter 0.8 mm; internal diameter 0.5 
mm), using a 23g needle (BD Precision Glide 0.6mm x 32mm) attached to a 
3ml syringe (Terumo Medical Corporation 3cc / mL). 
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 Samples (microlitre volumes) were then applied onto the surface of a 
silica disc for measurement of surface tension in the surface force 
measurement device using the “Pull Off Force” technique. 
 
 
Polysomnography 
 The study was conducted over a single night, and all 
polysomnographic studies were undertaken at the Westmead Hospital Sleep 
Laboratory. The variables monitored overnight included EEG 
(electroencephalogram), ECG (electrocardiogram), submental and 
diaphragmatic EMG (Electromyogram), left and right EOG (electro-
oculogram), respiratory inductance plethysmography (for thoraco-abdominal 
movement), arterial oxygen saturation, sound, and body position, whilst oral 
and nasal airflow was monitored using nasal pressure cannulae (1600 Nasal 
Cannula; Salter Labs Inc., Arvin, CA, USA) and oro-nasal thermistors (F-
ONT2A; Grass, West Warwick, RI, USA). Video monitoring was recorded for 
all subjects. All signals were recorded on a Compumedics Profusion 3 
software system. Sleep staging was performed on the overnight EEG using 
Rechtschaffen and Kales rules (Rechtschaffen and Kales 1968) to score 
sleep staging, while  obstructive events were scored using “Chicago” criteria 
(AASM, 1999). Arousals from sleep were scored based on American Sleep 
Disorders Association criteria (Bonnet M, 1992). 
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6.3.3  Protocol 
 
 The study was conducted over one night at the Westmead Hospital 
sleep laboratory. Subjects arrived at the Westmead Hospital Sleep 
Laboratory between 1700 and 1900 hours on the night of their diagnostic 
sleep study. Upon arrival in the sleep laboratory, the subjects were set up by 
the sleep laboratory sleep technicians after patient identification and PSG 
documentation was checked. Subjects were then set up with PSG monitoring 
which included EEG with electrode placement based on the international 10-
20 system (Klem et al., 1999), EMG, EOG, ECG, respiratory inductance 
plethysmography, finger oximeter probe, nasal pressure cannulae and oro-
nasal thermistors. Signals were then verified by the sleep laboratory 
technician. Sampling of Saliva and UAL occurred following patient set-up and 
calibration and was performed in the sleep laboratory.  
 
 Subjects remained nil by mouth for one hour prior to sampling time, 
which was between 2100 and 2200 hours. The subject spent a minimum of 
15 minutes of nasal only breathing prior to sampling. Sampling of both UAL 
and Saliva was performed whilst the subject was awake and in the seated 
position, with UAL and salivary sampling performed using the polyethylene 
tube aspiration method as described above. Samples contained within the 
polyethylene tubes were taken within 1-2 hours of sampling for measurement 
ST using the “Pull Off Force” technique on the evening of the study. 
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6.3.4  Data Analysis 
 
Sleep Parameters 
 Sleep studies were scored for sleep stage using Rechtschaffen and 
Kales criteria (Rechtschaffen and Kales 1968).  The Respiratory Disturbance 
Index  (RDI) was derived from flow signals using a nasal pressure transducer 
and a nasal thermistor to determine the aggregate number of apnoeas and 
hypopnoeas per hour of sleep. Respiratory Events were identified using 
American Academy of Sleep Medicine “Chicago” Criteria (AASM Task Force; 
Sleep 1999). An obstructive apnoea was defined as a 10 second or greater 
absence of airflow with oximetry demonstrating a 3% or greater reduction in 
oxygen saturation in comparison to baseline oximetry. Two types of 
obstructive hypopnoea (duration of which being 10 seconds or greater) were 
defined according to AASM “Chicago Criteria”, 1) as greater than a 50% 
reduction in a valid measure of airflow or 2) those with a lesser airflow 
reduction together with oximetry demonstrating a 3% or greater reduction in 
oxygen saturation (compared to baseline) or terminating in an EEG arousal 
(AASM, 1999).  
 
 The overall Respiratory Disturbance Index (RDI) was calculated as the 
total number of both obstructive apnoeas and hypopnoeas divided by the 
total sleep time during overnight polysomnography. The Arousal Index (AI) 
was calculated as the total number of EEG arousals divided by the Total 
Sleep Time (TST). The Sleep Efficiency (SE) was calculated by dividing the 
total number of minutes of sleep divided by the number of minutes in bed. 
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Statistical Analysis 
 All data were expressed as mean ± SD and compared using repeated 
measures ANOVA. Single comparisons were made using paired t-test. 
Correlations were examined using linear regression.  
Statistical data were graphically represented and analysed using Graphpad 
Prism version 6.0.  A p-value < 0.05 was considered significant. 
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6.4  Results 
 
6.4.1  STUAL vs ST Saliva 
 
 The mean evening STUAL for all subjects was 61.4 ± 5.2 mN/m with 
the range being 45.1 mN/m to 73.7 mN/m (Figure 6.1). The mean evening 
ST Saliva for all subjects was 61.3 ± 5.1 mN/m with values ranging from 49.5 
mN/m to 77.2 mN/m (Figure 6.2).  
 
 Similar to the previous chapter for healthy subjects, the values for 
STUAL and ST Saliva in subjects with OSA demonstrated no significant 
overall difference (Bland-Altman, Figure 6.3).  The group mean difference 
between ST of UAL and Saliva was 0.1 ± 0.7 mN/m and there was no 
significant difference in the mean values. There was a strong correlation 
between STUAL values and ST Saliva values with r = 0.78 (p < 0.0001) 
(figure 6.4). 
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6.4.2  STUAL and ST Saliva vs age 
 
 For the group as a whole, there was no correlation between STUAL 
and  age (Figure 6.5).  However, when only subjects aged ≥ 40 years with an 
RDI ≥ 30 events per hour were considered (32 out of 95 subjects), there was 
an association between STUAL and age in this sub-group with severe OSA, 
with STUAL demonstrating an increase with ageing (Figure 6.6).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
Figure 6.1   Frequency Histogram for STUAL in OSA subjects 
Frequency Histogram (bins of 2 mN/m) for STUAL (mN/m) obtained from 95 OSA subjects. 
The mean evening STUAL for all subjects was 61.4 ± 5.2 mN/m. STUAL = Surface Tension 
Upper Airway Liquid. 
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Figure 6.2  Frequency Histogram for ST Saliva in OSA subjects 
Frequency Histogram (bins of 2 mN/m) for ST Saliva (mN/m) obtained from 95 OSA 
subjects. Mean evening ST Saliva for all subjects was 61.3 ± 5.1 mN/m. ST = Surface 
Tension 
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Figure 6.3  Bland-Altman graph for STUAL vs ST Saliva in OSA subjects 
Bland Altman graph of average STUAL and ST Saliva vs the difference between STUAL and 
ST Saliva. No significant difference was observed between STUAL and ST Saliva (mean 
difference was 0.1 ± 0.7 mN/m = dotted black line). Dashed lines = 95% Confidence Interval 
limits. ST = Surface Tension; STUAL = Surface Tension Upper Airway Liquid. 
 
 
 
50 60 70 80
-10
-5
0
5
10
Mean ST (mN/m)
(STUAL and ST Saliva)
ST
UA
L-
 S
T 
Sa
liv
a 
 (m
N/
m
)
STUAL vs ST Saliva
 
 
 79 
 
Figure 6.4  Relationship between ST Saliva and STUAL 
There was a strong correlation between ST Saliva and STUAL values (r = 0.78, p <0.0001). 
Solid line = linear regression line. Dashed lines = 95% Confidence Interval limits. ST = 
Surface Tension. STUAL = Surface Tension Upper Airway Liquid. 
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Figure 6.5  STUAL vs age for OSA subjects 
Surface tension of the upper airway lining liquid (STUAL) for the whole OSA group as a 
function of increasing age. There was no association between age and STUAL when the 
subject group was observed as a whole. STUAL = Surface Tension Upper Airway Liquid. 
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Figure 6.6  STUAL vs age ≥ 40 years (OSA subjects) 
Relationship between STUAL and Age for subjects aged ≥ 40 yrs with severe OSA (RDI ≥ 30 
events per hour). For patients with severe OSA, increasing age was associated with 
increasing STUAL (r = 0.39, p = 0.03). Solid line = linear regression line. Dashed lines = 95 
% confidence interval limits. STUAL = Surface Tension Upper Airway Liquid.  
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6.4.3  STUAL vs RDI 
 
 The mean RDI for the group was 30.9 ± 22.5 events per hour, with the 
range varying between 2 to 97 events per hour of sleep (Figure 6.7).  
 
 The data were examined for other univariate relationships besides RDI 
and STUAL.  There was no significant correlation found between the RDI and 
ST of Saliva. Other sleep parameters including sleep efficiency and arousal 
index were examined for an association with STUAL and ST Saliva, 
however, no significant associations were found.  
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Figure 6.7  STUAL vs RDI in OSA subjects 
STUAL for the whole OSA group as a function of increasing RDI. STUAL = Surface Tension 
Upper Airway Liquid. RDI = Respiratory Disturbance Index. 
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6.5  Discussion 
 
 This study demonstrated a wide range of surface tension values in 
subjects with OSA. There was a strong correlation between STUAL and ST 
of Saliva in this group of OSA subjects. In general, age did not influence 
STUAL in OSA patients. However, in older subjects with severe OSA, 
increasing age was weakly associated with increasing STUAL. 
 
 
6.5.1  Critique of Methods 
 
 Although all the subjects in this study were kept nil by mouth in the 
hour before sampling, they were not controlled for food or liquid intake prior 
to this. Similarly, the route of breathing was not controlled prior to the 
enforced period of nasal breathing for 15 minutes before sampling time. It 
remains unclear as to the magnitude and duration of effect that ingested food 
or liquids will have on STUAL.  Furthermore, despite criteria which excluded 
subjects with smoking, inhalers, medical conditions or inflammatory 
conditions which may affect the nature and volume of saliva produced, many 
of the prescribed drugs in use by our patients for common medical conditions 
have the potential to either be present in saliva, or may affect salivary output 
(Wolff et al., 2008), hence potentially affecting both ST of Saliva and STUAL. 
This could potentially account for some of the variation in STUAL values. 
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 Previous published work from our laboratory also demonstrates a 
significant effect of breathing route upon STUAL (Verma et al., 2006). In that 
study a significant difference in STUAL between oral and nasal route of 
breathing was not observed until 90 minutes into the enforced route of 
breathing challenge. In the present study, enforced nasal route of breathing 
was undertaken for only 15 minutes prior to the evening sample time for 
practical reasons. It remains unclear the degree to which the route of 
breathing in the hours prior to sampling in this study may have influenced 
evening STUAL and ST Saliva values. 
 
 Additionally, the single sample of both UAL and Saliva collected in the 
evening prior to “lights out” reflects the STUAL and ST Saliva at the time of 
collection. This value for STUAL and ST Saliva may not be representative of 
the values overnight or across the day (Chapter 5), and may potentially be 
influenced by the other factors described above. 
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6.5.2  STUAL and ST Saliva 
 
 Values measured for STUAL and ST Saliva were not significantly 
different with the group mean difference being 0.1 ± 0.7 mN/m. As such, 
based on the results of this current study, and with the liquid lining of the oral 
cavity and the posterior oropharyngeal wall presumably predominantly 
comprised of saliva, under appropriately controlled circadian timing and 
environmental conditions STUAL and ST Saliva may be regarded as having 
essentially the same surface tension.  
 
 The mean evening STUAL in this group of OSAHS patients is very 
similar to previous results published in a smaller group of patients with 
OSAHS (60.1 mN/m vs 61.4 mN/m[current study]) (Kirkness et al., 2005b). 
There was a wide range of values observed in this study, with the lowest 
evening STUAL being 45.1 mN/m and the highest value being 73.7 mN/m. 
The minimum value seen in this study is similar to that observed in subjects 
given exogenous surfactant (Kirkness et al., 2003c), and there were two 
subjects with STUAL values below 50 mN/m. These values are inconsistent 
with surface tension values seen in human STUAL and ST Saliva, and may 
possibly be due to ingested food or drink in the hours prior to the period of nil 
by mouth and enforced nasal breathing prior to evening sampling.  
 
 Food or liquid containing alcohol, or foods which contain certain 
phospholipids may affect the surface tension of upper airways lining liquid 
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(van der Touw T et al. Retention of ingested phospholipids on the oral 
mucosa, Respirology, 2009), and the duration of the effect upon surface 
tension may potentially be longer than the period of “nil by mouth” the 
subjects underwent in this current study.  
 
 The highest surface tension values for UAL seen in this study are the 
same as the surface tension seen in normal saline (0.9% w/v of NaCl), which 
has one of the highest surface tension values of any liquid with the exception 
of liquid mercury. Overall, there were 4 subjects who had evening STUAL 
values greater than 70 mN/m, and values of 70 to 73mN/m are usually 
observed in saline solution (dependent upon concentration and temperature). 
Again whether these “high range” evening STUAL values are due to external 
influences such as ingested food or liquid prior to the “nil by mouth” period 
specified in the study protocol, remains unclear. 
 
 
 
6.5.3  STUAL and Age 
 
 For the group as a whole, there was no correlation seen between 
STUAL and age. However, for the subgroup of OSA subjects ≥ 40 years of 
age with a RDI ≥ 30 events per hour of sleep (i.e. older OSA subjects with 
severe disease), there was an association between increasing STUAL with 
increasing age. 
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The association demonstrated in this study for higher STUAL with increasing 
age in subjects with severe OSA may potentially be due to the effect of route 
of breathing in older subjects. Oral breathing, nasal breathing, and oro-nasal 
breathing all occur during sleep in variable proportions. Verma, et al. 
demonstrated that increased oral breathing during daytime hours increases 
STUAL, and the same effect is likely to occur with increased oral breathing 
during sleep (Verma et al., 2006).  
 
There is evidence of a positive association between age and oro-nasal route 
of breathing during sleep, with a strong correlation between  oral breathing 
and age in males in a small study (Gleeson et al., 1986), with a larger study 
in  healthy subjects without OSA demonstrating an association between age 
≥  40 years and oro-nasal route of breathing, but only a weak association 
was observed (Madronio et al., 2004). In this study, by Madronio, et al. the 
authors found that subjects ≥ 40 years of age were approximately six times 
more likely than younger subjects to spend > 50% of the night with oro-nasal 
breathing route.  
 
The present study does not address the question of whether or not route of 
breathing may influence the STUAL. However, the association demonstrating 
higher STUAL with increasing age in subjects with severe OSA raises the 
question of whether or not this outcome is, at least partially, influenced by the 
breathing route. There are no data demonstrating that STUAL changes 
simply due to increasing age, but a potential mechanism for any increase in 
STUAL may be via changes in breathing route with increasing age. 
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6.6  Conclusion 
  
 This study demonstrates a wide range of STUAL values in the largest 
group of subjects with OSA tested to date. The mean surface tension values 
are similar to previous studies performed in this laboratory by Kirkness et al. 
(2005), but the present study demonstrates a wider range in values, with 
some values as low as those seen with exogenous surfactant, and some 
higher range values similar to the surface tension of normal saline. 
Additionally, the ST saliva and STUAL values demonstrated a strong 
correlation. 
 
The finding of a positive association between older subjects with severe OSA 
(aged ≥ 40years) and increased STUAL is unexpected and the mechanisms 
which may potentially underlie this remain unknown, but the route of 
breathing during sleep is a major plausible mechanism. The following chapter 
will investigate the relationship between STUAL and overnight route of 
breathing with the aim of exploring potential underlying mechanisms. 
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Chapter 7:  Non-enforced Breathing Route 
and Surface Tension of Upper Airway 
Liquid in Subjects with Obstructive Sleep 
Apnoea 
 
7.1  Introduction 
 
 Although there are data regarding the route of breathing during sleep 
in subjects without evidence of obstructive sleep apnoea (Madronio et al., 
2004) there are limited observational data regarding the route of breathing 
during sleep in subjects with OSA. Furthermore, there are few data regarding 
the effect of route of breathing upon overnight STUAL, and whether or not 
this may, in turn, affect the collapsibility of the upper airway in a subject with 
OSA.  
 
Breathing route may potentially affect the collapsibility of the upper airway in 
sleep disordered breathing. The degree of jaw or “bite opening” may be an 
anatomical factor in upper airway collapsibility in OSA (Meurice et al., 1996), 
whilst patients with a greater proportion of the night spent oral breathing may 
have more episodes of apnoea (Gleeson et al., 1986). Mouth opening may 
also increase the critical pressure for collapse at the velo- or oro-pharyngeal 
level without changing the airway patency upstream towards the nose, with 
anatomical and neuromuscular mechanisms accounting for upper airway 
collapsibility (Ayuse et al., 2004) i.e. posterior movement of the jaw may 
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cause a reduction in size of the upper airway predisposing to airways 
collapse at the level of the oropharynx. A change in length-tension 
relationship of upper airways muscles due to this posterior jaw translation 
may affect the ability of these upper airway muscles to maintain patency. 
 
The breathing route may influence upper airway collapsibility via anatomical 
or neuromuscular mechanisms. In addition, breathing route may also 
influence upper airway patency by an effect upon STUAL. Saliva contains 
surface active phospholipids and this contributes to the surfactant effect. The 
previous chapters have examined STUAL and ST Saliva values in both 
healthy subjects and also in subjects with OSA. The mean value for STUAL 
and ST Saliva in OSA patients in the previous chapter was ~ 61 mN/m. 
Enforced oral route of breathing in normal subjects during the day has shown 
that the value of STUAL may increase up to 77 mN/m after 120 minutes of 
enforced oral breathing (Verma et al., 2006). 
 
Therefore, route of breathing during sleep  may also influence the 
collapsibility of the upper airway via surface tension mediated mechanisms, 
with nasal breathing reducing STUAL potentially leading to a reduction in the 
severity of OSA, and oral breathing increasing STUAL, potentially increasing 
the severity of OSA.  
 
 
 
 
 
 
 92 
7.2  Aims 
 
 The aim of the study described in this chapter is to measure both the 
evening and morning STUAL values for subjects with OSA, and to determine 
if there is a relationship between the change in overnight STUAL and the 
route of breathing overnight. 
 The secondary aims include measuring any changes in both the 
mucosal wetness and salivary flow between evening and morning sampling 
to determine any relationship with route of breathing overnight. 
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7.3  Methods 
 
7.3.1  Subjects 
 
 Study subjects were recruited from the Westmead Hospital Sleep 
laboratory between June 2008 and August 2010. These subjects were 
recruited from patients referred into the Westmead Hospital Sleep Laboratory 
for investigation of sleep disordered breathing with polysomnography. There 
were 43 subjects recruited, and of these, 13 were female and 30 were male. 
Age ranged from 24 years to 82 years with a mean of 52.3  ± 13.1 years. BMI 
ranged from 22 kg/m2  to 58 kg/m2 with a mean of 32.3 ± 7.0 kg/m2. 
 
Exclusion criteria for the study included current smoking status, current 
respiratory tract infection on history, any inflammatory condition or medical 
illness affecting the mouth or upper aerodigestive tract, previous head and 
neck irradiation, and history of airways disease requiring inhaled steroid 
medication or inhaled anticholinergic agent. 
 
Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service Ethics 
Committee. 
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7.3.2  Measurements 
 
Surface Tension 
 UAL samples were aspirated from the posterior pharyngeal wall using 
fine bore polyethylene tubing (Tyco electronics; external diameter 0.8mm, 
internal diameter 0.5mm), attached to a 23g needle (BD Precisionglide 
0.6mm x 32mm) and a 3 ml syringe (Terumo Medical Corporation 3cc / mL).  
 
Small microlitre volumes were aspirated into the tubing and subsequently 
transferred with a 1 µl syringe (7500.5N, Hamilton Company, Reno, NV, 
USA) to the surface of a silica disc for measurement of Surface Tension 
using the “Pull off force” technique (Kirkness et al., 2005a) as  described in 
Chapter 3 (figure 3.5). 
 
This method measures the force required to separate two silica discs bridged 
by a droplet of the liquid, with the force required for disc separation taken as 
the liquid’s surface tension. 
 
Salivary Flow Rate 
 Non-stimulated salivary flow was measured by collecting saliva into a 
polystyrene cup, with the subject sitting forward with an open mouth to drool 
saliva into the collection cup for a period of 5 minutes.  The subject was 
asked to breathe nasally and not to swallow during this period of time. This 
method of “salivary flow rate” measurement (Navazesh and Christensen, 
1982) was used to collect a volume of saliva which was subsequently 
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weighed and the flow rate expressed as ml / min salivary flow rate. The 
weight of collected saliva was determined by weighing the polystyrene cup 
before and after salivary collection with the difference in weight taken as the 
weight of collected saliva following the 5 minute collection period. 
 
Mucosal Wetness 
 Mucosal “wetness” of the upper airway was measured using a timed 
gravimetric contact absorbent paper strip method described by Ciantar and 
Caruana in 1998. The absorbent paper strip (Sialo-Strip for saliva collection, 
Oraflow Inc, New York, USA) was placed centrally in contact with posterior 
part of the tongue for 5 seconds. The volume of fluid was calculated by 
comparing the weight of the paper strip before and after collection and 
expressed as microlitres / 5 s. 
 
Polysomnography 
 All subjects underwent overnight polysomnography for investigation of 
sleep disordered breathing. Studies were all undertaken at the Westmead 
Hospital Sleep Laboratory. 
 
Variables monitored during the overnight polysomnography included nasal 
pressure (1600 Nasal Cannula; Salter Labs Inc., Arvin, CA, USA), EEG 
(electroencephalogram), ECG (electrocardiogram), submental and 
diaphragmatic EMG (electromyogram), left and right EOG (electro-
oculogram), respiratory impedance plethysmography (for thoraco-abdominal 
movement), oxygen saturation, sound, and body position. Monitored signals 
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were recorded on a Compumedics Profusion 3 software system for further 
sleep stage and respiratory event scoring and analysis. Sleep staging was 
performed on the overnight signals using Rechtschaffen and Kales scoring 
criteria (Rechtschaffen and Kales 1968). Arousals from sleep were scored 
according to the American Sleep Disorders Association criteria (Bonnet M, 
1992). 
 
Obstructive events were scored according to “Chicago” criteria using the 
American Academy of Sleep Medicine criteria (American Academy of Sleep 
Medicine task force, 1999).    
 
Route of Breathing 
 The route of breathing was determined by using a dual channel oro-
nasal thermocouple device (F-ONT2A; Grass, West Warwick, RI, USA). The 
thermocouple leads were placed into the nares and anterior to the 
oropharynx to detect flow, and secured to the patient’s face with surgical tape 
(3MTM MicroporeTM Microporous Hypo-Allergenic Surgical Tape). The 
qualitative signals from the thermocouple device were check recorded for 
nasal-only, oral-only, and oro-nasal flow at the start of the study. The signals 
were checked for cross contamination and to confirm route of breathing by 
having each subject perform periods (up to 10 breaths) of exclusive nasal, 
exclusive oral breathing, and oro-nasal breathing in the supine posture.
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7.3.3  Protocol 
 
 The study was conducted over one night. Subjects arrived at the 
Westmead Hospital Sleep Laboratory by 6pm on the study night and were 
set up with PSG monitoring after patient identification and PSG 
documentation was checked. The PSG set up included EEG with electrode 
placement based on the international 10-20 system (Klem et al., 1999), 
EMG, EOG, ECG, respiratory inductance plethysmography, finger oximeter 
probe,  nasal pressure cannulae, and dual channel oro-nasal thermistors. Nil 
by mouth was maintained for a minimum time of one hour prior to “lights out” 
time at approximately 2200 hours. Evening (pm) UAL samples for ST were 
taken from the posterior oropharynx, and saliva samples for ST were taken 
sublingually with the subject in the seated position, immediately following 15 
minutes of nasal only breathing, and prior to “lights out”. 
 
Mucosal wetness was then sampled immediately after ST sample collection, 
followed by salivary flow rate collection into a cup over a 5 minute period. 
 
Following sampling, the subject was allowed to go to sleep. All PSG 
monitored parameters were recorded on a computer using a Compumedics 
Profusion software system. The subject was permitted to sleep in their 
preferred posture and route of breathing was monitored overnight. The 
placement of nasal pressure cannulae and oro-nasal thermistors was 
checked if movement during the night resulted in dislodgement. A re-
calibration of the nasal pressure and oro-nasal flow signal was performed 
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during the night if required. The subject was allowed to sleep until 0600 
hours, at which time they were awoken if not so already.  
 
 Morning (am) sampling of UAL ST, saliva ST, mucosal wetness, and 
salivary flow rate was repeated as soon as possible following awakening at 
approximately 0600 hours. 
 
7.3.4  Data Analysis 
 
Sleep Parameters 
 Sleep studies were sleep staged for each 30 second epoch using 
Rechtschaffen and Kales scoring criteria (Rechtschaffen and Kales 1968). 
Respiratory events were scored according to American Academy of Sleep 
Medicine criteria (American Academy of Sleep Medicine task force, 1999), 
with the respiratory disturbance index (RDI) calculated as the total number of 
both apnoeas and hypopnoeas divided by the total sleep time during 
overnight polysomnography.  
 
Route of Breathing Analysis 
 The subject’s route of breathing was determined by analysis of the 
nasal and oral thermocouple signals, and each 30 second epoch of sleep 
was scored as a nasal-only, oral-only, or oro-nasal breathing epoch. Nasal-
only route of breathing epochs were defined as those which contained ≥ 3 
consecutive breaths seen only on the nasal thermocouple signal. Oral-only 
route of breathing epochs were defined as those which contained ≥ 3 
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consecutive breaths seen only on the oral thermocouple signal. Oro-nasal 
route of breathing epochs were defined as those which contained ≥ 3 
consecutive breaths seen on both the oral and nasal thermocouple signals. 
Epochs where the route of breathing could not be confirmed based on the 
above criteria were excluded from analysis e.g. a combination of less than 3 
consecutive oral, nasal or oro-nasal breaths within the same epoch. This, 
however, was rarely observed. 
 
 Epochs which contained respiratory events, significant cortical 
arousals, movement or signal artifacts were excluded from route of breathing 
analysis. i.e. epochs containing obstructive apnoeas or hypopnoeas were 
excluded from analysis. The proportions of nasal, oral, or oro-nasal breathing 
route were expressed as a percentage of the total sleep epochs which were 
analysed for breathing route. 
 
 The occurrence of nasal-only, oral-only or oronasal route of breathing 
was expressed as a percentage of the total sleep epochs (TSE) analysed. 
 
Statistical Analysis 
 All data were expressed as mean ± SD. Statistical data were 
graphically represented and analysed using Graphpad Prism. Single 
comparisons were made using paired t-test. Linear regression analysis was 
used to search for univariate correlation between breathing route and the 
overnight change in: i) STUAL; ii) mucosal wetness; and iii) salivary flow rate.  
P < 0.05 was considered significant. 
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7.4  Results 
 
7.4.1  STUAL 
 
 The mean pm STUAL for the group was 61.2 ± 5.0 mN/m while the 
mean am STUAL was 61.4m ± 4.3 mN/m. Overall, comparison with t-test 
demonstrated  no significant difference (p = 0.56) in STUAL between pm and 
am values (∆ STUAL)  (Figure 7.1).  
 
 The maximum and minimum pm STUAL values respectively were 73.2 
mN/m and 47.6 mN/m, respectively. The maximum and minimum pm STUAL 
values were 72.4 mN/m and 47.5 mN/m, respectively. The STUAL decreased 
overnight in 22 subjects and increased in 21 subjects. 
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Figure 7.1  STUAL values pm vs am 
Plot demonstrating the STUAL values in individual subjects (n = 43) with OSA both in the 
evening (pm) before, and in the morning (am) after overnight polysomnography. Individual 
data for STUAL are plotted as dots for both evening and morning values, with a line between 
each subject’s pm and am value. Horizontal bars are the group mean data for pm and am 
STUAL. Overall, there was no significant difference in pm and am values (t-test, p= 0.56 ), 
but some individuals showed large increases and decreases in ST. STUAL = Surface 
Tension Upper Airway Liquid.  
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7.4.2  Salivary Flow Rate 
 
 The group mean pm salivary flow rate was 0.56 ± 0.36 ml/min while 
the am rate was 0.41 ± 0.31 ml/min (Figure 7.2). This represented a 
significant difference between pm and am salivary flow rate (mean difference 
of pm - am value [or mean ∆ salivary flow rate]) of  -0.15 ml/min (t-test, p < 
0.05). 
 
 The maximum and minimum pm values for salivary flow rate were 
1.58 ml/min and 0.03 ml/min, respectively. The maximum and minimum am 
values for salivary flow rate were 1.58 ml/min and 0.02 ml/min, respectively. 
The salivary flow rate decreased overnight in 34 subjects and increased in 9 
subjects. 
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Figure 7.2  Salivary flow rate pm vs am 
Salivary flow rate in individual subjects with OSA both before (pm) and after (am) overnight 
polysomnography. There was a significant decrease in am salivary flow rates when 
compared to pm salivary flow rates (p < 0.05). Individual data for salivary flow rate are 
plotted as dots for both evening and morning values, with a line between each subject’s pm 
and am value. Horizontal bars denote mean values. * p < 0.05 (t-test). 
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7.4.3  Mucosal Wetness (MW) 
 
 The mean pm mucosal wetness for the group was 4.6 ± 0.6 μl (5s)-1 
while the am mucosal wetness was 3.8 ±  0.6 μl (5s)-1 (Figure 7.3). There 
was a significant decrease in am mucosal wetness when compared to pm 
mucosal wetness (mean difference of pm - am value or ∆ MW) of 0.8  μl (5s)-
1  (t test, p < 0.05). 
 
 The maximum and minimum PM mucosal wetness values were 31.6 μl 
(5s)-1 and 0.3 μl (5s)-1, respectively. The maximum and minimum AM 
mucosal wetness values were 26.0 μl (5s)-1 and 0.0 μl (5s)-1, respectively.  
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Figure 7.3  Mucosal Wetness pm vs am 
Mucosal wetness in individual subjects with OSA before (pm) and after (am) 
polysomnography. In comparison to the pm mucosal wetness, there was a significant 
decrease in the am mucosal wetness. Individual data for mucosal wetness are plotted as 
dots for both evening and morning values, with a line between each subject’s pm and am 
value. Horizontal bars denote mean values. * p < 0.05 (t-test). MW = Mucosal Wetness 
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7.4.4  RDI and Sleep Efficiency 
 
 The mean RDI for the group was 30.7 ±T21.2 events per hour of sleep 
with a minimum RDI of 9.0 and a maximum RDI of 91.0 events per hour of 
sleep. Of the 43 subjects, there were 9 with mild OSA (RDI 5 -14 events per 
hour of sleep), 20 with moderate OSA (RDI 15 - 30 events per hour of sleep), 
and 14 with severe OSA (RDI > 30 events per hour of sleep). The mean 
sleep efficiency for all subjects was normal at 77.5 ± 10.9%, with a minimum 
sleep efficiency of 49% and a maximum sleep efficiency of 98%.  
 
 
7.4.5  Route of Breathing During Sleep 
 
 The route of breathing overnight was expressed as a percentage of 
the night spent oronasal breathing. Following analysis of route of breathing in 
all subjects, there were no exclusively oral breathing epochs identified, 
although oronasal route of breathing was identified in variable proportions for 
all subjects overnight. Therefore, route of breathing was either oro-nasal or 
nasal-only in varying proportions for all subjects. 
 
The mean percentage of overnight breathing epochs spent oronasal 
breathing was 29.0 ± 28.4%. The minimum proportion of oronasal breathing 
epochs seen amongst all subjects was 0%, with the maximum proportion of 
oronasal breathing epochs observed amongst all subjects being 100%.  
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 When the data were examined for univariate relationships, there was 
no significant relationship between route of breathing overnight and ∆ 
STUAL, ∆ salivary flow,  ∆ mucosal wetness, RDI, or age (Figures 7.4 to 7.8).  
 
The data were also examined for the percentage of epochs spent 
oronasal breathing in the final hour of sleep before AM sampling, and 
univariate analysis was also performed on these data, with no significant 
relationships identified. 
 
 Table 7.1 demonstrates the proportion of subjects (age > 40 years vs 
age ≤ 40 years) who utilised either ≤ 50% of total sleep epochs oronasal 
breathing route or  > 50% of total sleep epochs utilising the oronasal 
breathing route. For those subjects aged >40 years, seven (or 16.3%) of the 
subjects had increased oronasal breathing ( > 50% TSE). However, in light of 
the small sample size of the study group, this observation should be 
interpreted with caution and the study may be underpowered for this result to 
be statistically significant. 
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Figure 7.4  Plot of RDI as a function of Epochs of Oronasal Breathing 
No significant relationship was identified. RDI = Respiratory Disturbance Index. 
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Figure 7.5  Plot of ∆ STUAL as a function of Epochs of Oronasal Breathing 
No significant relationship was identified. STUAL = Surface Tension Upper Airway Liquid. 
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Figure 7.6  Plot of ∆ Salivary Flow Rate as a function of Epochs of Oronasal Breathing  
No significant relationship was identified. 
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Figure 7.7  ∆ Mucosal Wetness (MW) as a function of Epochs of Oronasal Breathing
   
Plot of ∆ Mucosal Wetness (MW) as a function of Epochs of Oronasal Breathing. No 
significant relationship was identified. 
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Figure 7.8   Age as a function of Epochs of Oronasal Breathing 
Plot of Age as a function of Epochs of Oronasal Breathing. No significant relationship was 
identified. 
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Epochs of Oronasal 
breathing (% total) 
Age < 40 years Age ≥ 40 years 
≤ 50% 8 (18.6%) 27 (62.8%) 
> 50% 1 (2.3%) 7 (16.3%) 
Total (n=43) 9 (20.9%) 34 (79.1%) 
 
 
Table 7.1  Occurrence of oronasal breathing route during sleep in younger and older 
subjects.  
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7.5  Discussion 
 
 This study demonstrated that in subjects with OSA, oronasal breathing 
may be present anywhere between 0% to 100% of TSE. There was no 
relationship between the % TSE spent oronasal breathing to STUAL, MW, 
SF and age. There were significant differences in pm vs am MW and SF, 
with mean values decreasing overnight.  
 
7.5.1  Critique of Methods 
 
 The method of analysis for determining route of breathing for each 
epoch was the same as that previously used in our laboratory (Madronio et 
al., 2004). In a previous paper published on route of breathing,  this method 
of route of breathing analysis was used to determine nasal, oral, or oro-nasal 
route of breathing for each epoch (Madronio et al., 2004). Epochs with 
scored respiratory events (i.e. epochs with obstructive apnoeas or 
hypopnoeas), were excluded from analysis, and hence it is not possible to 
determine whether epochs where respiratory events are detected are 
associated more frequently with nasal, or oro-nasal breathing. Furthermore, 
a respiratory event and subsequent EEG arousal often resulted in substantial 
breathing signal artifact, making it impossible to score the route of breathing 
until stable sleep had resumed.  
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 Route of breathing in this study was determined by use of a dual 
channel oral and nasal thermocouple device. Despite utility in determining 
the route of breathing during polysomnography, there were potential 
methodological problems, which included changes in device positioning 
during the study as a result of movement or posture changes overnight, or 
cross contamination of the oro-nasal route with nasal breathing,. These 
potential issues were identified, and were minimised by careful checking, 
adjustment and recording of thermistor flow signals separately for the oral, 
nasal, and oro-nasal breathing route prior to the study, in addition to securing 
the thermocouple device both to the subject’s cheeks and also by looping 
behind the ears. In addition, the signals from the thermocouple device were 
carefully monitored by the sleep laboratory technicians overnight for any 
dislodgement or signal aberration which was addressed as required. 
 
 Analysis of route of breathing signals in this manner was primarily to 
qualitatively detect the route of breathing and there was no quantitative 
analysis of airflow, since these thermocouple devices are highly sensitive to 
the presence or absence of airflow (Norman et al., 1997) and are not linearly 
related to total flow rate. This is a major drawback of this technique as it is 
unable to quantify the amount of oral airflow during oro-nasal breathing which 
may be critical to understanding its influence on measures of STUAL and 
mucosal wetness. 
 
 Significant variability was observed between pm and am STUAL 
values in some patients. The coefficient of variation in the ST measurement 
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is approximately 5%, however some subjects have changes (increase or 
decrease in STUAL) which were greater than 10% overnight. This may 
potentially be due to ingested food or liquid in the hours leading up to the 
evening sampling, which may have influenced the initial STUAL value 
despite the nil by mouth period. Alternately, there may have been changes in 
breathing route overnight in these individuals which may have significantly 
altered STUAL values from the morning sample. 
 
 Furthermore, fluid sampling was only performed at two time points, 
being the evening prior to the study and the morning after the study, with no 
sampling points during the middle of the night. Route of breathing exhibited 
significant variability during the night for individual subjects, with variable 
periods of nasal and oro-nasal breathing during the night, and the 
percentage of oro-nasal breathing expressed as a percentage of all scored 
epochs during the night may not reflect the variability seen with changing 
breathing route during sleep. The timeline for breathing route to influence 
STUAL is unknown, and it may not be appropriate to examine whole of night 
breathing route in the context of an early morning UAL sample. Nevertheless, 
examination of the breathing route over the final hour of sleep did not 
demonstrate any better relationship with STUAL or mucosal wetness. 
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7.5.2  STUAL 
 
 In the present study, there was no significant difference in STUAL 
between evening and morning samples in subjects with non-enforced 
breathing route. There was no significant relationship between epochs of 
oronasal breathing overnight and STUAL, MW, Salivary Flow, or RDI . The 
STUAL values were similar to those seen in previous chapters for both 
normal subjects and subjects with OSA. 
 
There is evidence that STUAL may be influenced by breathing route. 
During enforced oral breathing during the day, the STUAL increases 
significantly from approximately 64 mN/m to 77 mN/m in healthy subjects, 
with enforced nasal breathing resulting in a decrease from 59 mN/m to 52 
mN/m after two hours of enforced breathing route (Verma et al., 2006). In this 
study, the spontaneous nocturnal breathing route was monitored, but not 
enforced, and in the setting of significant variability in breathing route seen 
during the night, the STUAL might also have changed during the course of 
the night (increased oronasal breathing associated with increased STUAL). 
However, no such relationship between STUAL and oronasal breathing route 
was observed. To account for the possibility that STUAL may only be 
influenced by breathing route in the hour or two prior to sampling (rather than 
a whole night effect), further analysis was performed for route of breathing in 
the final hour of sleep prior to morning sampling. There was no significant 
difference between epochs of oronasal breathing in the final hour of sleep 
and either the am STUAL or the overnight ∆ STUAL. From this present study, 
there does not appear to be any significant relationship between overall 
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proportion of oronasal breathing route overnight and STUAL in OSA subjects 
with non-enforced route of breathing. 
 
 
7.5.3  Salivary Flow 
 
 There was a significant difference seen between pm and am salivary 
flow. This difference was expected and is consistent with literature describing 
a reduction in salivary production during sleep. Physiologically, salivary flow 
rate decreases overnight during sleep (Dawes, 1975), and reduced saliva 
production is seen in pathology such as in patients with Sjogren’s syndrome 
(Fox et al., 1984). The significance of a reduction in salivary production 
during sleep is unknown, but it is a recognised phenomenon, and in certain 
circumstances may contribute to xerostomia overnight during sleep (Thie et 
al., 2002). There was no significant relationship between ∆ salivary flow and 
proportion of TSE utilizing oronasal breathing route, nor were there any 
significant relationships identified between epochs of oronasal breathing 
overnight and (pm and am) salivary flow rates. 
 
 
7.5.4  Mucosal Wetness 
 
 A significant decrease was seen in mucosal wetness overnight in this 
study which is similar to the decrease seen in salivary flow. It is likely that a 
combination of both reduced saliva production during sleep, and a degree of 
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oronasal breathing, results in a “drying out” effect on the tongue and oral 
mucosa. Verma et al, in addition to describing changes in surface tension 
with enforced breathing route in awake subjects, also demonstrated a 
significant reduction in mucosal wetness after enforced oral route of 
breathing (Verma et al., 2006), with the mucosal wetness at 120 minutes 
being at the lower limits of detection at 0.1 μl. (5s)-1. There were no 
significant relationships identified between mucosal wetness, and the % 
oronasal breathing. Although both mucosal wetness and salivary flow were 
significantly reduced at 4 and 8 hours respectively compared to 0 hours, 
there was no significant correlation between mucosal wetness and salivary 
flow. 
 
7.5.5  Route of Breathing 
 
 Nasal, oral and oronasal breathing occurs during sleep. Oral or 
oronasal route of breathing may, in turn, affect the STUAL overnight, both 
due to a “drying effect” of the oral route, such as described by Verma et al in 
their enforced daytime route of breathing study, or due to reduced salivary 
production during sleep. Even in the absence of a reduction in salivary 
production, evaporative water loss from the mucosal surfaces overnight may 
affect STUAL. However, the lack of an identified relationship between epochs 
of oronasal breathing and STUAL may possibly be due to the variability of 
route of breathing overnight, variability in quantity of oral breathing, and 
variability in oral flow rates, such that the proportion of the night as a whole 
spent nasal vs oronasal breathing (measured qualitatively) does not reflect 
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the dynamic and changing influence of switching breathing route overnight 
and varying the proportions of oral flow quantity and oral flow rate. 
 
In the present study, subjects were observed to either breathe nasally, or 
oronasally, but there was no exclusive oral route of breathing observed. The 
predominant route of breathing overall was nasal breathing. This may also 
have contributed to the absence of any relationship seen in this study. There 
were no relationships identified between route of breathing and STUAL, MW, 
salivary flow, or RDI.  
 
In contrast to previous published data which demonstrated a weak 
correlation between epochs of oronasal breathing and age (Madronio et al., 
2004), there was no significant relationship between epochs of oronasal 
breathing and age in the present study. Previous literature has reported a 
relationship between age and breathing route, with older subjects having an 
increased proportion of oronasal route of breathing seen during sleep. This 
observation, reported by Madronio et al. (2004) which was performed in 
subjects without OSA, was not seen in the present study in which all subjects 
had OSA with varying degrees of severity. Furthermore, the route of 
breathing during a respiratory event i.e. during apnoeas and hypopnoeas, 
was excluded from analysis, firstly for consistency in analysis since the 
previous study published by Madronio et al. (2004) was scored for breathing 
route in an identical manner, and secondly due to limitations in signal 
interpretation during epochs containing respiratory events. These epochs 
were often difficult to analyse for breathing route due to signal artifact from 
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the respiratory disturbance and subsequent arousal.  One of the possible 
reasons for not observing a relationship between route of breathing and age 
may be the subject population for this study. The subjects in this study had a 
significant degree of OSA, with the mean RDI being 30.7 ± 21.2 events per 
hour of sleep, and this, in turn, reduces the number of sleep epochs which 
may be analysed for breathing route. The route of breathing and age 
relationship found in the Madronio et al. (2004) study was relatively weak, 
and the severity of OSA in the subject population in the present study may be 
a factor in the difference found between the two studies. 
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7.6  Conclusion 
 
 In subjects with OSA, nasal and oronasal breathing routes are 
observed during sleep. Nasal route of breathing occurs in all subjects and is 
the predominant breathing route, whilst oronasal route of breathing is also 
observed in the majority of subjects. There were no exclusive oral breathing 
epochs observed in any of the subjects, which is consistent with previous 
literature which has demonstrated that exclusive oral route of breathing 
epochs occur rarely during sleep. 
 
There was no significant relationship between the route of breathing during 
sleep and STUAL. There is evidence of enforced route of breathing in awake 
subjects altering STUAL, with oral breathing increasing STUAL and nasal 
breathing decreasing STUAL. However in the present study, there was 
significant variability between subjects seen in breathing route overnight. The 
overall epochs of oronasal breathing overnight (measured qualitatively) not 
adequately convey this variability in breathing route overnight, and hence the 
influence of uncontrolled breathing route on STUAL in OSA subjects  during 
sleep is difficult to accurately quantify. The methodology of the current study 
may have contributed to the negative findings, and a relationship between 
route of breathing and STUAL has not been confidently excluded. A study 
with controlled or enforced breathing route (measured quantitatively) during 
sleep, may potentially better determine the effect of breathing route upon 
STUAL, salivary flow, mucosal wetness, and possibly RDI. 
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The subsequent chapters will investigate the relationship of breathing route, 
STUAL, and severity of OSA further using enforced oral or nasal overnight 
breathing routes. 
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Chapter 8: Influence of Enforced Breathing 
Route on Surface Tension of Upper Airway 
Liquid and Severity of Sleep Disordered 
Breathing in Healthy Subjects 
 
 
8.1  Introduction 
 
 Both nasal and oral breathing occur during sleep. Nasal, oral and oro-
nasal breathing route is observed during sleep in subjects without 
polysomnographic evidence of obstructive sleep apnoea (Madronio, Di 
Somma et al. 2004). In this study, oral only breathing occurred rarely, while 
most subjects switched between nasal and oro-nasal breathing.  
 
Oral route of breathing has been associated with increasing upper airway 
lining liquid surface tension (Verma, Seto-Poon et al. 2006). In a study of 
awake normal subjects, the STUAL, and mucosal “wetness” were measured 
after 120 minute periods of enforced oral breathing, and enforced nasal 
breathing. During enforced oral route of breathing, the STUAL increased 
from 64.4 mN/m to 77.4 mN/m, while nasal route of breathing resulted in a 
decrease in STUAL from 59.3 mN/m to 51.8 mN/m. The authors speculated 
that nasal breathing may contribute to reducing the severity of sleep 
disordered breathing by reducing STUAL. Kirkness et al have previously 
shown that changing STUAL may effect the severity of sleep disordered 
breathing (Kirkness et al., 2005b), and hence breathing route, with its effects 
on surface tension, may play a role. 
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 Upper airways resistance is also higher with enforced oral breathing 
route.  Fitzpatrick et al investigated the effect of enforcing oral or nasal 
breathing route on the upper airways resistance and the severity of sleep 
disordered breathing (Fitzpatrick et al., 2003). Subjects who breathed via the 
oral route only during sleep had a higher upper airways resistance, and 
obstructive apnoeas and hypopnoeas were more frequent. The subjects in 
this study demonstrated no significant obstructive sleep apnoea with nasal 
only breathing, but demonstrated severe obstructive sleep apnoea in the 
supine posture  (31± 8 events per hour of sleep) as well as in the lateral 
posture (29 ± 9 events per hour) with oral breathing.   
 
 Patients with more oral breathing epochs during sleep have higher 
AHIs and longer duration of obstructive events than snorers without clinically 
significant OSA (Koutsourelakis, Vagiakis et al. 2006), implying a 
pathophysiological relationship.  
 
 In subjects with severe nasal obstruction and obstructive sleep 
apnoea, McLean et al demonstrated a modest reduction in the severity of 
obstructive sleep apnoea following treatment of nasal obstruction in 10 
subjects (McLean, Urton et al. 2005). In this group of patients with nasal 
obstruction, the oral fraction for route of breathing during sleep fell from a 
mean of 39% to 8% following topical nasal decongestant. However, this did 
not result in the complete elimination of oral breathing nor bring the severity 
of sleep disordered breathing back to the normal range. Similarly, studies 
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looking at treating nasal congestion using nasal steroids, nasal dilators, and 
nasal decongestants, have shown only modest reductions in the severity of 
obstructive sleep apnoea (Kohler, Bloch et al. 2007). 
 
 
8.2   Aims 
 
 The aim of this chapter is to study the effect of enforced nasal and oral 
route of breathing on the surface tension of upper airway lining liquid and any 
resultant change in the severity of sleep disordered breathing in healthy 
subjects. Specifically, the aim was to attempt to produce sleep disordered 
breathing by enforced oral route of breathing, and to examine the influence of 
enforced oral breathing route at night on STUAL and the severity of any 
resultant sleep disordered breathing. 
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8.3  Methods 
 
8.3.1  Subjects 
 
 Healthy subjects were screened by questionnaire and clinical history. 
The subjects were recruited from amongst staff members from Westmead 
Hospital and from the Ludwig Engel Centre for Respiratory Research.  
8 healthy volunteers were recruited for this study (6 male, 2 female; age: 
30.3 ± 4.0 years, range 24 – 34 years; BMI: 24.4 ± 3.3 kg / m2, range 21.5 – 
32.6 kg / m2). Subjects with any nasal obstruction, or history of nasal or sinus 
pathology were excluded from the study. 
 
 Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service 
Human Ethics Committee. 
 
 
8.3.2  Measurements 
 
 
Surface Tension 
 Surface Tension of Upper Airway Lining Liquid (STUAL) was 
measured by the “Pull Off Force Technique” (Kirkness et al., 2005a). This 
technique is described in previously in more detail in chapter 3 (Figure 3.5). 
Microliter volumes of upper airway lining liquid are placed between two silica 
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discs, and the force required to separate the discs with the microliter volume 
of liquid bridging both disc surfaces, is taken to be the surface tension. 
 
Upper Airway Lining Liquid 
 Upper airway lining liquid was sampled from the posterior 
oropharyngeal wall. Samples were aspirated into polyethylene tubing (Tyco 
Electronics; external diameter 0.8 mm; internal diameter 0.5 mm), using a 
23g needle (BD  PrecisionGlide 0.6mm x 32mm ) attached to a 3ml syringe 
(Terumo Medical Corporation 3cc / mL). 
 
 Samples were then applied onto the surface of a silica disc for 
measurement of surface tension in the surface force measurement device 
(Kirkness et al., 2005a). 
 
Salivary flow rate 
 Non-stimulated salivary flow rate was measured by collecting saliva 
into a polystyrene cup. The subject sits forward and drools into a collection 
cup over a five minute period as previously described by Navazesh et al. 
(1982). The saliva collected was weighed and the flow rate expressed as ml / 
min (salivary flow rate). 
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Mucosal Wetness 
 Mucosal “wetness” of the upper airway was measured using a timed 
gravimetric contact absorbent paper strip method described by Ciantar et al. 
in 1998 (Ciantar and Caruana, 1998). The absorbent paper strip (Sialo-Strips 
for saliva collection, Oraflow Inc, New York, USA) was placed centrally in 
contact with posterior part of the tongue for 5 seconds. The volume of fluid 
was calculated by comparing the weight of the paper strip before and after 
collection and expressed as microlitres / 5 seconds. 
 
Polysomnography 
 All polysomnographic studies were undertaken at the Westmead 
Hospital Sleep Laboratory. The variables monitored overnight included EEG 
(electroencephalogram), ECG (electrocardiogram), submental and 
diaphragmatic EMG (electromyogram), left and right EOG (electro-
oculogram), respiratory inductance plethysmography (for thoraco-abdominal 
movement), oxygen saturation, sound, and body position. Nasal pressure 
measurement for airflow was not utilized. All signals were recorded on a 
Compumedics Profusion 3 software system. Sleep staging was performed on 
the overnight signals using Rechtschaffen and Kales rules (Rechtschaffen 
and Kales 1968) and obstructive events were scored using “Chicago” criteria 
(American Academy of Sleep Medicine task force, 1999). Arousals were 
scored using the American Sleep Disorders Association criteria (Bonnet M, 
1992). All studies were scored by a single sleep technician. 
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Route of Breathing 
 Route of breathing was confirmed by using a dual channel oro-nasal 
thermocouple device (F-ONT2A; Grass, West Warwick, RI, USA).  The 
thermocouple was secured to the patient’s face using tape (3MTM  
MicroporeTM  Microporous Hypo-Allergenic Surgical Tape), with the 
thermocouple leads looped behind both ears. The qualitative signals from the 
thermocouple device were check recorded for nasal-only, oral-only, and oro-
nasal flow at the start of the study. The signals were checked for cross 
contamination and to confirm route of breathing by having each subject 
perform periods (up to 10 breaths) of exclusive nasal, exclusive oral 
breathing, and oro-nasal breathing in the supine posture. Furthermore, to 
prevent movement or dislodgement during sleep, the thermocouple device 
was secured to the skin behind the ears and lateral to the cheeks with 
adhesive tape. Overnight, the signals were checked following any movement 
or awakening which resulted in dislodgement of the thermocouple device and 
signals were checked and re-calibrated if necessary. 
 
 
8.3.3  Protocol 
 
 All subjects arrived at the Westmead Sleep laboratory by 6pm on the 
night of the study and were set up with PSG monitoring after patient 
identification and PSG documentation was checked by the sleep laboratory 
technician. The PSG set up included EEG with electrode placement based 
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on the international 10-20 system (Klem et al., 1999), EMG, EOG, ECG, 
respiratory inductance plethysmography, finger oximeter probe, nasal 
pressure cannulae, and dual channel oro-nasal thermocouple device. 
Subjects remained nil by mouth for at least one hour prior to “lights out” 
which was approximately 2200 hours. Sampling for STUAL was taken with 
the subject seated upright following 15 minutes of nasal only breathing, 
before “lights out”. Immediately following UAL sampling, mucosal wetness 
was sampled, and the salivary flow was then collected with the subject 
seated in a forward position, and saliva collected into a cup over a 5 minute 
period. 
 
 
The study was conducted over two separate nights. The subject was 
randomised to either enforced nasal or oral route of breathing for one full 
night each. Oral route of breathing was enforced with cotton wool inserted 
into both nares, with tape (3MTM Leukosilk®)  external to the nares to seal 
both nostrils. Nasal breathing route was enforced by using tape (3MTM 
Leukosilk®) over the mouth. Enforcement of breathing route took place after 
all samples were taken in the evening and immediately before “lights out”. 
Sampling for UAL, mucosal wetness, and salivary flow was repeated at 4 
hours after lights out, and at 8 hours after lights out at the end of the sleep 
recording. The patients were woken from sleep for the 4 and 8 hour sampling 
(Figure 8.1). 
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8.3.4  Data Analysis 
 
Sleep Parameters 
 Studies were sleep staged for each 30s epoch using Rechtschaffen 
and Kales criteria (Rechtschaffen and Kales 1968). The Respiratory 
Disturbance Index (RDI) was derived using the respiratory inductance 
plethysmography signal (RIP) as the primary scoring channel, together with 
oximetry and EEG arousals. The total RDI was an aggregate of the number 
of apnoeas and the number of hypopnoeas (including “Chicago type” 
hypopnoeas) divided by the total sleep time during polysomnography. 
Respiratory Events were identified using American Academy of Sleep 
Medicine criteria (AASM Task Force; Sleep 1999). An obstructive apnoea 
was defined as a 10 second or greater absence of airflow (thermistor) with 
oximetry demonstrating a 3% or greater reduction in oxygen saturation 
compared to baseline. A hypopnoea was defined as a greater than 30% 
reduction in respiration (RIP), together with oximetry demonstrating a 3% or 
greater reduction in oxygen saturation, for a duration of 10 seconds or more. 
A “Chicago” type hypopnoea was defined as a subjective reduction in 
respiration (RIP) resulting in an oxygen desaturation of 3% or more, or 
terminating in an arousal, with the duration of the event being 10 seconds or 
more (AASM Task Force; Sleep 1999). Additionally, polysomnographic 
variables were analysed for sleep staging, Sleep Efficiency, Arousal Index, 
and Respiratory vs Spontaneous Arousals. 
 
 
 133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1  Overnight protocol for STUAL sampling 
Overnight protocol. Subjects had a 15 minute period of enforced nasal breathing prior to 
sampling for UAL, Mucosal Wetness, and Salivary flow rate (at 0 hours; STUAL 0).  Nasal or 
Oral Breathing was enforced from “lights out” onwards (2200 hours). Sampling of UAL, 
Mucosal Wetness, and Salivary flow rate was repeated 4 hours after lights out (STUAL 4), 
and at the end of the study, 8 hours after lights out (STUAL 8). STUAL = Surface Tension 
Upper Airway Liquid. 
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Breathing Route 
 Route of breathing was confirmed by using a dual channel oro-nasal 
thermocouple device (F-ONT2A; Grass, West Warwick, RI, USA). Oral route 
of breathing epochs were defined as nasal or oral based on analysis of 
phasic signals from the dual channel thermocouple. Nasal-only breathing 
epochs were defined as epochs containing ≥ 3 consecutive breaths only from 
the nasal thermocouple signal. Oral-only breathing epochs were defined as 
epochs containing ≥ 3 consecutive breaths from the oral thermocouple 
signal. The presence of nasal breathing or oral breathing was expressed as a 
percentage of the total sleep epochs analysed.  
 
Statistical Analysis 
 All data were expressed as mean ± SD. For samples of salivary flow 
rate, STUAL, and mucosal wetness, individual data were pooled to obtain 
group mean data for each time period of sampling. Thus, group mean data 
were obtained for 0 hours, 4 hours and 8 hours. Single comparisons were 
made using paired t-tests. Differences between the time periods and for the 
enforced breathing route were analysed using repeated measures ANOVA.  
P ≤ 0.05 was considered significant. 
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8.4  Results 
8.4.1  STUAL 
 On the oral enforced route of breathing night, in comparison to 
baseline STUAL at 0 hours, there was a significant increase in STUAL at 4 
hours and 8 hours (60.4 ± 3.3 mN/m vs 64.9 ± 4.8 mN/m vs 65.9 ± 5.2 mN/m, 
respectively; ANOVA p < 0.05; Figure 8.2). Individual data for STUAL for 
both nights are demonstrated in Figure 8.3, with individual data for STUAL 
plotted as dots for each sampling time point, with a line between values for 
each subject.  
 
For the enforced nasal route of breathing night, there was no significant 
difference in the STUAL between 0 hours (57.1 ± 3.7 mN/m), 4 hours (57.0 ± 
3.7 mN/m), and 8 hours (58.2 ± 3.6 mN/m), respectively (ANOVA, p = 0.56). 
There was a significant difference in the mean STUAL at 0 hours between 
the enforced oral and enforced nasal route of breathing nights of 3.3 ± 3.9 
mN/m (t-test, p = 0.048), which is within the limits of variability for the 
measurement of surface tension using the “pull-off force” technique (Kirkness 
et al., 2005a).  
 
No relationship was identified between STUAL and RDI. The difference 
between STUAL on oral vs nasal enforced breathing night (STUAL Oral – 
Nasal) was compared with the difference in RDI between the two nights (RDI 
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Oral – Nasal). No significant relationship was found when data were 
analysed using linear regression (p = 0.53) 
 
8.4.2 Salivary Flow Rate 
 
 The salivary flow rate exhibited no significant change on the enforced 
nasal breathing night (ANOVA, p = 0.12), although a trend for the salivary 
flow rate to reduce overnight was noted. The salivary flow rates at 0, 4 and 8 
hours were 1.9 ± 0.6, 1.5 ± 1.3, and 1.3 ± 0.8 ml/5min respectively. On the 
enforced oral route of breathing night, there was a significant reduction in the 
salivary flow rate from 0 hours to 4 hours (2.7  ± 1.8 ml/5min and 1.5 ± 1.4 
ml/5min, respectively; ANOVA p<0.05; Figure 8.04) which remained reduced 
compared with baseline at 8 hours (1.0 ± 0.7 ml/5min p = 0.007). (Figure 8.4) 
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Figure 8.2   Group mean values for STUAL on enforced breathing nights 
Group mean values (Bars = +1SD) for STUAL for enforced nasal breathing and enforced 
oral breathing nights. A significant increase was seen in STUAL at 4 and 8 hours compared 
to baseline for the oral breathing night but not for the nasal breathing night. ✱ p<0.05 relative 
to 0 hour value (ANOVA). STUAL = Surface Tension Upper Airway Liquid. 
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Figure 8.3   Individual data for STUAL on enforced Nasal and Oral breathing nights 
Individual data points for STUAL at 0, 4, and 8 hrs for enforced Nasal breathing vs enforced 
Oral breathing nights. All subjects increased their STUAL after 4 hours of enforced Oral 
breathing. STUAL = Surface Tension Upper Airway Liquid. 
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Figure 8.4  Salivary Flow Rate on enforced Nasal and Oral breathing nights 
Group mean data (Bars = +1SD) for salivary flow rate on the enforced nasal breathing vs 
oral breathing nights. No significant changes were seen across the night for enforced nasal 
breathing, but a significant reduction in salivary flow rate was seen for enforced oral 
breathing route at 4 hours and 8 hours compared to 0 hours. ✱ p<0.05 relative to 0 hour 
value (ANOVA). 
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8.4.3  Upper Airway Mucosal Wetness 
 
 The mucosal wetness on the enforced nasal breathing night did not 
increase in comparison to baseline. Upper airway mucosal wetness was 1.2 
± 0.3 μl/5s at 0 hours, 0.9 ± 0.4 μl/5s at 4 hours, and 1.2 ± 2.7 μl/5s at 8 
hours. 
On the enforced oral breathing night, the mucosal wetness values decreased 
significantly from 1.3 ± 0.6 μl/5s at 0 hours, to 0.3 ± 0.2 μl/5s at 4 hours, and  
remained decreased at 0.2 ± 0.2 μl/5s at 8 hours (P < 0.05, ANOVA; Figure 
8.5). The values for mucosal wetness at 4 and 8 hours on the oral breathing 
night were at the lower limits of detection. 
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Figure 8.5   Mucosal Wetness on enforced Nasal and Oral breathing nights 
Mucosal Wetness group mean data (Bars = +1SD) for enforced nasal breathing and 
enforced oral breathing route nights. No significant difference across the night for nasal 
breathing, but a significant reduction in mucosal wetness was seen for enforced oral 
breathing route at 4 hours and 8 hours compared to 0 hours. ✱ p<0.05 relative to 0 hour 
value (ANOVA). 
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8.4.4 Sleep Parameters 
  
 There was no significant difference in the sleep staging between the 
nasal and oral route of breathing nights. There were similar amounts and 
proportions of Stages 1-4 sleep and REM sleep when the two nights were 
compared (paired t-test). On the nasal breathing night, the proportion of 
sleep time in stages 1, 2, slow wave sleep (3 and 4 combined) and REM 
sleep were 1.5 ± 1.0%, 58.8 ± 8.4%, 19.9 ± 2.7%, and 19.6 ± 9.1%, 
respectively, and for the oral breathing night, proportions were 1.6 ± 0.9%, 
58.6 ± 6.2%, 21.2 ± 5.5%, 18.6 ± 4.1%, respectively (Table 8.1). 
 
Sleep variables including Sleep Efficiency, Arousal Index, the number of 
Spontaneous vs Respiratory arousals, and the Respiratory Disturbance 
Index (RDI) were compared for the two nights (paired t-test). There was a 
significant difference in the Arousal Index and RDI, with both being 
significantly higher on the enforced oral breathing night vs the nasal 
breathing night. The arousal index was 9.4 ± 5.2 events per hour of sleep on 
the nasal breathing night compared with 24.6 ± 12.3 events per hour on the 
oral breathing night (Table 8.2). The rate of Spontaneous Arousals for both 
nights was not significantly different, with the increased Arousal Index on the 
oral breathing vs nasal breathing night being due to an increase in 
respiratory arousals. 
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Sleep Stage 
(%TST) 
Nasal  Oral  
Stage 1 1.5 ± 1.0 1.6 ± 0.9 
Stage 2 58.8 ± 8.4 58.6 ± 6.2 
Stage 3/4 19.9 ± 2.7 21.2 ± 5.5 
REM 19.6 ± 9.1 18.6 ± 4.1 
 
Table 8.1   Sleep Stages on Nasal vs Oral breathing nights 
Comparison of sleep staging between the enforced nasal breathing night vs enforced oral 
route of breathing night. No differences in sleep stage were found between the nasal 
breathing vs oral breathing night. TST = Total Sleep Time; REM = Rapid Eye Movement. 
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 Nasal Oral 
Sleep Efficiency (%) 79.8 ± 8.7 75.5 ± 13.9 
Arousal Index (events / hr) 9.4 ± 5.2 24.6 ± 12.3 * 
Spontaneous Arousals (events / hr) 8.0 ± 5.7 8.8 ± 8.0 
RDI (events / hr) 1.9 ± 1.7 20.8 ± 17.2 * 
 
 
Table 8.2  Sleep Parameters for Nasal Breathing and Oral Breathing nights 
The Arousal Index and RDI were significantly higher for the Oral breathing night compared 
with the Nasal Breathing night. * p < 0.05 (paired t-test). RDI =  Respiratory Disturbance 
Index. 
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8.4.5 Sleep Disordered Breathing 
 
 There was a dramatic difference seen in the severity of sleep 
disordered breathing between the nasal breathing and oral breathing nights. 
On the nasal breathing night, the average group RDI was 1.9 ± 1.7 events 
per hour of sleep, while on the oral breathing night, the RDI was 20.8 ± 17.2 
events per hour of sleep (t-test, p = 0.01; Figure 8.6).  Changing from 
enforced nasal to enforced oral breathing had a dramatic effect by inducing 
severe obstructive sleep apnoea (RDI > 30 events per hour of sleep) in 3 
subjects.  Three more subjects had mild to moderate range OSA (RDI 5-30 
events per hour of sleep) on the enforced oral breathing night, while 2 
subjects did not have any evidence of OSA on either night. The RDI 
increased during enforced oral breathing in all subjects except for one 
(Figure 8.7).  
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Figure 8.6   Group mean RDI data for enforced Nasal vs Oral breathing nights 
Group mean Respiratory Disturbance Index (RDI) data (Bars = +1SD) for enforced nasal vs 
enforced oral breathing nights. The RDI increased significantly on the enforced oral night, 
with RDI increasing from 1.9 ± 1.7 events per hour of sleep to 20.8 ± 17.2 events per hour 
(paired t-test; p < 0.05) 
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Figure 8.7   Individual data for RDI on Nasal and Oral breathing nights 
Individual data for subject’s Respiratory Disturbance Index (RDI) for enforced nasal vs oral 
route of breathing. Different symbols represent individual subjects. The RDI increased on the 
oral breathing route night in 7 out of 8 subjects.  
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8.5  Discussion 
 
 The findings in this study show that enforced oral vs nasal route of 
breathing reduces measured salivary flow rate and mucosal wetness, while 
increasing both the STUAL and the severity of sleep disordered breathing. 
The major finding is that enforced oral route of breathing induces sleep 
disordered breathing in all but one subject in an otherwise healthy subject 
group, free of OSA at baseline. 
 
8.5.1  Critique of Methods 
 
 Breathing route was determined by a dual channel thermocouple 
device as per previous studies investigating route of breathing (Madronio, Di 
Somma et al. 2004). However, oral airflow could not be accurately quantified, 
and no nasal pressure cannula or means of quantifying oral or nasal airflow 
concurrently were used in this study. Other authors have previously 
measured oral and nasal breathing overnight by using a mask with 
partitioned independent nasal and oral compartments (Fitzpatrick, McLean et 
al. 2003). A similar method used in the current study may have influenced 
the STUAL via an artificial increase in humidification and hence was not 
considered. 
 
A combination of respiratory inductance plethysmography (thoraco-
abdominal bands), a dual channel thermocouple, and oximetry were used to 
score respiratory events. The lack of nasal pressure cannula may have led to 
an underscoring of potential respiratory events. However, it has been shown 
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that thoraco-abdominal bands have a similar sensitivity and specificity to 
oesophageal pressure for detecting upper airway resistance (ref) and may be 
able to detect respiratory events that are not detectable by analysis of oro-
nasal flow by a thermocouple device (Masa et al). 
 
The baseline values for STUAL between the enforced oral and nasal 
breathing nights were different (57.1 ± 3.7 mN/m vs 60.4 ± 3.3 mN/m).  
However, the difference seen in the baseline values for STUAL is within the 
coefficient of variation of surface tension measured by the “Pull-Off Force 
Technique” (Kirkness et al., 2005a). This finding is unusual since the 
subjects were randomized for route of breathing, and the methodology was 
identical for sampling on both nights. Calibration was performed on the “Pull 
Off Force” device on a regular basis, and it is unlikely that the difference 
would be due to slight differences in calibration between study nights.    
 
8.5.2  Surface tension of UAL 
 
 STUAL during enforced daytime route of breathing has been 
previously studied by Verma et al. (2006).  In this study, during enforced oral 
breathing over 120 minutes, the STUAL increased from 64.4 ±  2.7 mN/m to 
77.4 ±  1.1 mN/m, while with nasal breathing the STUAL decreased from 
59.3 ±  2.2 mN/m to 51.8 mN/m. In the present study, no decrease in STUAL 
was observed for nasal breathing, but an increase was seen with enforced 
oral breathing route.  
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 A possible explanation for the lack of decrease in STUAL with nasal 
breathing may relate to a reduction in salivary flow and production during 
sleep (Dawes 1975), coupled with a reduction in swallow rate during sleep 
(Thie, Kato et al. 2002), resulting in less transfer of saliva from the mouth to 
the posterior pharynx to maintain a lower surface tension (Sonies, Ship et al. 
1989). Salivary and nasopharyngeal secretions contain surface active 
phospholipids (Woodworth, Smythe et al. 2005) and a reduced transfer to the 
posterior pharyngeal wall due to a combination of reduced production and a 
decreased swallowing rate in the sleep state, may explain that lack of 
reduction with enforced nasal breathing during sleep.  
 
 The increased surface tension with oral breathing may be possibly due 
to evaporative losses from the upper airway, resulting in altered surfactant 
activity of phospholipids and surface active proteins in upper airway lining 
liquid and saliva. 
 
 When compared with the baseline values for STUAL from the Verma 
et al. (2006) study, the baseline values for STUAL between the enforced oral 
and nasal breathing nights were also different for the present study (57.1 ± 
3.7 mN/m vs 60.4 ± 3.3 mN/m). It is unknown whether anticipation of nasal or 
oral route of breathing by the subject may influence salivary production, and 
this may be a possible explanation for the increased baseline STUAL during 
oral breathing vs nasal breathing. This effect was observed both in the 
present study with enforced route of breathing during sleep, and in the 
 
 
 151 
Verma et al. (2006) study with enforced route of breathing in awake normal 
subjects. 
 
8.5.3 Salivary Flow Rate 
 
 The flow of unstimulated saliva has a circadian influence, as 
demonstrated by Dawes (1975).  This (non-enforced breathing route study) 
demonstrated salivary flow was highest at approximately 1700 hours, and 
lowest at approximately 0500 hours. In the present study, there was a trend 
for the salivary flow rate to decrease overnight on the nasal breathing night, 
but the trend did not show statistical significance, possibly since the closed 
mouth prevented an additional evaporative effect. On the oral breathing 
night, a combination of an evaporative effect, and a reduction in salivary 
production may have resulted in the decreased salivary flow rate observed 
overnight. For both the oral and nasal breathing route nights, the minimum 
values for salivary flow rate were similar to the values described by Dawes 
(1975).  
 
8.5.4 Mucosal Wetness 
 
 In the enforced oral breathing route group, the mucosal wetness 
decreased to the limits of detection during sleep, while there was no 
significant difference in mucosal wetness across the night with the nasal 
breathing group. This is likely to be due to evaporative loss of mucosal liquid 
 
 
 152 
during enforced oral breathing overnight, combined with the effects of low 
salivary production and reduced swallowing.  
 
 The values obtained for mucosal wetness in this study were less than 
the daytime values obtained previously (Verma et al., 2006). Daytime values 
for mucosal wetness in an enforced oral breathing group decreased from 4.5 
± 0.4 μl/5s at 0 minutes to  0.1 ± 0.2 μl/5s at 120 minutes (Verma, Seto-Poon 
et al. 2006), as compared with 1.3 ± 0.6 μl/5s at 0 hours and 0.2 ± 0.2 μl/5s 
at 8 hours on the enforced oral breathing night in this study.  The lower 
baseline mucosal wetness for this study when compared with the daytime 
study by Verma et al. (2006), may be due to the circadian changes in salivary 
production and flow, with a lower flow rate seen in the evening and overnight.  
 
 Oral route of breathing at night did not produce a lower mucosal 
wetness when compared with the daytime study, as the values for mucosal 
wetness were already at the lower limits of detection for the daytime values. 
An inverse relationship between upper airway mucosal wetness and STUAL 
was demonstrated in this study (Figure 8.08).  This relationship was also 
previously demonstrated in healthy subjects during daytime enforced oral 
route of breathing (Verma et al., 2006). 
 
 
 
 
 
 
 153 
8.5.5 Severity of Sleep Disordered Breathing 
 
 There was a significant difference in the severity of sleep disordered 
breathing when comparing the enforced nasal breathing night to the enforced 
oral breathing night. Three of the subjects had a normal RDI on the enforced 
nasal breathing night, but had severe sleep disordered breathing with their 
RDI > 30 events per hour of sleep on the enforced oral breathing night. 
Similar increases in the RDI and severity of sleep disordered breathing have 
been previously reported with enforced oral route of breathing (Fitzpatrick, 
McLean et al. 2003), but these studies have not measured the changes in 
salivary flow, mucosal wetness, and STUAL with the enforced breathing 
route. Although there were dramatic changes in RDI with enforced breathing 
route, the STUAL demonstrated significant variability and no significant 
relationship between change in STUAL and with RDI was identified.  
 
 Previous studies using instilled surfactant in the upper airway (Jokic, 
Klimaszewski et al. 1998; Morrell, Arabi et al. 2002; Kirkness, Madronio et al. 
2005), have shown that decreasing surface tension with exogenous 
surfactant can lead to reduced upper airway collapsibility and a reduction in 
the severity of sleep disordered breathing. In a rabbit model, Kirkness et al. 
(2003) have also previously demonstrated that the patency of the upper 
airway is influenced by STUAL. Enforced oral breathing in the present study 
has been associated with an overnight increase in STUAL, which may 
promote upper airway collapsibility.  
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 Oral breathing may result in an increase in the closing pressure of the 
oropharyngeal and velopharyngeal airway, via bite opening and mandibular 
position change (Ayuse, Inazawa et al. 2004; Isono, Tanaka et al. 2004). 
This represents a different anatomical mechanism whereby the degree of 
sleep disordered breathing may be greater with enforced oral breathing, 
separate to any consideration of the effect of changes in surface forces on 
upper airway collapsibility.  
 
 For enforced oral route of breathing, whether the increase in severity 
of sleep disordered breathing is due to an increase in surface tension, or a 
change in mandibular position and degree of bite opening, cannot be 
determined by the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 155 
8.6  Conclusion 
 
 This study demonstrates that enforced oral route of breathing induces 
sleep disordered breathing and increases STUAL.  
 
 STUAL is increased with oral breathing most likely due to evaporation 
of upper airway lining liquid, and reduction of salivary flow rate with sleep 
onset, consistent with our data showing a reduction in mucosal wetness and 
salivary flow rate with enforced oral route breathing.  
 
 The potential mechanisms whereby enforced oral route of breathing 
induces sleep disordered breathing include an overnight increase in STUAL, 
or changes in upper airway patency due to mandibular position change with 
an open mouth. With the dramatic increase observed in the severity of SDB 
with enforced oral breathing route demonstrated in this study, it is plausible 
that varying degrees of nasal obstruction may induce SDB in healthy 
individuals, with gross nasal obstruction predisposing to a greater severity of 
SDB 
 
 The next chapter will investigate whether the increase in sleep 
disordered breathing is due to changes in upper airway collapsibility with jaw 
position, or potentially due to the increased STUAL. 
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Chapter 9:  Effect of Exogenous Surfactant 
during Enforced Oral Breathing Route on 
Surface Tension of Upper Airway Liquid 
and Severity of Sleep Disordered 
Breathing in Healthy Subjects  
 
9.1  Introduction 
 
 Chapter 8 demonstrated that enforced oral route of breathing 
increased STUAL and induced sleep disordered breathing (SDB) in most 
normal subjects (severe SDB in some). The study did not determine the 
pathophysiological mechanisms contributing to the SDB and the postulated 
mechanisms include an increase in STUAL leading to increased propensity 
to upper airways collapse , or possibly, changes in mandibular position due 
to mouth opening with enforced oral breathing route, leading to changes in 
length/ tension relationships of upper airway muscles and consequent 
changes in upper airway geometry and anatomical collapsibility (Meurice et 
al., 1996). No studies to date have examined the effect of lowering STUAL 
on subjects with oral breathing induced sleep disordered breathing. Previous 
studies have demonstrated increases in upper airways resistance and 
severity of SDB with enforced oral breathing (Fitzpatrick et al., 2003), and 
this study will examine whether or not higher STUAL values seen with 
enforced oral breathing route may be a factor in determining the severity of 
SDB. 
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9.2  Aims 
 
 Enforced oral route of breathing is postulated to increase the STUAL, 
thereby increasing the severity of sleep disordered breathing. In this part of 
the study, exogenous surfactant was administered to subjects during 
enforced oral breathing route to reduce the increases in STUAL seen during 
oral route breathing, and to monitor for any subsequent decrease in the 
severity of sleep disordered breathing. 
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9.3  Methods 
 
9.3.1  Subjects 
 
 Subjects recruited for this study were from the normal subjects 
previously recruited for the enforced route of breathing study in Chapter 8. 
Healthy subjects were screened by questionnaire and clinical history. The 
subjects were recruited from amongst staff members from Westmead 
Hospital and from the Ludwig Engel Centre for Respiratory Research.  
 
Of the 8 subjects who participated in the enforced route of breathing study, 6 
subjects consented to participate in the present study (5 male, 1 female; age: 
30.0 ± 4.6 years, range 24 – 34 years; BMI: 24.2 ± 2.5 kg/m2, range 21.5 – 
32.6 kg / m2). 
 
 
Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service 
Human Ethics Committee. 
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9.3.2  Measurements 
 
Surface Tension 
 Surface Tension of Upper Airway Lining Liquid (STUAL) was 
measured by the “Pull Off Force Technique”. This technique is described in 
the methodology of previous chapters (ref). Microliter volumes of upper 
airway lining liquid are placed between two silica discs, and the force 
required to separate the discs with the microliter volume of liquid bridging 
both disc surfaces, is taken to be the surface tension. 
 
Upper Airway Lining Liquid 
 Upper airway lining liquid was sampled from the posterior 
oropharyngeal wall. Samples were aspirated into polyethylene tubing (Tyco 
Electronics; external diameter 0.8 mm; internal diameter 0.5 mm), using a 
23g needle (BD  PrecisionGlide 0.6mm x 32mm ) attached to a 3ml syringe 
(Terumo Medical Corporation 3cc / mL). 
 
 Samples were then applied onto the surface of a silica disc for 
measurement of surface tension in the surface force measurement device 
(Kirkness et al., 2005a). 
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Salivary flow rate 
 Non-stimulated salivary flow rate was measured by collecting saliva 
into a polystyrene cup. The subject sits forward and drools into a collection 
cup over a five minute period as previously described by Navazesh et al.  
(1982). The saliva collected was weighed and the flow rate expressed as ml/ 
5 min (salivary flow rate). 
 
Mucosal Wetness 
 Mucosal “wetness” of the upper air way was measured using a timed 
gravimetric contact absorbent paper strip method described by Ciantar and 
Caruana (Ciantar and Caruana, 1998). The absorbent paper strip (Sialo-
Strips for saliva collection, Oraflow Inc, New York, USA) was placed centrally 
in contact with posterior part of the tongue for 5 seconds. The volume of fluid 
was calculated by comparing the weight of the paper strip before and after 
collection and expressed as microlitres / 5 seconds. 
 
Polysomnography 
 All polysomnographic studies were undertaken at the Westmead 
Hospital Sleep Laboratory. The variables monitored overnight included EEG 
(electroencephalogram), ECG (electrocardiogram), submental and 
diaphragmatic EMG (electromyogram), left and right EOG (electro-
oculogram), respiratory inductance plethysmography (for thoraco-abdominal 
movement), oxygen saturation (pulse oximetry), sound, and body position. 
Nasal pressure measurement for airflow was not utilized. All signals were 
recorded on a Compumedics Profusion 3 software system. Sleep staging 
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was performed on the overnight signals using Rechtschaffen and Kales rules 
(Rechtschaffen and Kales, 1968) and obstructive events were scored using 
“Chicago” criteria (American Academy of Sleep Medicine task force, 1999). 
Arousals were scored using the American Sleep Disorders Association 
criteria (Bonnet M, 1992).  All studies were scored by a single sleep 
technician. 
 
Route of Breathing 
 Route of Breathing was confirmed by using a dual channel oro-nasal 
thermocouple device (F-ONT2A; Grass, West Warwick, RI, USA).  The 
thermocouple was secured to the patient’s face using tape (3MTM  
MicroporeTM  Microporous Hypo-Allergenic Surgical Tape), with the 
thermocouple leads looped behind both ears. The qualitative signals from the 
thermocouple device were checked for oral-only flow at the start and during 
the study, to confirm oral-only breathing during the entire sleep period. 
 
 
9.3.3  Protocol 
 
 All subjects arrived at the Westmead Sleep laboratory by 6pm on the 
night of the study. They remained nil by mouth for at least one hour prior to 
“lights out” which was approximately 2200 hours. PSG preparation and set 
up as per Chapter 8. Sampling for STUAL was taken with the subject seated 
upright following 15 minutes of nasal-only breathing, before “lights out”. 
Immediately following UAL sampling, mucosal wetness was sampled, and 
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the salivary flow was then collected with the subject seated in a forward 
position, and saliva collected into a cup over a 5 minute period. 
 
 The study was conducted over one night. Oral route of breathing was 
enforced for the whole night with cotton wool inserted into both nares, with 
tape ( 3MTM Leukosilk®)  external to the nares to seal both nostrils.  A sample 
of STUAL was obtained prior to collection of samples for mucosal wetness 
and salivary flow. Exogenous surfactant (2.5ml Beractant, Abbott, USA) was 
then administered by atomiser spray into the nose and oropharynx. Half of 
the dose (1.25ml) was sprayed by atomizer onto the posterior pharyngeal 
wall, whilst the other 1.25ml of the dose was sprayed towards the posterior 
nasopharynx. An extension tube attached to the atomizer was used for 
delivery of surfactant and was passed through the nares to direct surfactant 
to the posterior nasopharynx.   
 
 Enforcement of oral breathing route took place after all samples were 
taken in the evening and immediately before “lights out”. The patient was 
woken, and sampling for UAL, mucosal wetness, and salivary flow were 
repeated 4 hours after lights out. A further dose of 2.5ml exogenous 
surfactant was administered using the same methodology after the 4 hour 
sampling was performed. The subjects were then allowed to return to sleep 
for another 4 hour period before final sampling for STUAL, mucosal wetness, 
and salivary flow at 8 hours after lights out at the end of the sleep recording. 
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2.5 ml exogenous surfactant was administered via atomiser spray with the 
patient in the seated position. The dose was split with 1.25ml delivered into 
the nasopharynx via a nostril and the remaining 1.25ml was delivered into 
the posterior oropharynx. 
 
 
9.3.4  Data Analysis 
 
 Data from the matching six subjects from Chapter 8 were used to 
compare to the data obtained in this study. 
 
Sleep Parameters 
 Studies were sleep staged for each 30s epoch using Rechtschaffen 
and Kales criteria (Rechtschaffen and Kales, 1968). Respiratory Events were 
identified using the 1999 American Academy of Sleep Medicine task force 
criteria (AASM, 1999). An obstructive apnoea was defined as a 10 second or 
greater absence of airflow (thermistor) with oximetry demonstrating a 3% or 
greater reduction in oxygen saturation compared with baseline. A hypopnoea 
was defined as a greater than 30% reduction in respiration (RIP), together 
with oximetry demonstrating a 3% or greater reduction in oxygen saturation, 
for a duration of 10 seconds or more. A “Chicago” type hypopnoea was 
defined as a subjective reduction in respiration (RIP) resulting in an oxygen 
desaturation of 3% or more, or terminating in an arousal, with the duration of 
the event being 10 seconds or more (American Academy of Sleep Medicine 
task force, 1999).  
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  The Respiratory Disturbance Index (RDI) was derived from the 
respiratory inductance plethysmography signal (RIP) as the primary scoring 
channel, together with oximetry and EEG arousals. The total RDI was an 
aggregate of the number of apnoeas and the number of hypopnoeas 
(including “Chicago type” hypopnoeas) per hour of sleep. 
 
Breathing Route 
 The absence of nasal breathing and the presence of oral only 
breathing was confirmed by using the dual channel oro-nasal thermocouple 
device (F-ONT2A; Grass, West Warwick, RI, USA).  
 
Statistical Analysis 
 All data were expressed as mean ± SD. For samples of salivary flow 
rate, STUAL, and mucosal wetness, individual data were pooled to obtain 
group mean data for each time period of sampling. Thus, group mean data 
were obtained for 0 hours, 4 hours and 8 hours. Single comparisons were 
made using paired t-tests with Bonferroni correction. Differences between the 
time periods for the enforced breathing route were analysed using repeated 
measures ANOVA. P≤ 0.05 was considered significant.  
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9.4  Results 
 
9.4.1  Surface Tension of UAL 
 
 Following administration of exogenous surfactant at “lights out”, 
STUAL decreased from 62.6 ± 1.6 mN/m at baseline to 57.6 ± 3.6 mN/m 
(ANOVA, p < 0.05).  
 
 At 4 hours after lights out, STUAL remained decreased at 57.4 ±  3.6 
mN/m, and following a further 2.5ml of exogenous surfactant, this decreased 
to 55.5  ±  1.8 mN/m (ANOVA, p < 0.05). Final sampling of STUAL at 8 hours 
demonstrated a STUAL of 60.4 ± 1.3 mN/m (Figure 9.1). 
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Figure 9.1   Group mean values for STUAL 
Group mean values (Bars = +1SD) for STUAL during enforced oral breathing with 
exogenous surfactant. ES = Post Exogenous Surfactant. Note significant reduction in STUAL 
with ES at 0 hours which persists for 4 hours. STUAL increases from 4 to 8 hours (despite 
ES), but only to levels typical for Nasal Breathing.   ✱ p<0.05 relative to 0 hour value 
(ANOVA). STUAL = Surface Tension Upper Airway Liquid. 
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9.4.2 Salivary Flow Rate 
 
The results for salivary flow rate during nasal breathing (from Chapter 8), oral 
breathing (from Chapter 8), and oral breathing with exogenous surfactant are 
shown in Figure 9.02. 
 
 On the enforced oral breathing with exogenous surfactant night, there 
was a significant reduction in the salivary flow rate between 0 to 4 hours, 
from 2.3 ± 1.1 g/5min to 1.1 ± 0.6 g/5min. The salivary flow remained 
reduced when sampled at 8hrs at 0.9 ± 0.7 g/5min. There was no significant 
difference in the salivary flow rate at 0 hours, 4 hours or 8 hours compared 
across the three different nights (ANOVA, all p > 0.05). 
 
 For both the enforced oral route of breathing and the enforced oral 
breathing route with exogenous surfactant nights, there was a decrease in 
salivary flow rate at 4 hours and at 8 hours relative to 0 hours, but this 
decrease was not evident on the nasal breathing night (Figure 9.2). 
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Figure 9.2   Salivary Flow Rate across the 3 study nights 
Salivary flow rate at 0, 4, and 8 hours on the nasal breathing, oral breathing, and oral 
breathing with exogenous surfactant nights. There is a decrease in salivary flow rate at 4 
and 8 hours on the oral breathing with ES night. Data are mean; bars = 1SD (n = 6).  
* p < 0.05 relative to 0 hour value (ANOVA). ES = Exogenous Surfactant. 
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9.4.3  Mucosal Wetness 
 
 The mucosal wetness on the oral breathing with exogenous surfactant 
night demonstrated a significant reduction at 4 and 8 hours compared with 
baseline. On the surfactant study night, the mucosal wetness values 
decreased significantly from 1.6 ± 0.4μl/5s at 0 hours, to 0.6 ± 0.2 μl/5s at 4 
hours, and  remained decreased at 0.4 ± 0.2 μl/5s at 8 hours (P<0.05, 
ANOVA; Figure 9.3). The measured values for mucosal wetness at 4 and 8 
hours were reduced by a similar amount to the enforced oral breathing night 
without exogenous surfactant (Figure 9.3). 
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Figure 9.3   Mucosal Wetness across the 3 study nights 
Mucosal wetness at 0, 4, and 8 hours on the nasal breathing, oral breathing, and oral 
breathing with exogenous surfactant nights. Note the decrease in mucosal wetness at 4 and 
8 hours on both oral breathing nights. Data are mean; bars = 1SD (n = 6).  * p<0.05 relative 
to 0 hour (ANOVA). 
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9.4.4 Sleep Parameters 
 
 As described in Chapter 8, there was no significant difference in Sleep 
Efficiency between the enforced nasal and oral breathing nights. There was a 
significant increase in the Arousal Index when comparing the enforced oral 
and nasal breathing nights. On the enforced oral route of breathing with 
exogenous surfactant night, the Arousal Index was increased to a similar 
degree to the oral breathing night at 22.8 ± 10.6 events per hour of sleep. On 
further review of arousal type, the majority of these were respiratory 
arousals. Spontaneous arousals were 9.5 ± 3.8 events per hour of sleep, 
which was similar to that seen on both the nasal and oral breathing nights 
(table 9.1). 
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 Nasal Oral Oral + ES 
Sleep Efficiency (%) 
 
79.5 ± 9.7 71.45 ± 14.4 70.7 ± 8.6 
Arousal Index 
(events / hour) 
9.3 ± 6.0 26.45 ± 13.6* 22.8 ± 10.6* 
Spontaneous 
Arousals 
(events / hour) 
7.8 ± 6.7 6.0 ± 5.8 9.5 ± 3.8 
 
 
Table 9.1   Sleep Parameters for Nasal, Oral, and Oral + ES nights 
Sleep parameters on the nasal breathing, oral breathing, and oral breathing with exogenous 
surfactant (Oral + ES) nights. Overall sleep efficiency was similar between the three nights. 
However the Arousal Index was increased on the oral breathing and oral breathing + ES 
nights, due to an increase in respiratory arousals. Data are mean ± SD; n = 6. * p<0.05 
relative to nasal (ANOVA). 
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9.4.5  Sleep Disordered Breathing  
 
 There was a significant and dramatic increase in the RDI from the 
nasal route of breathing night to the oral route of breathing night. The RDI 
increased from 2.1 ± 1.9 events per hour of sleep to 26.4 ± 14.1 events per 
hour of sleep (n = 6). On the oral breathing with exogenous surfactant night, 
the RDI was reduced at 17.8 ± 13.6 events per hour of sleep, which was a 
significant decrease when compared to the enforced oral breathing night 
(Figure 9.4). Respiratory events were analysed for the first vs second part of 
the night, for nasal and oral breathing route, and no significant differences 
were observed. All of the subjects demonstrated a reduction in RDI on the 
enforced oral breathing night with exogenous surfactant, although sleep 
disordered breathing was still present (Figure 9.5).  
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Figure 9.4   Mean RDI  values for  3 study nights. 
Respiratory Disturbance Index (RDI) on the nasal breathing, oral breathing, and oral 
breathing with exogenous surfactant nights. Data are mean; bars = 1SD (n = 6).  For the oral 
breathing route, there was moderate to severe sleep disordered breathing, which was 
significantly reduced, although not eliminated, with exogenous surfactant. * = p < 0.01 
relative to nasal; + = p < 0.01 relative to oral route (paired t-tests with Bonferroni correction). 
ES = Exogenous Surfactant. 
 
 
 
 
 
 
 
 
Nasal Oral Oral + ES
0
10
20
30
40
50
R
D
I (
ev
en
ts
/h
r o
f s
le
ep
)
*
+
 
 
 175 
 
 
Figure 9.5   Individual Subject Data for RDI  
Individual data for Respiratory Disturbance Index (RDI) for each subject  (n = 6; different 
symbols) during the enforced nasal, oral, and oral with exogenous surfactant nights. With 
enforced oral breathing, exogenous surfactant reduced the RDI in all subjects. 
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9.5  Discussion 
 
 The findings in this study show that exogenous surfactant reduces 
STUAL and the severity of sleep disordered breathing during enforced oral 
route of breathing. All subjects had a reduction in their RDI, with a drop in 
STUAL similar to values seen in the enforced nasal route of breathing night 
(Chapter 8). Similar to the enforced oral breathing night in the previous 
Chapter, there were significant decreases in salivary flow rate and mucosal 
wetness on the enforced oral breathing with surfactant night.  
 
9.5.1  Critique of Methods 
 
 The limitations of this study are similar to those encountered in 
Chapter 8, namely the limitations of quantifying breathing route, and scoring 
of respiratory events without nasal pressure cannula signals (respiratory 
events were scored from dual channel nasal thermocouple device, 
respiratory inductance plethysmography (thoraco-abdominal bands), and 
oximetry). 
 
 The reduction in STUAL seen in this study was not as low as 
previously reported with exogenous surfactant (Kirkness, et al, JAP 2003, 
Morrell et al, ERJ, 2002).  Previous studies utilising exogenous surfactant on 
subjects with OSA performed in our laboratory (Kirkness et al., 2003c) have 
used Exosurf Neonatal (Exosurf Neonatal, Glaxo Smith Kline, Greenville, 
NC), but the current study uses 2.5ml Beractant (Abbott, USA). It is unclear 
whether Beractant and Exosurf are equivalent in terms of surface tension 
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lowering effect or if the mucosal spreading qualities are the same for the 
same dose.  
 
 This study demonstrates a reduction in both STUAL and RDI with 
exogenous surfactant in patients who have enforced oral route of breathing, 
but does not eliminate SDB or return it to nasal route of breathing values. 
Other variables such as differences in mandibular position and muscle length 
tension relationships may account for some the difference seen in severity of 
SDB with different breathing routes, but this study does not address these 
other factors. 
 
9.5.2  Surface tension of UAL 
 
 The STUAL seen with exogenous surfactant and enforced oral route 
of breathing is similar to the STUAL seen on the enforced nasal route of 
breathing night. Exogenous surfactant did not reduce STUAL to that seen in 
previously published studies(Morrell et al., 2002, Kirkness et al., 2003c). In 
previous studies investigating the effect of exogenous surfactant, Exosurf 
(Exosurf neonatal GSK) was instilled into the nasopharynx, while in this 
study, Beractant (Abbott, USA) was used as exogenous surfactant. Exosurf 
is a protein free synthetic surfactant, while Beractant is a modified bovine 
surfactant extract. It is not known whether Beractant has the same dose - 
effect for surface tension lowering as Exosurf, and the mucosal spreading 
qualities may be different for the two agents. Despite the instillation of 
Beractant into the naso- and oro-pharynx in this study, the values observed 
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for STUAL remained higher than in previous studies. The lowest values for 
surface tension in this study were similar to the STUAL observed on the 
nasal breathing night.  
 
 The STUAL with exogenous surfactant and oral breathing reached a 
nadir value of 55.5 ± 1.8 mN/m which is not as low as in previous work by 
Kirkness et al. (2003). This may be due to the enforced oral route of 
breathing keeping the ST higher, but possibly also due to the different type of 
surfactant used in the two studies. 
 
 Additionally, the STUAL demonstrated a return to baseline values at 8 
hours. It is possible that upon wakening, subjects may swallow more 
frequently, thereby clearing any remaining surfactant from the upper airways 
and increasing the surface tension back to baseline values for the oral 
breathing route. 
 
 
9.5.3  Salivary Flow Rate 
 
 The salivary flow rate values on the enforced oral breathing with 
exogenous surfactant night demonstrated a reduction across the night. It is 
likely that the evaporative effects of oral route of breathing resulted in a 
reduction in measured salivary flow rate overnight. However when the data 
for the 6 subjects were analysed for salivary flow rate on the enforced oral 
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breathing night, there was no longer a significant reduction seen across the 
night. This may possibly due to a type II error.  
 
 
9.5.4  Mucosal Wetness 
 
 Mucosal wetness values on the enforced oral breathing with 
exogenous surfactant night were similar to the values obtained on the 
enforced oral route of breathing night. There was no difference in mucosal 
wetness between oral route of breathing and oral route of breathing with 
surfactant nights, and the 4 and 8 hour values were reduced to the limits of 
detection. Despite the administration of exogenous surfactant, there was a 
reduction in mucosal wetness that was similar to that seen on the enforced 
oral breathing night. It should be noted that the exogenous surfactant was 
not directly applied to the mucosa where mucosal wetness testing was 
undertaken 
 
9.5.5  Severity of Sleep Disordered Breathing 
 
 This study demonstrates that despite enforced oral route of breathing, 
there was a reduction in RDI in all subjects when exogenous surfactant was 
administered to the upper airway. The RDI was significantly reduced from 
26.3 ± 16.1 to 17.8 ± 13.6 events per hour of sleep, but exogenous surfactant 
did not eliminate the presence of moderate obstructive sleep apnoea seen 
with oral route of breathing. Despite exogenous surfactant, the RDI did not 
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return to the values seen on the enforced nasal breathing route night from 
the first part of this study (Chapter 8). This suggests that although surface 
tension forces represent part of the pathophysiology leading to sleep 
disordered breathing during enforced oral route breathing, there are other 
pathophysiological factors which also play a significant role in upper airway 
collapse during oral route breathing while asleep. This study does not 
address the question of what other factors may be responsible for the 
dramatic difference seen in sleep disordered breathing during nasal and oral 
route breathing. Although oral route of breathing changes surface forces in a 
direction which increases the propensity to upper airways collapse, the 
mechanical effect of an open mouth on upper airway anatomy, the change in 
length/ tension relationships of upper airway muscles, and any posterior 
movement of upper airways structures with the mouth open may potentially 
have a greater impact.  
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9.6  Conclusion 
 
 Oral breathing route induced sleep disordered breathing appears to be 
partially mediated by the increases in STUAL. In Chapter 8, the study 
demonstrated that enforced oral route of breathing induces sleep disordered 
breathing and increases STUAL. The hypothesis for this part of the study 
was that oral route breathing induced sleep disordered breathing can be 
reduced or eliminated by applying exogenous surfactant to prevent oral 
breathing associated increases in STUAL. The MW was dramatically 
reduced on the oral compared to the nasal breathing night, and the “drying” 
effect oral breathing was not normalised by the administration of exogenous 
surfactant. While the STUAL was may have been reduced with 
administration of exogenous surfactant, there may have been little liquid 
present at the upper airway mucosal surface to provide a therapeutic effect. 
Hence, despite reducing STUAL to levels seen on nasal breathing nights, the 
RDI on the enforced oral breathing with surfactant night was not reduced to 
the RDI seen on the nasal breathing night, but nonetheless did decrease in 
all subjects.  
 
 In conclusion, for healthy humans during sleep, enforced oral route of 
breathing is associated with induction of sleep disordered breathing and is 
associated with increased STUAL. Lowering STUAL with exogenous 
surfactant to nasal breathing levels reduces, but does not eliminate oral 
breathing induced sleep disordered breathing. Therefore, we conclude that 
oral breathing induced sleep disordered breathing in healthy subjects is only 
partially mediated by the associated increases in STUAL. 
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Chapter 10: Effect of Exogenous 
Surfactant in Subjects with Mild to 
Moderate Obstructive Sleep Apnoea   
 
10.1  Introduction 
 
 Surface tension of upper airways lining liquid (STUAL) influences 
upper airway patency. Previous animal studies have demonstrated the 
effects of surfactants in reducing upper airways resistance and snoring in 
anaesthetised dogs (Widdicombe and Davies, 1988). Studies in 
anaesthetised rabbits demonstrated the influence of exogenous surfactant on 
upper airways collapse, with a reduction of STUAL leading to reduced upper 
airways collapsibility, lower opening pressures, and increased upper airway 
patency (Kirkness et al., 2003a). Further studies in anaesthetised rabbits 
demonstrated re-opening and closing pressures increased when salivary 
production decreased and STUAL was increased using atropine, 
demonstrating that altering surface tension affects upper airways 
collapsibility and re-opening (Lam et al., 2008). 
 
 In human subjects, instillation of exogenous surfactant reduces 
STUAL, and subsequently leads to a reduction in the intraluminal pressure 
required to re-open the closed pharyngeal airway (Kirkness et al., 2003b). 
 
 Several studies have demonstrated that lowering of STUAL may 
reduce the severity of sleep disordered breathing in subjects with OSA, and 
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lead to a reduction in pharyngeal resistance (Jokic et al., 1998, Morrell et al., 
2002, Kirkness et al., 2003c). 
 
 In a single night observational study performed by Kirkness et al. 
(2003) on 9 subjects with severe OSA, 2.5 mL of exogenous surfactant 
(Exosurf neonatal, GSK) was instilled into the posterior pharyngeal airway via 
a nasopharyngeal catheter. The study was divided into two halves, with the 
first half of the study spent determining the effects of exogenous surfactant 
on Pcrit changes. Exogenous surfactant was re-administered during the 
second half of the study and the effects on AHI and RDI were measured. The 
study demonstrated a reduction in STUAL by approximately 25% in sleeping 
OSA subjects following instillation of exogenous surfactant. This was 
associated with a significant group mean reduction in the RDI by 
approximately 31%. Interestingly, no significant relationships were identified 
between the reduction in STUAL and measures for upper airway mechanics 
including Pcrit and upstream upper airway resistance (RUS), but the lack of a 
relationship may have potentially reflected the small number of subjects in 
the study.  
  
 Instillation of exogenous surfactant in this study reduced STUAL and 
served to generate the hypothesis that exogenous surfactant can reduce the 
severity of sleep disordered breathing. 
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10.2  Aims 
 
 The aims of the studies in this chapter are: 1) to develop a pilot 
randomised controlled trial of exogenous surfactant (ES) in subjects with mild 
to moderate severity OSA; 2) to pilot a new, less invasive delivery method for 
ES; and 3) to pilot a different surfactant agent (Beractant, Abbott, USA) and 
investigate its potential use as a therapeutic agent in OSA. 
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10.3  Methods 
 
10.3.1  Subjects 
 
 Study subjects were recruited from the Westmead Hospital Sleep 
laboratory between June 2009 and June 2012. These subjects were 
recruited from patients referred into the Westmead Hospital Sleep Laboratory 
for investigation of sleep disordered breathing with diagnostic 
polysomnography. Patients who had mild to moderate obstructive sleep 
apnoea as defined by an RDI of 5 to 29 events per hour of sleep were 
eligible for recruitment into the study. 
 
12 subjects were recruited into the study (8 male, 4 female). The mean age 
for the group was 51.5 ± 10.8 years (range 37 to 78 years), and average BMI 
was 30.2 ± 6.1 kg/m2 (range 25-35 kg/m2). 
 
Exclusion criteria for the study included current smoking status, current 
respiratory tract infection on history, any inflammatory condition or medical 
illness affecting the mouth or upper aerodigestive tract, previous head and 
neck irradiation, and history of airways disease requiring inhaled steroid 
medication or inhaled anticholinergic agent. Subjects who could not ingest 
products containing bovine derived protein for medical, cultural, or religious 
reasons were also excluded as Beractant is a surfactant agent derived from 
a bovine source. 
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Informed written consent was obtained from each subject and ethics 
approval was obtained from the Western Sydney Area Health Service Ethics 
Committee. 
 
10.3.2: Measurements 
 
Surface Tension 
 UAL samples were aspirated from the posterior pharyngeal wall using 
fine bore polyethylene tubing (Tyco electronics; external diameter 0.8mm, 
internal diameter 0.5mm), attached to a 23g needle (BD Precisionglide 
0.6mm x 32mm) and a 3 ml syringe (Terumo Medical Corporation 3cc / mL).  
 
 Small microlitre volumes were aspirated into the tubing and 
subsequently transferred with a 1 ml syringe (7500.5N, Hamilton Company, 
Reno, NV, USA) to the surface of a silica disc for measurement of Surface 
Tension using the “Pull off force” technique as described in chapter 3 (figure 
3.5)  (Kirkness et al., 2005a).  
 
 This method measures the force required to separate two silica discs 
bridged by a droplet of the  liquid, with the force required for disc separation 
taken as the liquid’s surface tension. 
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Polysomnography 
 All subjects underwent overnight polysomnography for investigation of 
sleep disordered breathing. Studies were all undertaken at the Westmead 
Hospital Sleep Laboratory. 
 
 Variables monitored during the overnight polysomnography included 
nasal pressure (1600 Nasal Cannula; Salter Labs Inc., Arvin, CA, USA), EEG 
(electroencephalogram), ECG (electrocardiogram), submental and 
diaphragmatic EMG (electromyogram), left and right EOG (electro-
oculogram), respiratory inductance plethysmography (for thoraco-abdominal 
movement), oxygen saturation, sound, and body position. Monitored signals 
were recorded on a Compumedics Profusion 3 software system for further 
sleep stage and respiratory event scoring and analysis. Sleep staging was 
performed on the overnight EEG using Rechtschaffen and Kales scoring 
criteria (Rechtschaffen and Kales 1968).  
 
 Obstructive events and cortical arousals from sleep were identified by 
using recommended American Academy of Sleep Medicine (AASM) criteria 
(AASM Manual for the Scoring of Sleep and Associated Events, Iber et al., 
2007). The Respiratory Disturbance Index (RDI) was calculated by adding 
Respiratory Effort Related Arousals (RERAs) to the Apnoea Hypopnoea 
Index (AHI). 
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10.3.3  Protocol 
 
 The study was conducted over three nights. The first night was a 
standard diagnostic polysomnography night.  Subsequently, subjects were 
randomised to a Normal Saline (NS) night or Exogenous Surfactant (ES) 
treatment night for the second and third nights of the study. 
 
 Subjects arrived at the Westmead Hospital Sleep Laboratory by 6pm 
on the study night. Nil by mouth was maintained for a minimum time of one 
hour prior to “lights out” time at approximately 2200 hours. UAL samples 
were taken from the posterior oropharynx with the subject in the seated 
position immediately following 15 minutes of nasal only breathing, at 2100 
hours. Following sampling, the subject was allowed to retire to sleep at 
approximately 2200 hours. 
 
 On the second and third study nights, either 2.5mls of normal saline or 
Beractant was administered via an atomiser into the nasopharynx (1.25mls) 
and also the oropharynx (1.25mls) immediately before “lights out”. UAL was 
sampled following either ES or NS administration at 2200 hours, with a 
period of 5 minutes between administration of ES or NS, and sampling of 
UAL. Overnight, at approximately 0200 hours, subjects were woken from 
sleep for sampling and for administration of ES or NS. Sampling of UAL was 
performed 5 minutes before and 5 minutes after administration of either ES 
or NS at ~0200 hours.  Final sampling of UAL was performed at 0600 hours 
the following morning. 
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10.3.4  Data Analysis 
 
Sleep Parameters 
 Studies were sleep staged for each 30 second epoch using 
Rechtschaffen and Kales scoring criteria (ref). Respiratory events were 
scored according to American Academy of Sleep Medicine criteria (AASM 
Manual for the Scoring of Sleep and Associated Events, Iber et al., 2007) 
with the respiratory disturbance index (RDI) calculated as the total number of 
both apnoeas, hypopnoeas, and RERAs divided by the total sleep time 
during overnight polysomnography. An apnoea was defined as a complete 
cessation of airflow on the  nasal pressure cannula signal, for ≥ 10s, with 
continued respiratory effort evident on thoracic and abdominal movement 
bands, associated with oxygen desaturation or arousal from sleep. 
Hypopnoeas were defined by a ≥ 50% airflow reduction and a ≥ 3% 
desaturation on oximetry or and EEG arousal. Increased respiratory efforts 
and arousals related to these efforts were scored as RERAs (Respiratory 
Effort Related Arousals). 
 
Statistical Analysis 
 All data were expressed as mean ± SD. Data were compared using 
ANOVA to determine differences between time points. Single comparisons 
were made using paired t-tests. Statistical data were graphically represented 
and analysed using Graphpad Prism. P < 0.05 was considered significant. 
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10.4  Results 
 
10.4.1  STUAL values for 3 nights 
 
Diagnostic Night 
 For the diagnostic polysomnography night, the mean pm STUAL for 
the group was 63.3 ± 3.1 mN/m while the mean am STUAL was 62.7m ± 2.7 
mN/m. Overall, there was no significant difference (t-test, p = 0.62) in STUAL 
between pm and am values (Figure 10.1).  The STUAL values observed on 
the diagnostic polysomnography night were similar to the values described in 
earlier chapters. 
 
Normal Saline Night 
 For the NS night, the sampling times were 2100, 2200, 0155, 0205 
and 0600 hours. The mean STUAL values for the group for these sampling 
times were 62.5 ± 2.4 mN/m, 63.5 ± 3.0 mN/m, 62.4 ± 3.8 mN/m, 61.7 ± 4.1 
mN/m, and 61.8 ± 2.6 mN/m, respectively (Figure 10.2). There were no 
significant differences identified between these sampling times during the NS 
night (ANOVA, p = 0.37). There was no significant difference between 
baseline pm STUAL values on the diagnostic night and 2100 hour values on 
the NS night (t-test, p = 0.57). Similarly, there were no differences in 0600 
STUAL values between the NS night and diagnostic PSG night (t-test, p =  
0.39). 
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Figure 10.1   Group Mean Values for STUAL (Diagnostic night) 
Group mean values (error bars = +1SD) for evening (pm) and morning (am) STUAL on the 
diagnostic polysomnography night. No significant difference between PM and AM values (t-
test, p = 0.62). STUAL = Surface Tension Upper Airway Liquid. 
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Figure 10.2   Group Mean STUAL values (NS night) 
Group mean values (error bars = +1SD) for STUAL on the NS night at the five time points 
sampled. No significant difference in STUAL values were identified across the sampling 
times (ANOVA, p = 0.37). STUAL = Surface Tension Upper Airway Liquid. 
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Exogenous Surfactant Night 
 The sampling times on the ES night were the same as for the NS night 
(2100, 2200, 0155, 0205 and 0600 hours), with the group mean STUAL for 
these times being 63.8 ± 2.3 mN/m, 61.4 ± 2.6 mN/m, 57.2 ±  3.1 mN/m, 55.5 
± 3.2 mN/m, and 61.8 ± 1.2 mN/m, respectively. In comparison to the STUAL 
value at 2100 hours, there was a significant decrease (ANOVA, p < 0.05) in 
STUAL at 0155 hours and 0205 hours.  
 
 There was no significant difference in STUAL at 2100 hours vs 2200 
hours, whilst at 0155 hour vs 0205 hour sampling times (done approximately 
5 minutes pre and post administration of ES), and there was also no 
significant difference  seen in STUAL (ANOVA, p = 0.29). By 0600 hours, the 
STUAL values had returned to the baseline STUAL seen at 2100 hours 
(Figure 10.3). The group mean values for STUAL on the ES night are 
demonstrated in Figure 10.3. Individual data for STUAL on both ES and NS 
nights are demonstrated in Figure 10.4 
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Figure 10.3   Group Mean STUAL values (ES night) 
Group mean values (error bars = +1SD) for STUAL on the ES night at the five time points 
sampled. In comparison to 2100 hours, STUAL values at 0155 hours and 0205 hours were 
significantly reduced. STUAL returned to baseline values by 0600 hours. * ANOVA, p<0.05 
relative to 2100 hour value. STUAL = Surface Tension Upper Airway Liquid. 
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Figure 10.4   Individual subject data for STUAL on ES and NS nights 
Plot demonstrating the STUAL values across the nights in individual subjects (n = 12) with 
mild to moderate OSA on both the ES night and NS night. Individual data for STUAL are 
plotted as dots for each sampling time point, with a line connecting values for each subject. 
Sampling times were at 0, 60, 295, 305, and 540 minutes  which represented sampling at 
2100, 2200, 0155, 0205, and 0600 hours respectively. STUAL = Surface Tension Upper 
Airway Liquid; ES = Exogenous Surfactant; NS = Normal Saline.  
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10.4.2  Polysomnography Results 
 
Sleep Parameters 
Sleep architecture was observed across the three study nights, and no 
significant differences were seen in the proportion of sleep spent in Stages 
1,2, slow wave sleep (SWS) and REM sleep (ANOVA, all p > 0.07). 
The was no significant difference seen in the group mean arousal index 
between the diagnostic night, NS night and ES night with the arousal indices 
for these 3 nights being  21.6 ± 12.8, 21.6 ± 12.0, and 20.6 ±  8.0 arousals / 
hour, respectively (ANOVA, p = 0.95). When the proportion of respiratory 
arousals to spontaneous arousals was analysed, there were no differences 
seen between the three study nights.  Other parameters which were 
analysed are demonstrated in Tables 10.1 and 10.2, and did not demonstrate 
a significant difference between the three nights included sleep efficiency, 
and oxygen desaturation index (ANOVA, all p > 0.45)  
 
Sleep Disordered Breathing 
The AHI (apnoeas + hypopnoeas) and RDI (AHI + RERAs) were 
analysed separately. The AHIs for the diagnostic, NS, and ES nights were 
10.2 ± 9.4, 6.6 ± 6.7, and 7.1 ± 7.5 events / hour, respectively. The RDIs for 
the three study nights were 16.5 ± 7.4, 18.3 ± 11.9, and 19.9 ± 13.1 events / 
hour, respectively. There were no significant differences seen for either AHI 
or RDI across the three study nights (ANOVA, all p > 0.45). Individual data 
for AHI and RDI for the three study nights demonstrated significant variability, 
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and no consistent pattern was apparent for individual subjects over the three 
study nights (Figures 10.5 and 10.6). 
 
The RDI and ST values for the NS night and ES night were analysed 
further for any relationship. The difference in RDI between the NS and ES 
nights was expressed as ∆ RDI (RDI on ES night – RDI on NS night) whilst 
the difference between individual mean STUAL values on the two nights was 
expressed as ∆ STUAL (mean STUAL on ES night – mean STUAL on NS 
night). There was no relationship identified between ∆ RDI and ∆ STUAL 
(linear regression, p = 0.33). 
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 Diagnostic NS ES 
Sleep Efficiency (%) 78.1 ± 8.7 79.3 ± 10.0 79.3 ± 9.4 
Arousal Index  
(events/hr) 
21.6 ± 12.8 21.6 ± 14.0 20.6 ± 8.0 
Spontaneous 
Arousals 
(events/hr) 
8.1 ± 7.4 6.8 ± 3.5 6.3 ± 3.9 
Respiratory Arousals 
(events/hr) 
10.7 ± 5.9 13.4 ± 14.2 13.6 ± 7.5 
RDI (events/hr)  16.5 ± 7.4 18.3 ± 11.9 19.9 ± 13.1 
AHI (events/hr) 10.2 ± 9.4 6.6 ± 6.7 7.1 ± 7.5 
RERA (event/hr) 8.1 ± 7.4 6.8 ± 3.5 6.3 ± 3.9 
 
 
Table 10.1  Sleep Parameters and Severity of OSA across 3 study nights 
Sleep Efficiency, arousal indices, RDI, AHI, and RERAs for the three nights of the study. The 
severity of sleep disordered breathing was similar for all 3 nights of the study (ANOVA, all p 
> 0.45). NS = Normal Saline night; ES = Exogenous Surfactant night; RDI = Respiratory 
Disturbance Index; AHI = Apnoea Hypopnoea Index; RERA = Respiratory Effort Related 
Arousals.  
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 Diagnostic NS ES 
Stage 1 (%TST) 8.5 ± 8.9 2.6 ± 1.9 3.1 ± 4.2 
Stage 2 (%TST) 49.0 ± 10.2 54.7 ± 10.6 57.2 ± 8.0 
Slow Wave Sleep 
(%TST) 22 ± 6.8 23.0 ± 9.2 20.3 ± 8.3 
REM (%TST) 20 ± 6.9 19.6 ± 5.4 17.9 ± 5.6 
 
 
Table 10.2: Sleep Architecture across 3 study nights 
Sleep Architecture across the 3 nights of the study (Diagnostic PSG night, Normal Saline 
(NS) night, and Exogenous Surfactant (ES) night). There were no significant differences 
seen in sleep architecture for the group across the 3 nights of the study (ANOVA, all p > 
0.07). REM = Rapid Eye Movement; TST = Total Sleep Time. 
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Figure 10.5   Individual subject data for AHI and RDI 
Individual subject data for AHI and RDI across the three study nights. Study night 1 = 
Diagnostic sleep study; study night 2 = normal saline night ; study night 3 =  exogenous 
surfactant night.  Each symbol represents an individual subject. Note the variability seen in 
AHI and RDI for individual subjects, with no consistent pattern. AHI = Apnoea Hypopnea 
Index; RDI = Respiratory Disturbance Index. 
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Figure 10.6   Change in RDI vs change in STUAL 
The change in RDI (between Surfactant and Normal Saline nights) plotted against the 
change in STUAL (mean STUAL on Surfactant night – mean STUAL on Normal Saline night) 
for individual subjects. Decreasing STUAL did not have any significant effect on RDI (linear 
regression, p = 0.33).  RDI = Respiratory Disturbance Index; STUAL =  Surface Tension 
Upper Airway Liquid; ES = Exogenous Surfactant night; NS =  Normal Saline night. 
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10.5  Discussion 
 
 This study demonstrates that exogenous surfactant delivered via 
atomizer spray reduces the STUAL in subjects with OSA. However, there is 
individual variability seen in the overnight change in RDI following 
administration of exogenous surfactant or normal saline. There is no overall 
reduction in the severity of OSA seen with an exogenous surfactant  
(Beractant) administered to a group of subjects with mild to moderate OSA. 
 
10.5.1  Critique of Methods 
 
 In comparison to previous studies performed by our laboratory, the 
methods used in this study differ with regard to the type of surfactant used 
and the delivery method. This may partially explain the reason for the lack of 
a significant effect of surfactant on RDI between the NS night and ES nights. 
 
 In previous studies performed through our laboratory (Kirkness et al., 
2003c)(Kirkness et al., 2003b) the exogenous surfactant used was Exosurf 
Neonatal (Exosurf Neonatal; GSK, Greenville, NC, USA). 2.5ml of Exosurf 
was instilled into the posterior wall of the nasopharynx in human subjects 
over a period of one minute. However, in the present study, the exogenous 
surfactant used was Beractant (Abbott, USA), due to Exosurf no longer being 
available at the time of this study. 
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 The surface tension lowering effect of Beractant was similar to that 
seen for Exosurf. However, Exosurf is a protein - free surfactant and utilises 
spreading agents, whereas Beractant is derived from a bovine extract, and 
does not contain spreading agents.  
 
 The delivery method utilised in this study also differs from the previous 
study by Kirkness et al investigating the relationship of STUAL and upper 
airway collapsibility in OSA (Kirkness et al., 2005b).  In the current study, 
surfactant was delivered by atomiser, with 1.25 mls sprayed into the 
nasopharynx, and 1.25 mls sprayed into the oropharynx. For the current 
study, there are potentially two issues regarding this administration. Firstly, 
since Beractant does not contain additional spreading agents, its spreading 
properties may not be the same as those found in Exosurf, and the 
distribution and time taken for the delivered dose to spread through the upper 
airways may be affected. Secondly, the delivery of surfactant via atomiser 
spray may have different upper airway deposition patterns in comparison to 
the instilled method. In this study, half the dose of Beractant was delivered 
into the oropharynx (aimed at the posterior oropharyngeal wall) whilst the 
other half of the dose was delivered into the nasopharynx, with the potential 
for increased time taken for the dose to spread to the posterior 
nasopharyngeal region, and for some of this dose to be retained at the level 
of the turbinates and sinuses. 
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 The route of breathing in this study was not enforced. Previous 
chapters have demonstrated the effect of enforced route of breathing upon 
STUAL values and also upon severity of OSA, and non-enforced route of 
breathing in this study may  have potentially affected the efficacy of any 
surfactant dosing depending upon the amount of any oro-nasal breathing in 
any individual subject overnight. The subjects were not controlled for sleep 
posture, however, there were no significant differences observed in sleep 
posture between nights for individual subjects. Similarly, sleep architecture 
did not demonstrate any significant  variations for individual subjects between 
the three study nights. 
 
 Subjects were woken prior to sampling and surfactant administration 
overnight in the present study. Any swallowing or increase in oro-nasal 
breathing during the awake period may have potentially affected the STUAL, 
or the clearance of any surfactant from the upper airways at the time of 
overnight sampling prior to repeat Beractant administration.  
 
 
10.5.2  STUAL 
 
 Both the diagnostic and NS nights in this study did not demonstrate 
any significant change in STUAL overnight. The STUAL values measured on 
the diagnostic and NS nights are similar to those seen in previous chapters. 
Interestingly, although normal saline has a higher surface tension of 
approximately 72 mN/m, there was no significant increase in STUAL on the 
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NS night, either after initial administration at 2200 hours or before and after 
sampling at approximately 0200 hours. Delivery of normal saline into the oro-
pharynx and nasopharynx may have potentially stimulated salivary 
production (Neyraud et al., 2003) which may have reduced the concentration 
of the atomised normal saline and potentially mitigated the surface tension 
increasing effect of saline upon STUAL. Alternately, normal saline may not 
have the same spreading or binding effects on the local airway mucosa, and 
its effect and presence in the upper airway may be short-lived.  
 
 On the ES night, the STUAL demonstrated a significant decrease 
overnight. However, this decrease was not apparent until the STUAL sample 
taken prior to the 0200 dose of surfactant. Only a small, but insignificant 
decrease was seen immediately after the first ES administration. The STUAL 
values from 0155 hours and 0205 hours were not significantly differently from 
each other, although a trend to a small reduction in STUAL was observed 
immediately following 0200 dosing. Both values were significantly decreased 
when compared to the 2100 hour sample. STUAL samples taken just after 
the 2200 hour dose of ES did not demonstrate a significant reduction 
compared to the baseline samples, consistent with the lack of change seen 
at the middle of the night sample. This suggests the possibility of inadequate 
time for the delivered dose to spread through the oro-pharynx and 
nasopharynx. However, these data do demonstrate that the delivered dose of 
surfactant used in this protocol does have a surface tension lowering effect 
that persists for up to four hours.  
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 Although the sampling at approximately 0200 hours indicates a 
persistent reduction in STUAL compared with baseline, this persistent 
reduction is not repeated following the administration of surfactant at 0200 
hours (i.e. between 0200 and 0600 hours). By 0600 hours, the STUAL 
returns to baseline in all of the subjects on the ES night. Human saliva is 
known to contain surfactant, and also exhibits a circadian rhythm, whereby 
production is at its nadir in the early hours of the morning (Dawes, 1975). 
This has also been demonstrated in previous chapters, with lower salivary 
flow and mucosal wetness in the morning. It is possible that the surface 
active effects of ES may require the normal physiological production of saliva 
to have a significant effect in lowering STUAL.  Another possibility may 
include an increase in oronasal breathing upon wakening which increases 
STUAL. However, this is unlikely as even in the presence of enforced oral 
breathing the STUAL takes 1-2 hours to increase significantly, and most 
subjects were actually woken from sleep for the 0600 sampling, which 
minimised the time available for awake oronasal breathing to occur.  
 
 The minimum STUAL values that were obtained in the present study 
using Beractant were not as low as those seen in the Kirkness et al. (2003) 
study using Exosurf. The differences in both delivery of surfactant and the 
surface active and spreading properties in the two surfactant agents may 
have made a significant difference to the SDB outcomes seen in this study. 
The reductions achieved in STUAL may not have been of sufficient 
magnitude to have made a significant reduction in sleep disordered breathing 
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10.5.3  Sleep Disordered Breathing 
 
 The overall group values for AHI and RDI in this study were fairly 
similar across the three nights, with no significant differences found in the 
severity of sleep disordered breathing between the three nights. Previous 
studies in our laboratory (Kirkness et al., 2003c)  have demonstrated a 
decrease in the RDI which correlated to a decrease in the surface tension of 
liquid lining the upper airway, with 8 of 9 subjects demonstrating a significant 
reduction in RDI from 51 events / hour of sleep to 35 events / hour of sleep. 
The sleep disordered breathing was severe on the diagnostic night, and 
although significantly reduced with surfactant, still remained severe on the 
surfactant night in the Kirkness et al. (2003) study. The subject group in the 
present study only had mild to moderate OSA. The reduction in RDI was not 
replicated with the current study using a different surfactant, a new method of 
dose delivery, and a less severe target patient group. It is possible that not all 
OSA patients will respond to the surfactant therapy, and it may be that a 
particular subgroup of patients (or phenotypic group) will need to be defined 
to further test this type of intervention, as it appears to be more effective in 
severe patients than in mild to moderate OSA patients. 
 
 The previous chapter demonstrated a significant reduction in RDI 
when normal subjects with oral breathing induced OSA were given ES. It 
remains possible that, for this combination of surfactant and method of 
delivery, a reduction in the severity of sleep disordered breathing may not be 
achieved without enforcing breathing route (i.e., combination of enforced 
nasal breathing route, together with exogenous surfactant delivered via 
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atomiser oronasally). It is possible that a combination of enforced nasal 
breathing route and exogenous surfactant may still be useful in the mild to 
moderate OSA group, but this study was not designed to test this hypothesis. 
 
 
10.6  Conclusion 
 
 Although a reduction was seen in the STUAL on the ES night, there 
was no associated reduction in the severity of OSA on the ES night. There 
was a small (but not statistically significant) reduction in STUAL immediately 
after ES administration, with a further sustained decrease at 4 hours. There 
was a further (but not statistically significant) decrease after the second ES 
dose, which was not sustained at a further 4 hours. 
 
 Individual subjects demonstrated substantial variability in RDI when 
comparing diagnostic vs NS vs ES nights, with large changes seen in both 
directions. However, there was no overall reduction in the severity of OSA 
with exogenous surfactant administered to a group of patients with mild to 
moderate OSA. Future studies investigating a surfactant intervention to 
improve SDB may need to better define the suitable patient phenotype who 
will respond to this therapy and also to control for overnight breathing route. 
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Chapter 11: General Discussion 
 
 
 
This thesis has examined the role of surface tension and breathing 
route on the severity of sleep disordered breathing (SDB). Our laboratory has 
previously examined the influence of breathing route and surface tension on 
obstructive sleep apnoea (OSA) separately. The series of experiments 
contained within this thesis examines the influence of both breathing route 
and surface tension, by firstly enforcing breathing route,  secondly by 
manipulating surface tension with exogenous surfactant, and finally, by 
enforcing oral breathing route and lowering surface tension of upper airway 
liquid concurrently. 
 
The range of surface tension values across the day for upper airway 
liquid in healthy subjects was defined in Chapter  5, which demonstrated that 
STUAL values remained relatively stable across a 24 hour period. This has 
not been previously described, with other studies demonstrating changes 
between evening and morning STUAL values only (Kirkness et al., 2005b). 
The range of STUAL values in subjects with OSA was examined in Chapter 
6, and demonstrated surface tension values as low as that seen with 
exogenous surfactant administered to the upper airway (approximately 45-60 
mN/m), and as high as that seen with normal saline (72 mN/m).  This 
represents a wide range of STUAL values in the largest cohort of OSA 
subjects tested to date. 
 
 
 
 
 210 
 
A positive association was found between OSA subjects ≥ 40 years of 
age and increased STUAL. Interestingly, there is increased oro-nasal 
breathing route in “older” healthy subjects ≥  40 years of age (Madronio et al., 
2004), which raises the question of whether  this phenomenon of increased 
oro-nasal breathing route is influencing STUAL in “older” OSA subjects. 
 
The role of breathing route was further examined in Chapter 7 in OSA 
subjects. Breathing route was not enforced in this study, but quantified by a 
method of scoring breathing route previously used in our laboratory 
(Madronio et al., 2004). There was no association found between breathing 
route and STUAL,  and there were no significant differences found in pm and 
am STUAL. However, there was a decrease in salivary flow rate and 
mucosal wetness overnight, which are likely to reflect circadian changes, with 
salivary production reduced overnight during sleep (Dawes, 1975).  
 
To determine the effect of enforced breathing route on STUAL and 
severity of sleep disordered breathing, a three night study was performed. 
Subjects had one night each utilising enforced nasal breathing route and 
enforced oral breathing route, with the subjects on the final study night 
utilising oral breathing route and given exogenous surfactant (administered 
both nasally and orally). Compared with the nasal breathing night , enforced 
oral breathing route induced a moderate degree of SDB in normal subjects.  
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Similar results have previously been reported with oral enforced 
breathing route inducing sleep apnoea (Fitzpatrick et al., 2003), however a 
causal mechanism between route of breathing and OSA has not been 
elucidated.  
 
Exogenous surfactant (Beractant) administered on the enforced oral 
breathing route night to healthy subjects was shown to reduce STUAL in 
Chapter 9. In comparison to the enforced oral route of breathing night without 
exogenous surfactant, the RDI on the exogenous surfactant night decreased 
in all of the subjects. Additionally, although exogenous surfactant was able to 
reduce the STUAL to values seen on the nasal breathing night, this did not 
eliminate oral breathing induced SDB. It is likely that surface tension forces 
partially mediate the severity of SDB due to enforced oral breathing route, 
but other mechanisms such as anatomical factors with conformational 
changes in upper airway i.e. jaw position, soft palate and tongue position 
(Meurice et al., 1996), may also play an important role in upper airway 
closure.    
 
Although exogenous surfactant was shown to decrease the RDI in 
healthy subjects with oral breathing route induced SDB, this was not evident 
when OSA subjects were administered exogenous surfactant.  In the final 
study of this thesis (Chapter 10), exogenous surfactant was administered to 
subjects with mild to moderate severity of OSA. Breathing route was not 
enforced in this study, and the subjects underwent a diagnostic 
polysomnography night, and two intervention nights, one with exogenous 
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surfactant (Beractant) administered and one with Normal Saline. Although 
exogenous surfactant reduced STUAL, there was no associated reduction in 
the severity of OSA. The possible causes for this may include the new 
delivery method used in this study or, more likely, the type of surfactant used. 
Our laboratory has previously used a different type of surfactant (Exosurf 
neonatal, Burroughs Wellcome Australia) with the surfactant used in this 
study being Beractant, which may not have the same surface tension 
characteristics, duration of action, or spreading and mucosal adherence 
qualities as Exosurf.  
 
In summary, surface tension forces have been recognised to influence 
upper airway patency (Morrell et al., 2002, Van der Touw et al., 1997), with a 
reduction in STUAL resulting in decreased upper airway collapsibility (Lam et 
al., 2008, Kirkness et al., 2003a) and decreased severity of OSA (Kirkness et 
al., 2003c). Both nasal and oronasal route of breathing occur in healthy 
subjects (Madronio et al., 2004) and in subjects with OSA, with enforced oral 
breathing increasing  the severity of OSA (Fitzpatrick et al., 2003). The link 
between enforced oral route of breathing and increased surface tension has 
been reported in awake subjects (Verma et al., 2006), while in healthy, 
“older”  subjects, there is a greater proportion of oronasal breathing during 
sleep (Madronio et al., 2004).  
 
 
The work in this thesis has 1) established a wide range of surface 
tension values in healthy subjects and subjects with OSA; 2) explored the 
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route of breathing and its influence on surface tension in healthy and OSA 
subjects; 3) examined the effect of enforced route of breathing on STUAL 
and  sleep disordered in healthy subjects; 4) induced a moderate degree of 
SDB in healthy subjects with enforced oral breathing route; 5) demonstrated 
a reduction in the severity of this oral breathing induced SDB with exogenous 
surfactant; 6) piloted a trial of a different exogenous surfactant agent and a 
new, less invasive delivery method to reduce STUAL in subjects with mild to 
moderate OSA. 
 
Although we did not find an effect of exogenous surfactant in 
decreasing the severity of OSA in Chapter 10 of this thesis, it remains 
possible that exogenous surfactant therapy may have a role in a certain 
patient phenotype with OSA. Future trials may need to better define the 
subject population who may respond to this intervention, and perhaps 
subjects with mild OSA and predominantly oral route of breathing may be an 
appropriate group to study. Alternately, enforced nasal breathing route may 
be utilized together with exogenous surfactant in this patient group to 
determine if the combination of lowering STUAL and nasal breathing route 
has any influence on the severity of sleep disordered breathing.  
 
It is becoming apparent that there is an increasing focus not only in 
Sleep Medicine, but with medical management of diseases in general, on 
moving towards an era of personalized medicine, where identifying the 
combination of disease characteristics and patient  risk factors and traits in 
defining the patient’s phenotype may maximize the efficacy of medical 
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intervention, and also help identify novel therapeutic targets.  With regards to 
OSA, the phenotypic traits may include the patient’s upper airway anatomy 
and craniofacial shape, breathing route during sleep, their upper airway 
neuromuscular responses, ventilatory control manifested by loop gain, and 
cortical arousal thresholds.  
 
Perhaps it is now time to better define the measurement of the 
phenotypic traits of breathing route and surface tension to potentially identify 
phenotypic subgroups of OSA patients, and to consider the development of 
new targeted therapies for these novel phenotypic traits. 
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Chapter 12: Summary of Results 
 
 
12.1 Surface Tension of Upper Airway Liquid in Healthy 
Subjects 
 
Sampling UAL and Saliva across a 24 hour period in healthy subjects 
demonstrated: 
1) A wide range of STUAL with a range from 56.6 to 70.4 mN/m. 
2) A wide range of ST of Saliva with a range from 56.0 to 71/4 mN/m. 
3) ST of Saliva was positively correlated with STUAL across all time 
periods. 
4) STUAL values appeared unaffected by the time of day. 
 
12.2   Surface Tension of Upper Airway Liquid in Obstructive 
Sleep Apnoea Subjects 
UAL and Saliva samples were collected prior to sleep from subjects with 
OSA and the surface tension of these sample was measured. This study 
demonstrated: 
 
1) A strong correlation between ST Saliva and STUAL (r = 0.78,        
p < 0.0001). 
2)  A range of STUAL values, from 45.1 to 73.7 mN/m, and a mean 
STUAL of 61.4 ± 5.2 mN/m. 
3) A range of ST Saliva values, from 49.5 to 77.2 mN/m, and a mean 
ST Saliva of 61.3 ± 5.1 mN/m. 
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4) In older subjects with severe OSA, increasing age was weakly 
correlated with increasing STUAL 
 
12.3   Non-enforced Breathing Route and Surface Tension of 
Upper Airway Liquid in Subjects with Obstructive Sleep 
Apnoea 
 
Breathing Route and STUAL, MW, and Salivary Flow Rate were analysed in 
subjects with Obstructive Sleep Apnoea. The results are as follows: 
1) No difference between evening and morning values for STUAL.  
2) A significant decrease in MW overnight. 
3) A significant decrease in Salivary Flow Rate overnight. 
4) A range of nasal and oronasal breathing route. All subjects had 
nasal breathing , with the range of oronasal breathing ranging from 
0 – 100% of total sleep epochs.  
5) The mean percentage of total sleep epochs spent oronasal 
breathing was 29%. 
 
12.4   Influence of Enforced Breathing Route on Surface 
Tension of Upper Airway Liquid and Sleep Disordered 
Breathing in Healthy Subjects 
 
Healthy subjects were randomized to enforced nasal or oral route of 
breathing. The severity of OSA was determined by polysomnography and 
samples were obtained for STUAL, MW, and Salivary Flow Rate at 0,4, and 
8 hours from the start of the study. This demonstrated: 
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1) A significant increase in the severity of SDB was associated with 
increases in STUAL on the enforced oral route of breathing night.  
2) MW and Salivary Flow Rate decreased overnight on the enforced 
oral breathing night, but remained unchanged on the enforced 
nasal breathing night. 
3) Enforced oral breathing route induces sleep disordered breathing 
in normal subjects. 
 
12.5  Effect of Exogenous Surfactant during Enforced Oral 
Breathing Route on Surface Tension of Upper Airway Liquid 
and Severity of Sleep Disordered Breathing in Healthy 
Subjects 
 
Following on from the previous study examining the role of enforced oral 
breathing route on STUAL and severity of SDB in healthy subjects, a 
subsequent study was performed using exogenous surfactant (ES) to lower 
the STUAL during enforced oral breathing route. The results are as follows: 
1) ES significantly reduced the severity of oral breathing induced SDB 
in healthy subjects, but did not eliminate SDB. 
2) All of the subjects demonstrated a reduction in RDI when 
administered ES. 
3) ES administration resulted in STUAL values that were reduced to 
values seen with enforced nasal breathing route. 
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12.6   Effect of Exogenous Surfactant in Subjects with Mild to 
Moderate Obstructive Sleep Apnoea 
 
A pilot study was conducted to 1) develop a randomized controlled trial of 
exogenous surfactant (ES) in subjects with mild to moderate OSA; 2) to pilot 
a new, less invasive delivery method for ES; and 3) to pilot a different 
surfactant agent (Beractant, Abbott, USA) and investigate its potential use as 
a therapeutic agent in OSA. The study was conducted over 3 nights and 
subjects underwent a diagnostic polysomnography night, and two 
intervention nights receiving either normal saline (NS) or exogenous 
surfactant (ES) via atomizer spray. The results are as follows: 
1) ES delivered via atomizer spray reduces STUAL in OSA subjects. 
2) There is no overall reduction in the severity of OSA with ES. 
3) STUAL values decreased to a nadir at 4 hours and returned to 
baseline values by 8 hours. 
4) Individual subjects demonstrated substantial variability in RDI 
when comparing diagnostic vs NS vs ES nights, with large 
changes in both directions. 
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